



Annual Report 2011


ASAHI KASEI CORPORATION



We, the Asahi Kasei Group, contribute to life and living for people around the world.



History of Business Portfolio Transformation
(Sales Composition)




Always transforming its business portfolio to meet the changing needs of the times, the Asahi Kasei Group has developed into one of Japan's leading chemical manufacturers, with a selectively diversified array of businesses. With Asahi Kasei Corp. as a holding company, businesses are advanced by nine core operating companies in the four business sectors of Chemicals & Fibers, Homes & Construction Materials, Electronics, and Health Care.

In anticipation of emerging changes in social structures, we will offer new value from the perspectives of "living in health and comfort" and "harmony with the natural environment," aiming to achieve continuous growth in accordance with our Group Slogan—Creating for Tomorrow.



FY 2010



Contents

02	Consolidated Financial Highlights
04	To Our Shareholders
06	A Message from the President
11	New mid-term management initiative: "For Tomorrow 2015"
16	At a Glance
18	Operating Segments
18	Chemicals
20	Homes
22	Health Care
24	Fibers
26	Electronics
28	Construction Materials
30	Others
31	Toward Sustainable Growth
39	Financial Section
78	Major Subsidiaries and Affiliates
80	Corporate Profile
81	Investors Information

Consolidated Financial Highlights

Asahi Kasei Corporation and consolidated subsidiaries

Fiscal year beginning April 1	¥ billion					US\$ million*
	2010	2009	2008	2007	2006	2010
For the year						
Net sales	¥1,598.4	¥1,433.6	¥1,553.1	¥1,696.8	¥1,623.8	\$ 19,258
Operating income	122.9	57.6	35.0	127.7	127.8	1,481
Net income	60.3	25.3	4.7	69.9	68.6	726
Comprehensive income	45.1	—	—	—	—	543
Free cash flows	69.3	69.1	(66.9)	3.8	47.1	835
At year end						
Total assets	¥1,425.9	¥1,368.9	¥1,379.3	¥1,425.4	¥1,459.9	\$ 17,179
Net worth†	663.6	633.3	603.8	666.2	645.7	7,995
Interest-bearing debt	253.9	264.6	315.6	211.4	216.9	3,059
Per share						
Net income	¥ 43.11	¥ 18.08	¥ 3.39	¥ 50.01	¥ 49.00	\$ 0.52
Net worth‡	474.59	452.91	431.77	476.39	461.50	5.72
Cash dividends	11.00	10.00	10.00	13.00	12.00	0.13


Key indexes	¥					US\$*
	2010	2009	2008	2007	2006	2010
Operating margin	7.7%	4.0%	2.3%	7.5%	7.9%	
Payout ratio	25.5%	55.3%	295.0%	26.0%	24.5%	
ROA	4.3%	1.8%	0.3%	4.8%	4.8%	
ROE	9.3%	4.1%	0.7%	10.7%	11.1%	
Net worth to total assets‡	46.5%	46.3%	43.8%	46.7%	44.2%	
D/E ratio‡	0.38	0.42	0.52	0.32	0.34	

* U.S. dollar amounts in this annual report are translated from Japanese yen, for convenience only, at the rate of ¥83=US\$1 as described in Note 1 of Notes to Consolidated Financial Statements.


† Net assets less minority interest.

‡ At fiscal year end.


Net Sales




Operating Income, Operating Margin




Net Income, ROE



Strategic Management Initiatives




Total Assets, Net Worth to Total Assets




* At year end.

Interest-Bearing Debt, D/E Ratio



* At year end.

Free Cash Flows



To Our Shareholders

The Japanese economy was recovering in the first half of fiscal 2010 as corporate performance improved with the effect of government stimulus measures and thanks to economic recovery in emerging markets. In the second half, however, the economy was severely affected by the rapid rise of the yen, a decline in automotive sales due to the expiration of government subsidies for fuel-efficient vehicles, high feedstock prices driven by political unrest in North Africa and the Middle East, and the impact of the Great East Japan Earthquake, resulting in uncertainty regarding the economic outlook.

Consolidated results of Asahi Kasei Corp. and its consolidated subsidiaries and equity-method affiliates (the Asahi Kasei Group) reflected substantially stronger performance buoyed by higher market prices and increased overseas demand in the Chemicals segment as well as favorable performance in the Homes and Electronics segments. Net sales were ¥1,598.4 billion, an increase of ¥164.8 billion (11.5%) from a year ago. Operating income increased by ¥65.3 billion (113.3%) from a year ago to ¥122.9 billion. Ordinary income increased by ¥61.9 billion (109.7%) to ¥118.2 billion. Net income increased by ¥35.0 billion (138.4%) to ¥60.3 billion.

Based on these results, we paid a year-end dividend of ¥6 per share, which, combined with the interim dividend, brought the total annual dividend to ¥11 per share.

This April, the Asahi Kasei Group launched a new medium-term strategic management initiative, “For Tomorrow 2015,” for the five-year period from fiscal 2011 through fiscal 2015. At the same time, we also adopted a renewal of our Group Mission and Group Vision—with “Contributing to life and living for people around the world” as our Group Mission, and “Providing new value to society by enabling *living in health and comfort* and *harmony with the natural environment*” as our Group Vision.

“For Tomorrow 2015” provides a clear vision for the Asahi Kasei Group, with a focus not only on the proactive expansion of our globally competitive businesses, but also on the expansion of operations in fields related to the environment & energy, residential living, and health care from the perspectives of *living in health and comfort* and *harmony with the natural environment*. To further heighten corporate value, we will pursue growth by focusing the strengths of the Group on anticipating emerging social needs through our key strategies of “expansion of world-leading businesses” and “creation of new value for society.”

August 2011



Ichiro Itoh
Chairman



Taketsugu Fujiwara
President



Ichiro Itoh, Chairman (left), Taketsugu Fujiwara, President (right)



Taketsugu Fujiwara, President

Boldly advancing our “For Tomorrow 2015” management initiative, for the continuous enhancement of corporate value.

The Asahi Kasei Group has launched “For Tomorrow 2015,” our new strategic management initiative for the five years through fiscal 2015. Strategies for growth are to expand world-leading businesses and to create new value for society in environment and energy, residential living, and health care-related fields.

Review of “Growth Action – 2010”

Our previous strategic initiative, “Growth Action – 2010,” for the five-year period from April 2006 to March 2011, was focused on business portfolio realignment for expansion and growth with two key strategies of expanding global businesses and enhancing domestic businesses.

For the expansion of global businesses, we concentrated investments on businesses with competitive superiority in global markets. In petrochemicals, we adopted decisions to build a new acrylonitrile (AN) plant in Thailand and Korea, and a new solution-polymerized styrene-butadiene rubber (S-SBR) plant in Singapore. In electronics materials, we built a new plant for Hipore™ lithium-ion battery (LIB) separator in Hyuga, and expanded capacity at our plant in Moriyama. In electronics devices, we made a large expansion of our business for electronic compasses used in smartphones and other mobile electronics, and entered the field of power-management LSIs by acquiring the semiconductor business of Toko, Inc. In medical-related products, we formed strategic alliances in the field of hemodialysis with Kawasumi Laboratories, Inc. and NxStage Medical, Inc., and expanded our bioprocess equipment business by acquiring the business of TechniKrom, Inc.

We also took a number of steps for the enhancement of domestic businesses. In pharmaceuticals, we began marketing Recomodulin™ recombinant thrombomodulin and Famvir™ anti-herpes agent, and filed an application for approval for Teribone™ for osteoporosis. In homes, we developed a new framing system for next-generation energy conservation, and launched several new products for urban markets. In petrochemicals, we addressed an intermediate-term challenge related to the competitiveness of our naphtha cracker in Mizushima by establishing Nishi Nippon Ethylene LLP together with Mitsubishi Chemical. Unified management of our naphtha crackers began in April 2011, enabling unparalleled flexibility to adapt to changes in the operating environment.

Key results of “Growth Action – 2010”

Expanding global businesses

Globally competitive petrochemicals business

- Construction of new AN and methyl methacrylate (MMA) plants in Thailand, capacity expansion for AN in Korea
- Construction of new solution SBR plant in Singapore

Electronics

- Capacity expansion for Hipore™ LIB separator
- Electronic compass business, power-management semiconductors for cell phones and smartphones (acquisition of Toko, Inc.’s semiconductor business, etc.)

Health Care

- Polysulfone hollow-fiber membrane artificial kidneys business (incl. tie-ups with Kawasumi Laboratories, Inc. and NxStage Medical, Inc.)
- Market entry in bioprocess equipment and advanced medical devices businesses

Enhancing domestic businesses

Reinforcing pharmaceuticals business

- Market launch of Recomodulin™ recombinant thrombomodulin and Famvir™ anti-herpes agent, application for approval to manufacture and sell Teribone™ (teriparatide acetate) as an osteoporosis drug
- Strengthening homes business (three-story houses for urban life, peripheral businesses, etc.)

Restructuring

- Unified management of naphtha crackers in Mizushima, Japan; closure of polyester filament plant, etc.

	(¥ billion)	
	FY 2010 results	FY 2010 original targets
Net sales	1,598.4	1,800
Operating income	122.9	150
Net income	60.3	80
ROE	9%	≥10%

Operating performance exceeded our targets in fiscal 2006 and 2007, but the impact of the global financial crisis in autumn 2008 caused results to undershoot our targets by a wide margin in fiscal 2008 and 2009. In fiscal 2010, although we were unable to meet our original targets, a strong recovery of demand in emerging economies and an expansion of homes operations enabled our performance to recover to pre-crisis levels. All in all, I feel that we successfully strengthened our operational base during the five-year period under “Growth Action – 2010” for a new phase of development, even as we swiftly adjusted to drastic changes in the operating environment.

For Tomorrow 2015

We launched a new medium-term management initiative, “For Tomorrow 2015,” in April 2011. In formulating our strategies and plans, in addition to analyzing the major global trends that will be prominent over the coming years, we took a step back and had a fresh look at our basic principles, including our Group Mission and Group Values. We realized that our proper course for advancement was to create new value by anticipating changes in society from the two perspectives of *living in health and comfort* and *harmony with the natural environment*. This is the core concept of “For Tomorrow 2015,” the naming of which is an expression of our aspiration to create new value for the future.

Our two main strategies for growth are the expansion of world-leading businesses and the creation of new value for society. For the expansion of world-leading businesses, we will build on our established No. 1 and No. 2 global positions, advancing proactively in markets where we can exert leadership, with a focus on growth in developing countries. For the creation of new value for society, we will concentrate resources on the expansion of businesses related to the environment and energy, residential living, and health care, as fields that contribute to *living in health and comfort* and *harmony with the natural environment*. Leveraging the diverse strengths of the Asahi

Basic strategy and targets of “For Tomorrow 2015”

	(¥ billion)	
	FY 2010 results	FY 2015 targets
Net sales	1,598.4	2,000
Operating income	122.9	200
Net income	60.3	110
ROE	9%	≥10%
ROIC	7%	≥7%
Overseas sales ratio (excl. Homes & Const. Mat.)	28% (39%)	32% (45%)

The Asahi Kasei Group is creating new things for the future based on the perspectives of “living in health and comfort” and “harmony with the natural environment.”

Pursuit of growth

1. Expansion of world-leading businesses

2. Creation of new value for society

Promotion of businesses based on *living in health and comfort* and *harmony with the natural environment*

- Environment/energy-related
- Residential living-related
- Health care-related

Net sales

Operating income

Net income

ROE

ROIC

Overseas sales ratio (excl. Homes & Const. Mat.)

Kasei Group in these fields, we have established three “For Tomorrow” projects which extend across our various business units, to anticipate the world’s emerging needs with unique solutions that only we can provide.

To achieve these strategies we plan to invest some ¥1 trillion for the creation of new business over the five-year period through fiscal 2015, including M&A. We are targeting consolidated net sales of ¥2 trillion and operating income of ¥200 billion in fiscal 2015.

Effect of the Great East Japan Earthquake

To all those affected by the Great East Japan Earthquake, the Asahi Kasei Group expresses its sincere sympathy. It is our genuine hope that the afflicted areas will be restored and revitalized as soon as possible.

In terms of direct damage to Asahi Kasei Group assets, four of our plants were damaged by the earthquake: The Ishinomaki Plant of Asahi Kasei Power Devices Corp. in Miyagi Prefecture, the Sakai Plant and Neoma Foam Plant of Asahi Kasei Construction Materials Corp. in Ibaraki Prefecture, and the Tomobe Plant of Asahi Kasei Metals Ltd. in Ibaraki Prefecture. We established an emergency disaster response headquarters right after the quake to coordinate efforts to confirm the safety of all personnel and to minimize the effects on operations. All of the damaged plants resumed operation in May, and are now operating normally. The direct impact of the disaster on our fiscal 2010 operating results was an extraordinary loss of ¥800 million. We are forecasting the effect on fiscal 2011 results to be relatively minor.

Fiscal 2011 Outlook

Although there are some positive economic developments, such as a rebound in manufacturing activity following the temporary slowdown due to the earthquake, as well as growth in exports, the operating environment for the Asahi Kasei Group in fiscal 2011 generally remains obscure, with uncertain economic prospects in the US and Europe, the persistent strength of the yen, and electric power shortages in Japan. Even in these challenging circumstances, the Asahi Kasei Group is determined to achieve growth guided by our “For Tomorrow 2015” strategies of expanding our world-leading businesses and expanding businesses related to the fields of the environment and energy, residential living, and health care. The outlook for fiscal 2011 by business sector is as follows.

In Chemicals & Fibers, we are forecasting lower operating income in Chemicals as an effect of higher feedstock costs and the strengthening yen, although we believe shipments to Asian markets will remain favorable and market prices will be high, most notably for acrylonitrile. In Fibers, we are forecasting slightly lower operating income as an effect of higher feedstock costs, even as shipments are expected to grow in all major product areas.





In Homes & Construction Materials, we are forecasting higher operating income in Homes with deliveries of Hebel Haus™ unit homes increasing as an effect of strong growth in orders from fiscal 2010. In Construction Materials, we are forecasting higher operating income thanks to cost reductions in housing and building materials operations and shipment growth in foundation systems and insulation materials operations.

In Health Care, we are forecasting higher operating income with shipment growth for Recomodulin™ in pharmaceuticals and shipment growth for APS™ artificial kidneys and Planova™ virus removal filters in devices.

In Electronics, we are forecasting higher operating income with shipment growth in each product category in both electronic materials and electronic devices.

Overall, we believe operating income will be slightly lower than in the previous year, though net sales, ordinary income, and net income will all be higher.


Return to Shareholders

The annual dividend for fiscal 2010 was raised by ¥1 per share to ¥11, reflecting the improvement in financial results. For fiscal 2011, we believe further improved results will enable us to raise it by another ¥2 to ¥13 per share.

Our basic policy is to strive to continuously increase dividends through earnings growth while maintaining an appropriate cash reserve based on consolidated income.

Our cash reserve will be used as a source of funds required in order to achieve future earnings growth by expanding operations, both through investments in established businesses and through strategic investments and new business development expenditures in fields related to the environment and energy, residential living, and health care as the strategic focus of “For Tomorrow 2015.” We aim to continuously increase dividends by expanding earnings under “For Tomorrow 2015,” with a basic standard for payout ratio of 30%.


Dividends per Share, Payout Ratio



Asahi Kasei Group's new mid-term management initiative:

“For Tomorrow 2015” (fiscal 2011–2015)

Offering new value based on “living in health and comfort” and “harmony with the natural environment” in anticipation of changing social needs. Continuously enhancing our corporate value in accordance with our Group Slogan: Creating for Tomorrow.




- 1 Expansion of world-leading businesses
- 2 Creation of new value for society
- 3 Reformation of corporate systems
- 4 Performance plan by business sector & long-term investment plan


Expansion of world-leading businesses

We will expand our global No. 1 and No. 2 businesses with a focus on growth in emerging markets. For other businesses that are able to attain a leading position by utilizing our technology and market strengths, we will proactively expand as a global market leader.

Overseas sales ratio of world-leading businesses



Profit*




* Operating income of each business plus equity in earnings of AN affiliates.

Acrylonitrile (AN)


Based on our technological strengths of having the world's highest-yielding catalyst and the world's first propane process, we plan to gain the global No. 1 position through expansion centered in Asia.

- Completion of a new plant in Thailand (start-up in 2011)
- Capacity expansion in Korea (start-up in 2013)
- Establishment of a joint venture to implement a project to produce AN in Saudi Arabia

Share of production capacity in Asia (Asahi Kasei estimate)



Asahi Kasei production capacity for AN




Solution SBR (S-SBR)


S-SBR is an essential material for fuel-efficient tires, with particularly strong demand growth in Asia. Asahi Kasei is proactively expanding capacity for S-SBR which enables the production of tires that provide greater fuel efficiency while maintaining safety performance.

- Construction of a new S-SBR plant in Singapore (start-up in 2013)
- Capacity expansion at the Singapore plant (start-up in 2015)

Share of production capacity (Asahi Kasei estimate)



Asahi Kasei production capacity for S-SBR used in fuel-efficient tires



Other world-leading businesses


- Electronics: Hipore™ lithium-ion battery separator, LSIs, dry film photoresist, pellicles
- Health Care: Artificial kidneys (dialyzers), Planova™ virus removal filters
- Fibers: Roica™ elastic polyurethane filament

2


Creation of new value for society

We are concentrating resources on fields related to the environment & energy, residential living, and health care, to expand businesses which meet emerging social needs for *living in health and comfort* and *harmony with the natural environment*. To advance into these fields across different business units, three


new projects—“Environment & Energy for Tomorrow,” “Residential Living for Tomorrow,” and “Health Care for Tomorrow”—have been launched to create new system-based, combined-unit businesses, making the most of the Asahi Kasei Group’s diverse competencies.



Net sales



Operating income



Environment & Energy

Pushing diverse technology to tackle environmental challenges

Strategy for major businesses

- **Hipore™ lithium-ion battery (LIB) separator**
In addition to No. 1 position in LIBs for electronics, establishing firm lead in technology and market for automotive LIBs.
- **Sensors, power-saving LSIs**
Greater focus on infrastructure and automotive applications in addition to consumer electronics. Expansion focused on global markets in addition to Japan.
- **Neoma™ phenolic foam panels**
Helping society to conserve energy by supplying materials with world-leading insulation performance.
- **Water treatment/membrane business**
Accelerating the development of business in China with growing markets for water treatment.

Creation of new businesses through combined-unit projects

Based on our group technologies with competitive superiority, the Environment & Energy for Tomorrow project will advance the development of innovative materials and devices as well as the establishment of systems for application at each stage from power generation to energy storage and consumption—including cutting-edge battery materials, lithium ion capacitor modules and systems, next-generation energy-saving devices, and LED materials.

Residential Living

Providing comfortable living to more customers, more quickly

Strategy for major businesses

- **Houses, apartments**
Pursuing superior structural technology and lifestyle innovation to anticipate emerging needs in three-story and two-generation urban homes. Developing unique apartment buildings for the elderly, single women, pet owners, etc.
- **Real estate (condominium development, brokerage, subleasing)**
Maximizing the utilization of land value through consensus-building among diverse interested parties, etc.
- **Remodeling**
Providing greater satisfaction to Hebel Haus™ owners through remodeling and renovation aligned to lifestyle changes.

Creation of new businesses through combined-unit projects

Not only selling homes in the mature urban market, but providing innovative lifestyle proposals that add new value for society, for instance by showcasing our services in concept houses. Expansion of our housing business by emphasizing such elements as healthy and comfortable living environments, interpersonal bonds, energy and resource conservation, and maximum utilization of land value.

The Residential Living for Tomorrow project will bring together technologies from a fresh perspective, including those of the Asahi Kasei Group and those of generally available products. In addition, we will adopt innovative technologies, products, and systems from our Health Care for Tomorrow project and Environment & Energy for Tomorrow project for practical application in residential settings.

Health Care

Providing unique products and technologies for a lively society of health and longevity

Strategy for major businesses

- **Pharmaceuticals**
Focusing on the expansion of Recomodulin™ anticoagulant, launch and expansion of Teribone™ as an osteoporosis drug, reinforcement of pipeline by in-licensing new drugs, and strengthening of clinical development capability in the US.
- **Blood purification (artificial kidneys, apheresis)**
Accelerating full coverage of Europe, North America, and emerging markets, while enhancing cost competitiveness and product performance.
- **Bioprocess-related business**
Leading the market for process equipment and media for biologics through the provision of distinctive membrane modules and the expansion of sales together with bioprocess equipment.

Creation of new businesses through combined-unit projects

We seek to contribute to the advancement and widespread dissemination of Japanese medical technology as well as the establishment of Japanese society as a model for healthy longevity, through proactive collaboration with outside organizations, combining industry and academia and combining medicine and engineering. While utilizing the technology and know-how of the Asahi Kasei Group, we will execute M&As and form alliances to establish the platforms on which business expansion will be based, as we take on the three challenges of "heightening emergency and critical care," "utilizing medical IT to support healthy life," and "applying cell therapy and regenerative medicine."

3

Reformation of corporate systems

Our October 2003 transformation to a holding company configuration gave the core operating companies autonomous and independent management, resulting in improved cash flow and greater management speed. Nevertheless, we recognized the need to draw together the power of the Asahi Kasei Group for the creation of new value for society amidst the dramatically changing economic climate. We therefore reviewed a number of our corporate structures and systems, including for the creation of new businesses, global business expansion, human

resource policies, management control, and resource allocation.

Our previous new business development strategy was based on market-focused R&D performed by the relevant core operating company, and other R&D performed by the holding company. With the start of the new mid-term initiative, we have adopted a new configuration in which key projects that extend across different business units are performed either as “For Tomorrow” projects or by our Central R&D Laboratories.

4


Performance plan by business sector & long-term investment plan

Targets under “For Tomorrow 2015” include consolidated net sales of ¥2 trillion and operating income of ¥200 billion in fiscal 2015. For our new combined-unit “For Tomorrow” projects, we are aiming for net sales of ¥100

billion and operating income of ¥15 billion in fiscal 2015. Long-term investments of some ¥1 trillion will be made over the five-year period through fiscal 2015 to achieve these targets.

	(¥ billion)			
	Net sales		Operating income	
	FY 2010	FY 2015 target	FY 2010	FY 2015 target
Chemicals & Fibers	851.0	880.0	68.6	75.0
Homes & Const. Mat.	456.6	570.0	38.6	50.0
Electronics	158.3	250.0	14.3	40.0
Health Care	116.4	180.0	7.0	25.0
Others	16.0	20.0	(5.5)	(5.0)
Subtotal	1,598.4	1,900.0	122.9	185.0
“For Tomorrow” projects		↓ 100.0 (FY 2020) approx. 300		↓ 15.0 (FY 2020) approx. 50
Total	1,598.4	2,000.0	122.9	200.0

Long-term investment plan
























At a Glance

Operating segments	Core operating companies, main businesses/products	Major consolidated subsidiaries
<p>Chemicals</p> 	<p>Asahi Kasei Chemicals Corp.</p> <p>Chemicals and derivative products: Ammonia, nitric acid, caustic soda, acrylonitrile (AN), styrene, adipic acid, methyl methacrylate (MMA), and acrylic resin.</p> <p>Polymer products: Stylac™-AS styrene-acrylonitrile, Stylac™-ABS acrylonitrile-butadiene-styrene, Tenac™ polyacetal, Xyron™ modified polyphenylene ether (mPPE), Leona™ nylon 66, Suntec™ polyethylene (PE), synthetic rubber and elastomer, polystyrene.</p> <p>Specialty products: Coating materials, latex, Ceolus™ microcrystalline cellulose, explosives, explosion-bonded metal clad, Microza™ UF and MF membranes and systems, ion-exchange membranes and electrolysis systems, Saran Wrap™ cling film, Ziploc™ storage bags, plastic film, sheet, and foam.</p>	<ul style="list-style-type: none"> • Asahi Kasei Pax Corp. • Asahi Kasei Home Products Corp. • Japan Elastomer Co., Ltd. • PS Japan Corp. • Tong Suh Petrochemical Corp., Ltd. • Asahi Kasei Plastics Singapore Pte. Ltd. • Asahikasei Plastics (America) Inc. • Asahi Kasei Performance Chemicals Corp. • Asahi Kasei Microza (Hangzhou) Co., Ltd.
<p>Homes</p> 	<p>Asahi Kasei Homes Corp.</p> <p>Hebel Haus™ houses, Hebel Maison™ apartments, condominiums, residential land development, remodeling, real estate brokerage, home financing.</p>	<ul style="list-style-type: none"> • Asahi Kasei Jyuko Co., Ltd. • Asahi Kasei Mortgage Corp. • Asahi Kasei Reform Co., Ltd. • Asahi Kasei Real Estate, Ltd. • Asahi Kasei Home Construction Corp.
<p>Health Care</p> 	<p>Asahi Kasei Pharma Corp. Asahi Kasei Kuraray Medical Co., Ltd. Asahi Kasei Medical Co., Ltd.</p> <p>Pharmaceutical-related: Pharmaceuticals including Recomodulin™, Elicitonin™, Flivas™, Toledomin™, and Bredinin™, Lucica™ GA-L glycyated albumin assay kit, L-series enriched liquid diets.</p> <p>Medical device-related: APS™ polysulfone-membrane artificial kidneys (dialyzers), therapeutic apheresis devices, Planova™ virus removal filters, Sepacell™ leukocyte reduction filters.</p>	<ul style="list-style-type: none"> • Med-Tech Inc. • Asahi Kasei Bioprocess, Inc. • Asahi Kasei Medical (Hangzhou) Co., Ltd.
<p>Fibers</p> 	<p>Asahi Kasei Fibers Corp.</p> <p>Roica™ elastic polyurethane filament, Bemberg™ regenerated cellulose fiber, nonwovens including Eltas™ spunbond and Lamous™ artificial suede, Leona™ nylon 66 filament.</p>	<ul style="list-style-type: none"> • Kyokuyo Sangyo Co., Ltd. • Thai Asahi Kasei Spandex Co., Ltd. • Hangzhou Asahikasei Spandex Co., Ltd. • Asahi Kasei Spandex Europe GmbH • Asahi Kasei Spandex America, Inc. • Asahi Chemical (HK) Ltd. • Hangzhou Asahikasei Textiles Co., Ltd.
<p>Electronics</p> 	<p>Asahi Kasei Microdevices Corp. Asahi Kasei E-materials Corp.</p> <p>Electronic devices: Mixed-signal LSIs, Hall elements.</p> <p>Electronic materials: Hipore™ Li-ion battery separator, photomask pellicles, APR™ photosensitive resin and printing plate making systems, PimeI™ photosensitive polyimide precursor, Sunfort™ dry film photoresist, glass fabric for printed wiring boards.</p>	<ul style="list-style-type: none"> • Asahi Kasei Power Devices Corp. • AKM Semiconductor, Inc. • Asahi Kasei Electronics Materials (Suzhou) Co., Ltd. • Asahi-Schwebel (Taiwan) Co., Ltd. • Asahi Kasei Wah Lee Hi-Tech Corp. • Asahi Photoproducts (Europe) SA/NV
<p>Construction Materials</p> 	<p>Asahi Kasei Construction Materials Corp.</p> <p>Hebel™ autoclaved aerated concrete (AAC) panels, Neoma™ foam insulation panels, piles and foundation systems, steel-frame structural components.</p>	<ul style="list-style-type: none"> • Asahi Kasei Foundation Systems Corp. • Asahi Kasei Extech Corp.
<p>Others</p>	<p>Plant engineering, environmental engineering, research and analysis, personnel staffing and placement.</p>	<ul style="list-style-type: none"> • Asahi Research Center Co., Ltd. • Asahi Finance Co., Ltd. • Asahi Kasei Engineering Co., Ltd. • Asahi Kasei Amidas Co., Ltd.

Fiscal 2010 composition of sales, operating income

Net sales (¥ billion)

Operating income (¥ billion), operating margin (%)



Chemicals



We are pursuing opportunities in growing markets that make the most of our strengths and optimizing our operational configuration in line with the changing management climate, with a focus on enabling “living in health and comfort” and “harmony with the natural environment” throughout our broad range of business operations.

Masaki Sakamoto
President, Asahi Kasei Chemicals



Net sales vs. fiscal 2009
¥742.2 billion **+19.3%**

Operating income vs. fiscal 2009
¥64.4 billion **+147.0%**

Financial Highlights

(¥ billion)				
Fiscal year beginning April 1	2008	2009	2010	2011 forecast
Net sales	¥689.3	¥622.1	¥742.2	¥800.0
Overseas sales ratio	38.7%	39.2%	41.0%	—%
Operating income (loss)	(6.5)	26.1	64.4	54.5
Operating margin	-0.9%	4.2%	8.7%	6.8%
R&D expenditure	14.6	14.0	15.5	—
R&D expenditure as % of net sales	2.0%	2.3%	2.1%	—%
Capital expenditure	36.3	27.6	23.2	30.0
Depreciation and amortization	32.2	32.4	31.9	—

“Growth Action – 2010” recap

- New acrylonitrile (AN) and methyl methacrylate (MMA) plants in Thailand, capacity expansion for AN in Korea.
- New solution-polymerized styrene-butadiene rubber (S-SBR) plant in Singapore.
- New plant in China for assembly of Microza™ filtration modules for large-scale water treatment.
- Capacity expansion for ion-exchange membranes and for synthetic rubber and elastomer.
- Establishment of a limited liability partnership (LLP) with Mitsubishi Chemical for integrated and unified management of naphtha cracker operations in Mizushima, Japan.
- Structural improvement of fertilizer and industrial explosives operations through consolidation with other producers.

“For Tomorrow 2015” strategies

Aiming for leading position in globally competitive businesses

- Acrylonitrile: Serving global demand growth with the construction of cost-competitive plants, aiming for No. 1 position in the world.
- S-SBR: Proactive capacity expansion, aiming for No. 1 position in Asia in the growing fuel-efficient tire market.

Business expansion in growing emerging markets, particularly in Asia

- Performance plastics: Enhancing established position in target markets in Asia.
- Water treatment/membrane businesses: Further reinforcing membrane business, expanding operations in China.
- Duranate™ HDI-based polyisocyanate: Expanding business in Chinese market.
- Ceolus™ microcrystalline cellulose: Major expansion in emerging markets.

Creation of new businesses and business fields as next strategic pillars

- Expansion in healthcare areas (Ceolus™ microcrystalline cellulose, acetonitrile, active pharmaceutical ingredients, etc.)
- Establishment and expansion of new businesses in promising markets.

Fiscal 2010 Review

Sales increased by ¥120.1 billion (19.3%) from a year ago to ¥742.2 billion, and operating income increased by ¥38.3 billion (147.0%) to ¥64.4 billion.

Operating income in chemicals and derivative products operations increased as market prices for acrylonitrile and adipic acid remained high, buoyed by favorable demand in Asia. Operating income in polymer products operations increased as demand recovery in automotive and electronics applications led to greater shipments. Operating income in specialty products operations increased as home-use products such as Saran Wrap™ as well as functional additives and coating materials performed well.

Fiscal 2011 Outlook

We forecast sales to increase and operating income to decrease during fiscal 2011. Although sales of chemicals and derivative products to Asia are forecasted to remain favorable with high market prices, margins are expected to deteriorate due to higher feedstock prices.

Major Investments

Under construction in fiscal 2010

- New power generation facility for use with wood biomass fuel
- New AN and MMA plants in Thailand

R&D

Throughout the Chemicals segment, R&D focused on the environment, resources, and energy is advanced to provide new value to society through the enhancement of our established core technologies and the acquisition of new technologies.

In chemicals and derivative products, we are advancing the verification of two new process technologies to enable feedstock diversification: the "E-flex" process for highly efficient production of propylene using C₂ fractions or bioethanol as feedstock, and the "BB-flex" process to produce butadiene from butane. Studies on their commercialization are in progress. Current projects slated for completion within 1–2 years include the development of new processes to produce diphenyl carbonate (DPC) and isocyanate using CO₂ as feedstock.

In polymer products, current projects include the development of polyamide with ultra-high heat resistance, high rigidity, and excellent moldability using novel molecular

design, the development of modified polyphenylene ether (mPPE) expandable beads with high flame retardance and high heat resistance, as well as the development of new composite materials using interface control technology. Computer-aided engineering (CAE) technology we developed in-house has become an essential element of our R&D capability, and is playing an increasingly significant role in new market development and joint development with customers.

In specialty products, low-cost, safe, and low-waste processes to manufacture active pharmaceutical ingredients (APIs) are under development, utilizing our rich base in process development technology. In the field of membrane separation, the focus is on the development of membranes for the reduction of NO_x emissions from diesel engines as well as for bacteria separation in bioprocess applications. The creation and development of new products and businesses are advancing through the accelerated development of materials for renewable energy and energy conservation, combining technologies not only within the Asahi Kasei Group but also with outside companies.

Highlights

Decision to construct a new solution SBR plant in Singapore

Asahi Kasei Chemicals reached a decision to construct a new plant to produce solution-polymerized styrene-butadiene rubber (S-SBR) in Singapore. With tightening environmental regulations and heightening environmental awareness, demand for high-performance tires which provide improved fuel efficiency is growing throughout the world.



Passenger car tire

Demand for S-SBR which enables the production of tires that provide greater fuel efficiency while maintaining safety performance is therefore growing briskly. With its new S-SBR plant in Singapore, Asahi Kasei Chemicals will meet both the growing demand and heightening customer requirements.

Capacity expansion for acrylonitrile in Korea

In January 2011, Asahi Kasei Chemicals made a decision to construct a large new plant in Korea to expand its production capacity for acrylonitrile (AN), an intermediate chemical for plastic used in consumer electronics. Global demand growth for AN is forecasted to continue, and in April 2011 Asahi Kasei Chemicals also signed an agreement with Saudi Basic

Industries Corp. (SABIC) and Mitsubishi Corp. to establish a joint venture for a project to produce AN in Saudi Arabia.



AN plant in Korea

Homes



The order-built homes business will be expanded with dominant competitiveness as the differentiated market leader in the field of urban unit homes. Housing-related operations will be developed as an array of businesses, building and utilizing their own distinctive strengths.

Masahito Hirai
President, Asahi Kasei Homes



Net sales vs. fiscal 2009
¥409.2 billion +5.0%

Operating income vs. fiscal 2009
¥36.5 billion +43.9%

Financial Highlights

	(¥ billion)			
Fiscal year beginning April 1	2008	2009	2010	2011 forecast
Net sales	¥409.9	¥389.7	¥409.2	¥445.0
Overseas sales ratio	—%	—%	—%	—%
Operating income	21.9	25.3	36.5	42.0
Operating margin	5.3%	6.5%	8.9%	9.4%
R&D expenditure	2.5	2.1	2.0	—
R&D expenditure as % of net sales	0.6%	0.5%	0.5%	—%
Capital expenditure	7.0	6.0	6.3	8.0
Depreciation and amortization	3.4	4.3	4.3	—

“Growth Action – 2010” recap

- Launch of new products: Fine Hebel Haus™, Smart Hebel Haus™, Hebel Haus™ homes featuring electric power generation, Hebel Haus™ Frex “G3”, Hebel Haus™ “i_co_j”, Hebel Haus™ RONDO, Hebel Haus™ with lower living room floor, Hebel Haus™ Frex “monado”, etc.
- Increased promotion with Hebel Haus™ “street-corner showrooms.”
- Establishment of new housing R&D center.
- Development of a new framing system for next-generation energy conservation performance.
- Shared procurement with other home builders.

“For Tomorrow 2015” strategies

Our focus is on enhancing three-story houses and other products which incorporate innovative lifestyle proposals in order to secure the leading position in the urban homes market. We aim provide comfortable living to as many customers as possible, as quickly as possible, based on our commitment to providing fulfillment in living in a mature urban setting.

Houses, apartments

- Establishment of No. 1 position as a differentiated market leader in our competitive fields.
- Promotion of community-specific proposals to increase market share.
- Expansion of multi-dwelling homes business.

Real estate

- Reinforcing condominium business based on obtaining accord in exchange of equivalent value.
- Maximizing utilization of land value through brokerage-related operations.
- Heightening capability to secure tenants.

Expansion of housing-related operations

- Expansion of remodeling and renovation work.
- Enhancement of the energy-conservation product lineup.

Fiscal 2010 Review

Sales increased by ¥19.5 billion (5.0%) from a year ago to ¥409.2 billion and operating income increased by ¥11.1 billion (43.9%) to ¥36.5 billion. Orders for order-built homes increased by ¥47.7 billion to ¥354.5 billion.

Operating income in order-built and pre-built homes operations increased with a rise in orders resulting in greater deliveries of both Hebel Haus™ unit homes and Hebel Maison™ apartment buildings, and with continuous cost reductions. Although our in-house mortgage securitization business was impacted by an increase in the proportion of customers utilizing the “Flat 35” fixed-rate mortgage, remodeling and real estate businesses performed well and operating income in housing-related operations was level with a year ago.

Fiscal 2011 Outlook

With increased deliveries of order-built homes buoyed by a rise in orders, sales and operating income are forecasted to increase in fiscal 2011.


R&D

R&D is focused on enhancing core technologies. Shelter technology brings greater safety and security through earthquake resistance, seismic damping, base isolation, and fire resistance; greater long-term usability through physical durability/evaluation, systematic maintenance, and ease of remodeling; enhanced livability through thermal insulation, air circulation, and sound barrier; and enhanced ecology through energy conservation and reduced CO₂ emissions.


Lifestyle technology brings greater comfort, convenience, and satisfaction.

Evaluation/simulation technology is being enhanced to enable customers to more intuitively appreciate the real-world effects of variations and modifications, ensuring that the design of each home is optimized to match each customer's preferences. Additional research is focused on the physiological and psychological aspects of comfort, and how these can be utilized through technological development to achieve greater energy efficiency and environmental compatibility in homes optimized for health and comfort.

Sales Trends (Asahi Kasei Homes non-consolidated)



Orders Received (Asahi Kasei Homes non-consolidated)



Highlights

Successive launch of products incorporating innovative lifestyle proposals

Asahi Kasei Homes launched several new products that incorporate innovative lifestyle proposals, based on the results of research on urban



Hebel Haus™ i_co_i two-generation home

lifestyle conducted by our Lifestyle R&D Laboratory. In April 2010, we launched Hebel Haus™ “i_co_i” two-generation homes with features to facilitate raising grandchildren. Hebel Haus™ RONDO two-generation homes integrating rental units were launched in July with features to adapt to changing family structure, and Hebel Haus™ with lower living room floor for greater comfort was launched in August.

Launch of Hebel Haus™ Frex “monado”

Asahi Kasei Homes launched Hebel Haus™ Frex “monado” enhanced three-story houses for urban life. Improvements to the frame structure enable the creation of large, open living spaces within confined urban plots, which have many space constraints such as limited area and narrow frontage.



Hebel Haus™ Frex “monado”

Health Care



We are focused on providing the world with innovative new drugs that address unmet medical needs, as a specialized global pharmaceutical company.

Toshio Asano
President, Asahi Kasei Pharma



We are growing as a comprehensive leader in blood-related healthcare systems by providing optimal treatment and preventive therapy based on our unique experience and know-how in blood purification.

Yutaka Shibata
President, Asahi Kasei Kuraray Medical & Asahi Kasei Medical



Net sales vs. fiscal 2009
¥116.4 billion +2.8%

Operating income vs. fiscal 2009
¥7.0 billion +76.1%

Financial Highlights

(¥ billion)				
Fiscal year beginning April 1	2008	2009	2010	2011 forecast
Net sales	¥119.6	¥113.2	¥116.4	¥124.0
Overseas sales ratio	24.4%	22.3%	22.9%	—%
Operating income	12.0	4.0	7.0	8.0
Operating margin	10.1%	3.5%	6.1%	6.5%
R&D expenditure	16.4	18.4	16.5	—
R&D expenditure as % of net sales	13.7%	16.3%	14.2%	—%
Capital expenditure	31.6	9.2	7.4	14.0
Depreciation and amortization	10.3	12.2	11.4	—

“Growth Action – 2010” recap

Pharmaceutical-related:

- Market launch of two new products, Recomodulin™ anticoagulant for disseminated intravascular coagulation and Famvir™ anti-herpes agent.
- Application for approval to manufacture and sell Teribone™ teriparatide acetate as an osteoporosis drug in Japan.
- Acquisition of exclusive rights to develop and sell zoledronic acid as an osteoporosis drug in Japan.
- Acquisition of exclusive rights to develop and market XIAFLEX® collagenase clostridium histolyticum in Japan.
- Divestment of sales and R&D operations for contact lenses and related products.

Medical device-related:

- Capacity expansion for artificial kidneys and Sepacell™ leukocyte reduction filters.
- New plant for therapeutic apheresis devices.
- Capacity expansion for Planova™ virus removal filters in Oita, Japan.
- Integration of dialyzer business with Kuraray Medical Inc.
- Launch of Planova™ BioEX virus removal filters and BioOptimal™ MF-SL microfilters for bioprocessing.
- Acquisition of all shares of Med-tech Inc., making it a wholly owned subsidiary.
- Establishment of sales subsidiaries in China, Taiwan, and Korea.
- Expansion of polysulfone hollow-fiber membrane artificial kidneys business (incl. tie-ups with Kawasumi Laboratories, Inc. and US-based NxStage Medical, Inc.)
- Market entry in bioprocess equipment business (acquisition of business from US-based TechniKrom, Inc.)

Note: XIAFLEX is a registered trademark of Auxilium Pharmaceuticals, Inc.

“For Tomorrow 2015” strategies

Pharmaceutical-related:

In Japan, the primary objective is to increase earnings by fostering the growth of Recomedulin™ and Teribone™ as high-selling drugs. R&D-related investments will be increased to further reinforce the new drug pipeline, and clinical development will be accelerated.

In our main therapeutic field of orthopedics, we are advancing the development of drugs related to locomotive syndrome, including drugs for osteoporosis and rheumatoid arthritis, in order to build a world-leading position in this area.

Overseas, we are entering a new phase as a specialized global pharmaceutical company through the advancement of the clinical development of Recomedulin™ in Europe and the US, as well as reinforcement of our capabilities for clinical development and marketing in East Asia.

In diagnostics, we are reinforcing efforts to further expand the use of Lucica™ GA-L glycosylated albumin assay kit in Japan and to

obtain approval for it overseas, while advancing the development of infectious disease diagnostic kits.

Medical device-related:

We are shifting the focus of our business from individual devices for extracorporeal circulation to blood-related healthcare systems, spanning from disease treatment to preventive medicine and blood-based risk-factor analysis/diagnosis, while further developing business in the fields of regenerative medicine and the nervous system.

Our objective is to achieve a leading position in blood-related healthcare systems, establishing a new value chain of optimal treatment and preventive therapy that leverages our extensive experience and know-how in blood-related healthcare. We will also utilize the comprehensive strengths of the Asahi Kasei Group, increase emphasis on personnel development, and enhance management speed and agility.

Fiscal 2010 Review

Sales increased by ¥3.2 billion (2.8%) from a year ago to ¥116.4 billion and operating income increased by ¥3.0 billion (76.1%) to ¥7.0 billion.

Operating income in pharmaceuticals operations increased as Recomedulin™ recombinant thrombomodulin made a substantial contribution to results, and as shipments of the Flivas™ therapy for benign prostatic hyperplasia increased although NHI price revisions had a negative impact on product prices. Operating income in devices-related operations increased with greater shipments of APS™ polysulfone-membrane artificial kidneys and of therapeutic apheresis devices, although the strong yen had an impact on performance in each product category.

Fiscal 2011 Outlook

The overall sales and operating income for the segment are forecasted to increase. In pharmaceuticals operations, shipments of Recomedulin™ recombinant thrombomodulin are forecasted to increase, but we expect an impact from increased R&D expenses as well as higher selling, general and administrative expenses due to an increase in medical representatives. In devices-related operations, shipments of APS™ polysulfone-membrane artificial kidneys and Planova™ virus removal filters are forecasted to increase.

Major Investments

Completed in fiscal 2010

- New plant for therapeutic apheresis devices
- New plant for Planova™ virus removal filters in Oita, Japan

Under construction in fiscal 2010

- Medical Material Laboratory

R&D

In pharmaceuticals, we are focused on

addressing unmet medical needs, which are increasing together with maturing markets and the aging population, particularly in the fields of orthopedics and urology. To swiftly identify such needs and provide solutions, we are not only searching for new subjects for R&D, but also pursuing continuous proprietary technological innovation and enhanced collaboration with world-leading

technologies. In medical devices and related systems, we are further advancing technological developments in hemodialysis, therapeutic apheresis, leukocyte reduction, and virus removal, while also focusing on next-generation fields of research including regenerative medicine utilizing autohemotherapy.

Pharmaceutical Product Pipeline					(as of May 2011)
Development stage	Code name, form, generic name	Classifications	Indication	Remarks	
Pending approval	MN-10-T, injection, teriparatide acetate	Synthetic human parathyroid hormone (PTH)	Osteoporosis	New chemical entity	
Phase III	AK-120, oral, famciclovir	Antiviral	Herpes simplex	Additional indication	
Phase II	AT-877, oral, fasudil hydrochloride hydrate	Rho-kinase inhibitor	Pulmonary arterial hypertension	Additional indication, new dosage form	
	AK150, injection, pentosan polysulfate sodium	Anti-osteoarthritic	Osteoarthritis	New chemical entity	
Phase II (overseas)	ART-123, injection, recombinant thrombomodulin alpha	Recombinant human thrombomodulin	Sepsis with disseminated intravascular coagulation	New biologic	
	AK106	Anti-inflammatory	Rheumatoid arthritis	New chemical entity	

Highlights

Completion of a new plant for therapeutic apheresis devices

To meet forecasted global demand growth, Asahi Kasei Kuraray Medical constructed a new plant in Oita, Japan, for greater efficiency and productivity in manufacturing therapeutic apheresis devices. Production equipment located in several separate production sections within the existing plant was transferred to the new plant and incorporated into integrated production lines featuring the latest technology. Construction was completed and manufacturing at the new plant began in September 2010. As the world's pioneer in therapeutic apheresis,



New plant for therapeutic apheresis devices

we are accelerating the global growth of this business, pursuing new possibilities for the treatment of autoimmune disorders and intractable diseases which are difficult to treat with conventional therapies, while fulfilling our responsibility for reliable quality and stable supply as the world-leading manufacturer.

Application for approval to manufacture and sell Teribone™ in Japan

Asahi Kasei Pharma filed an application for approval to manufacture and sell Teribone™ (generic name: teriparatide acetate) as an osteoporosis drug in Japan in October 2010. With approval and market launch in 2011, we believe Teribone™ will make a significant contribution to the treatment of osteoporosis, a disease which affects a greater number of people as the population ages.

Fibers



We are proactively expanding unique businesses with growth potential as well as our world-leading businesses, based on the concepts of “harmony with the natural environment” and “living in health and comfort.”

Hidefumi Takai

President, Asahi Kasei Fibers



Net sales

¥108.8 billion

vs. fiscal 2009

+7.5%

Operating income

¥4.2 billion

vs. fiscal 2009

—%

Financial Highlights

(¥ billion)				
Fiscal year beginning April 1	2008	2009	2010	2011 forecast
Net sales	¥116.4	¥101.2	¥108.8	¥113.0
Overseas sales ratio	31.2%	32.7%	34.4%	—%
Operating income (loss)	(1.5)	(2.8)	4.2	4.0
Operating margin	-1.3%	-2.7%	3.9%	3.5%
R&D expenditure	3.9	3.8	3.2	—
R&D expenditure as % of net sales	3.8%	3.8%	2.9%	—%
Capital expenditure	12.4	4.6	3.7	4.5
Depreciation and amortization	5.2	7.7	7.0	—

“Growth Action – 2010” recap

- Capacity expansion for Roica™ spandex in Thailand.
- Establishment of a spunbond manufacturing company in Thailand.
- Establishment of a new technology and R&D center.
- Launch of Precisé™ spunbond nonwovens and deCOB™ environmentally efficient filter bag.
- Closure of polyester filament plant and withdrawal from the field of monofilament.
- Withdrawal from PTT fiber operations.

“For Tomorrow 2015” strategies

Proactive expansion of unique businesses with growth potential as well as world-leading businesses, in accordance with the two perspectives of “harmony with the natural environment” and “living in health and comfort.” Leveraging our strengths as a materials specialist in collaborative projects for the creation of new businesses.

Roica™ elastic polyurethane

- Development and commercialization of new high-function yarns.
- Securing a presence in growing Asian markets, with the plant in Thailand as a key manufacturing base.

Nonwovens

- Spunbond: Earnings growth in Asia with polypropylene spunbond for hygiene materials produced at plant in Thailand, expansion of Precisé™ spunbond nonwovens.
- Bemliese™ cupro cellulosic nonwoven: Securing stable earnings in the IT field in Asia, expansion in the medical and cosmetics fields.
- Lamous™ artificial suede: Steady expansion in Japanese, Europe, and US markets for car seat applications,

development of new applications in industrial fields.

- Eutec™ oil-water separation filter: Establishing niche market leadership in oil-water separation, expansion in applications with microfiltration, as well as in the solid-liquid and gas-liquid separation fields.

Bemberg™ regenerated cellulose

- Expansion in overseas markets for lining, particularly in Europe and China.
- Development and expansion of non-lining applications, including outerwear, innerwear, and beddings in Europe and the US.
- Production processes innovation.

Leona™ nylon 66 filament

- Stable earnings in tire cord applications.
- Expansion in air-bag applications.

Fiscal 2010 Review

Sales increased by ¥7.6 billion (7.5%) from a year ago to ¥108.8 billion and operating income increased by ¥7.0 billion to ¥4.2 billion.

Operations throughout the segment were impacted by the strong yen and high feedstock costs. Operating income from Bemberg™ regenerated cellulose increased with substantially greater shipments in non-lining applications such as innerwear and outerwear. Operating income from Roica™ elastic polyurethane filament increased with growing sales of functional yarns, from nonwovens with growing shipments in disposable diaper applications, and from Leona™ nylon 66 filament with growing shipments in automotive applications.

Fiscal 2011 Outlook

We forecast sales to increase and operating income to decrease slightly during fiscal 2011. Shipments of Roica™, spunbond, and Leona™ filament are expected to

increase, but we anticipate an impact from high feedstock prices.

R&D

In cooperation with other companies within the Asahi Kasei Group as well as with outside companies, we are enriching and enhancing our R&D functions to achieve results more quickly. Development of high-value added grades which meet market needs is advancing for Roica™ polyurethane, Bemberg™ regenerated cellulose, Leona™ nylon 66, and various nonwovens. In addition, the creation of new cellulose-related business and the development of new nonwovens are advancing in accordance with the concepts of “living in health and comfort” and “harmony with the natural environment.”

Highlights

Launch of Pulshut™ – a thin, lightweight noise suppression sheet


Asahi Kasei Fibers launched Pulshut™ as a high-performance noise suppression sheet in August 2010. In recent years, the evolution of electronics products has advanced rapidly, with greater miniaturization and higher performance in terms of speed and capacity, making it increasingly important to suppress the electromagnetic noise generated by the individual components within such

products. Using Precisé™, a specialty nonwoven fabric made with innovative technology, the thin, lightweight Pulshut™ provides a high noise suppression effect across a wide range of frequencies. Its adoption in a wide variety of electronic devices is forthcoming.

Establishment of a spunbond manufacturing company in Thailand

Asahi Kasei Fibers made a decision in

February 2011 to establish Asahi Kasei Spunbond (Thailand) Co., Ltd. as a subsidiary for the manufacture and sale of spunbond nonwovens in Thailand. With two spunbond production sites in Japan (Moriyama, Shiga, and Nobeoka, Miyazaki), Asahi Kasei Fibers has mainly focused on the Japanese market. As China, ASEAN, and other Asian markets continue their remarkable economic development, overseas demand for hygiene materials, particularly for disposable diapers, is forecasted to continue to increase significantly. Asahi Kasei Fibers will study the expansion of spunbond production capacity in Thailand in line with further market growth.



Pulshut™ – a thin, lightweight noise suppression sheet



Electronics



Making the most of our unique technology, we are building our position as a leading supplier of electronic components, which continues to develop and supply category-leading products to the global market, and expand business for all applications based on the trust we have earned from customers throughout the world.

Hideki Kobori

President, Asahi Kasei Microdevices



We are focused on materials that lead to reduced environmental burdens—both materials for energy storage and power generation devices, and electronics-related materials that enable energy conservation—based on our corporate commitment of “contributing to sustainable growth and prosperity, using chemical technology for green electronic materials, enhancing the environmental performance of electronic products.”

Makoto Konosu

President, Asahi Kasei E-materials



Net sales

¥158.3 billion

vs. fiscal 2009

+11.0%

Operating income

¥14.3 billion

vs. fiscal 2009

+96.9%

Financial Highlights

	(¥ billion)			
Fiscal year beginning April 1	2008	2009	2010	2011 forecast
Net sales	¥129.7	¥142.7	¥158.3	¥169.0
Overseas sales ratio	43.4%	46.5%	50.3%	—%
Operating income	7.3	7.2	14.3	15.5
Operating margin	5.6%	5.1%	9.0%	9.2%
R&D expenditure	18.4	18.4	18.4	—
R&D expenditure as % of net sales	20.1%	12.9%	11.6%	—%
Capital expenditure	31.8	22.8	20.3	16.0
Depreciation and amortization	19.8	23.6	23.9	—

“Growth Action – 2010” recap

Electronic devices:

- Expansion of LSI production capacity.
- Incorporation of local marketing subsidiaries in Korea, Europe, China and Taiwan.
- Full-scale entry into power management LSI business by acquisition of semiconductor business from Toko, Inc.
- Launch and expansion of electronic compass business.

Electronic materials:

- Capacity expansion for Hipore™ Li-ion battery separator: plant expansion in Moriyama, Shiga, Japan, and new

plant in Hyuga, Miyazaki, Japan.

- Capacity expansion for dry film photoresist in China.
- Capacity expansion for Pimel™ semiconductor buffer coat.
- New production line for photomask pellicles for 10G LCD panels.
- Establishment of pellicle sales subsidiary in Taiwan, market launch of new pellicle compatible with ArF exposure and capacity expansion for semiconductor pellicles.
- Strategic alliance in optical materials with Luminit, LLC.

“For Tomorrow 2015” strategies

Electronic devices:

Building our position as a leading supplier of electronic components, which continues to develop and supply category-leading products to the global electronic devices market, with a strategic product lineup that makes most of our unique strength in having both silicon semiconductor technology led by world-leading mixed-signal LSI technology, and compound semiconductor technology gained over many years of experience with magnetic sensors. Advancing well-balanced business expansion while maintaining high earnings, through the development and provision of high-quality products with new functions as required in the infrastructure, automotive, and industrial fields, in addition to our established applications in the field of consumer

electronics, including mobile terminal devices.

Electronic materials:

Reducing environmental burdens with “energy materials” for energy storage and power generation devices, and with electronics-related materials that enable energy conservation—based on our corporate commitment of “contributing to sustainable growth and prosperity, using chemical technology for green electronic materials, enhancing the environmental performance of electronic products.” Providing products that support living in health and comfort, including semiconductor process materials, interconnecting and insulation materials for electronics, and materials for information printing and display.

Fiscal 2010 Review

Sales increased by ¥15.6 billion (11.0%) from a year ago to ¥158.3 billion and operating income increased by ¥7.0 billion (96.9%) to ¥14.3 billion.

Operating income in electronic devices operations increased as growth in shipments of LSIs for smartphones and other portable devices, particularly overseas, outweighed a sharp impact from the strong yen. In electronic materials operations, although shipments grew, most notably in Hipore™ Li-ion battery (LIB) separator, operating income decreased slightly with the impact of declining product prices and high feedstock costs.

Fiscal 2011 Outlook

We forecast an increase in both sales and operating income during fiscal 2011. In electronic materials, shipments are projected to increase, but we expect an impact from increased depreciation as a result of capacity expansions and from higher feedstock prices. In electronic devices, shipments of LSIs for smartphones and other portable devices are expected to

increase, but we anticipate an impact from the strong yen.

Major Investments

Completed in fiscal 2010

- New plant for Hipore™ LIB separator in Hyuga

Under construction in fiscal 2010

- Capacity expansion for Hipore™ LIB separator in Hyuga

R&D

Swift R&D to keep pace with the rapid technology innovation of the electronics industry is directed toward the creation of products that meet the emerging needs and demanding requirements which are identified through close interaction with customers.

In electronic devices, advanced development of high-performance products is based on both compound semiconductor process technology gained through development of high-sensitivity magnetic sensors and mixed-signal LSI technology.


Development of new electronic materials which contribute to energy and resource

conservation, reduced environmental burdens, and living in health and comfort is advancing based on our core technologies for polymer design and synthesis, membrane formation, and precision surface processing. Environment and energy-related materials such as high-performance lithium-ion battery materials for both portable electronics and automotive applications, and materials for solar cells are currently under development, as are new materials which correspond to leading technological trends for finer patterning in both semiconductors and printed wiring boards.

Highlights

Development of world's first* surface mount current sensor

Asahi Kasei Microdevices developed the world's first and smallest-class surface mount current sensor with a magnetic core. Current sensors have been mainly used in control systems for industrial equipment. Miniaturization enables their use in a much broader range of applications, including consumer-oriented uses. It is expected that this new current sensor will lead to significantly enhanced energy conservation not only by enabling real-time monitoring of home appliances in smart grid and smart home systems,



World's first* surface mount current sensor

but also by enabling higher-precision and higher-efficiency control of power consumption in energy-saving home appliances.

* Asahi Kasei Microdevices estimate

Capacity expansion for Hipore™

Asahi Kasei E-materials adopted decisions in April and June 2010 to increase production capacity for



Hipore™ LIB separator

Hipore™ LIB separator at its plant in Hyuga, Miyazaki, Japan. In addition to the mainstream applications for notebook computers and mobile phones, Hipore™ is now being used in hybrid electric and all-electric vehicles worldwide. The company has been advancing a program of strategic expansion of its Hipore™ separator business to meet this growing demand in the LIB market.


Construction Materials



We are focused on the development and provision of products that provide safety, security, and comfort, in our core areas of AAC-related products, foundation systems, insulation materials, and structural components.

Hiroshi Kobayashi

President,
Asahi Kasei Construction Materials



Net sales vs. fiscal 2009
¥47.4 billion +0.8%

Operating income vs. fiscal 2009
¥2.1 billion +74.0%

Financial Highlights

(¥ billion)				
Fiscal year beginning April 1	2008	2009	2010	2011 forecast
Net sales	¥60.9	¥47.0	¥47.4	¥54.0
Overseas sales ratio	—%	—%	—%	—%
Operating income	1.7	1.2	2.1	3.5
Operating margin	2.8%	2.6%	4.4%	6.5%
R&D expenditure	1.0	1.1	1.1	—
R&D expenditure as % of net sales	1.7%	2.3%	2.4%	—%
Capital expenditure	2.4	1.2	1.7	4.5
Depreciation and amortization	3.6	3.3	2.8	—

“Growth Action – 2010” recap

- Launch of Jupii™ floor insulation panels for wood-frame houses.
- Start of handling of “Triangle A” fire insurance product for wood-frame homes built with AAC walls.
- Launch of DynaWing™ pre-cast concrete piling system featuring minimal soil disposal and high load-bearing capacity.
- Launch of CSV™ soil improvement system for small-scale architecture, featuring minimal soil disposal and semi-dry application.
- Launch of Freedomut™ system for reinforcement of openings to pass plumbing and wiring through I-beams.
- Opening of “Construction Materials Gallery” to showcase products.
- Reoptimization of AAC production infrastructure: closure of Shiraoi plant and one of two production lines in Hozumi.

“For Tomorrow 2015” strategies

1. Business expansion in fields of competitive superiority

Management resources are focused on businesses where we can exert our strengths in markets which are growing in step with ongoing changes, such as heightening environmental awareness and a society-wide transformation to longer-lasting, more sustainable infrastructure.

2. Transformation to solution-oriented business

A transformation of business is advancing to effect a shift from simply selling products to a more solution-oriented configuration encompassing peripheral fields and including systems and combination products.

AAC-related:

Enhancing cost competitiveness while pursuing further efficiency, in order to maintain stable profitability. Strengthening business for Hebel Powerboard™ AAC panels for wood-frame houses by expanding related businesses including painting. Utilizing our superior technology to reinforce the exterior renovation business targeting the extensive number of houses built with our AAC panels.

Foundation systems:

Expanding business by further reinforcement in fields other than homes and buildings, including transportation infrastructure and

seismic reinforcement, centered on competitive Eazet™ and ATT Column™ small-diameter steel-pipe piling systems.

Insulation materials:

Expanding business centered on our two phenolic foam insulation panel products, Neoma™ and Jupii™, whose competitiveness is further increasing with the growing adoption of next-generation standards for insulation performance in energy-efficient homes.

Structural materials:

Expanding business by reinforcing the product lineup with both new products and new variations of current products.

Fiscal 2010 Review

Sales increased by ¥0.4 billion (0.8%) from a year ago to ¥47.4 billion and operating income increased by ¥0.9 billion (74.0%) to ¥2.1 billion.

Although operating costs in housing and building materials operations were reduced, operating income decreased with fewer shipments of Hebel™ autoclaved aerated concrete panels. Operating income in foundation system operations increased with growing shipments of Eazet™ and ATT Column™ small-scale piles in new applications. Operating income in insulation materials operations increased as shipments of Neoma™ phenolic foam insulation panels grew substantially, supported by government policy such as the eco-point program for energy conservation. Operating income in

structural materials operations increased with growing shipments of the BasePack™ earthquake-resistant column base attachment system.

performance foundation systems, as well as on the proactive development of new products in peripheral areas.

Fiscal 2011 Outlook

We forecast an increase in sales and operating income during this fiscal year, thanks to continuing cost reductions in housing and building materials, an expansion of housing materials business, and increased shipments in foundation systems and insulation materials.

R&D

R&D is focused on strengthening the operational base for established businesses of AAC, phenolic foam insulation, and high-

Highlights

Launch of Jupii™ floor insulation panels for wood-frame houses

Asahi Kasei Construction Materials launched Jupii™ high-performance phenolic foam insulation panels for floors of wood-frame houses in October 2010. The new panels enable wood-frame houses to meet the performance standards specified in preferential policies for energy efficient

homes, including for long-life quality housing and the eco-point system for housing, without any structural modification. The company is focused on making further growth in insulation materials, positioning Jupii™ as a new flagship product together with its Neoma™ foam panels.



Jupii™ phenolic foam insulation panels for wood-frame houses

Others

Net sales
¥16.0 billion vs. fiscal 2009
-9.2%

Operating income
¥1.7 billion vs. fiscal 2009
-6.4%

Financial Highlights

	(¥ billion)			
Fiscal year beginning April 1	2008	2009	2010	2011 forecast
Net sales	¥27.3	¥17.6	¥16.0	¥19.0
Overseas sales ratio	20.9%	10.9%	7.5%	—%
Operating income	5.6	1.8	1.7	2.0
Operating margin	20.6%	10.3%	10.7%	10.5%
R&D expenditure	0.09	0.21	0.28	—
R&D expenditure as % of net sales	0.3%	1.2%	1.7%	—%
Capital expenditure	1.1	0.9	1.0	0.5
Depreciation and amortization	0.8	0.8	0.9	—

Fiscal 2010 Review

Sales decreased by ¥1.6 billion (9.2%) from a year ago to ¥16.0 billion and operating income decreased by ¥0.1 billion (6.4%) to ¥1.7 billion.

Operating income in engineering operations decreased as a curtailment of capital investments led to a decline in orders received.

R&D

Engineering developments in progress include technology to inspect for internal pipe corrosion as well as a joint project for the development of high-performance inspection equipment.

Fiscal 2011 Outlook

Overall sales and operating income are forecasted to increase in fiscal 2011 thanks to firm performance in engineering operations.

Toward Sustainable Growth

Contents

- 32 Corporate Governance
- 36 Corporate Social Responsibility
- 38 Directors, Corporate Auditors, Executive Officers

Corporate Governance

Basic Concept for Corporate Governance

We believe that constant effort to increase the efficiency and transparency of management is essential for continuous enhancement of the corporate value of the Asahi Kasei Group. One major reform for this purpose was the adoption of the structure of a holding company and core operating companies, since which time the Asahi Kasei Group has exercised corporate governance for the Group based on the following two principles.

1) Based on the structure of a holding company and core operating companies, the core operating companies are responsible for business execution and the holding company is responsible for oversight.


2) The Group Approval Authority Regulations are positioned as the highest ranking among all the regulations governing the overall Group for decision-making in executing business. Authority is distributed to each organ of the holding company and the core operating companies in accordance with the degree of influence on management.

In this context, corporate governance is further enhanced by implementing various measures, including the election of multiple Outside Directors and the institutionalization of Internal Auditing and Internal Control.

We will continue to advance measures to heighten corporate governance for the further enhancement of corporate value.

Structures Related to Management Decision-Making, Execution, and Oversight

Management Configuration (as of March 31, 2011)



Board of Directors

Oversees group management, and deliberates and decides on basic group policy and strategy, and on substantive proposals by the Strategic Management Council. The Chairman of the holding company chairs meetings of the Board of Directors. Meets once or twice per month.

Strategic Management Council

Deliberates and decides on substantive matters relating to the operation of the holding company and of the group. Its decisions are made by the President of the holding company, who chairs meetings of the council, after deliberation by the attending constituent members. Meets twice per month.

Group Advisory Committee

The advisory body to the holding company's Board of Directors. Meets twice per year.

Board of Corporate Auditors

Comprises four Corporate Auditors, two of whom are Outside Corporate Auditors. Corporate Auditors exchange views, deliberate, and decide on substantive matters relating to auditing. Meets at least once per quarter.

We employ an Executive Officer system, under which we have ten Directors, including three Outside Directors, and sixteen Executive Officers, including six who concurrently serve as Director, as well as a Corporate Auditor system, under which we have four Corporate Auditors, including two Outside Corporate Auditors. (as of June 29, 2011)

To help ensure that Directors and Corporate Auditors may perform their duties to the fullest extent, in accordance with Article 426 Paragraph 1 of the Corporation Law our Articles of Incorporation provide for the indemnification of Directors (including former Directors) and Corporate Auditors (including former Corporate Auditors) from liability stipulated in Article 423 Paragraph 1 of the Corporation Law, through resolution of the Board of Directors, within limitations set forth by law or ordinance.

Corporate Governance System

An outline of the corporate governance system of the Asahi Kasei Group is as follows.

- 1) Asahi Kasei Corporation is a holding company and has elected to take the form of a company with a Board of Corporate Auditors.
- 2) Two Outside Directors were elected in June 2007 to enable oversight of the management of the Asahi Kasei Group based on their wealth of experience and broad range of insight, for the further strengthening of the management oversight function of the Board of Directors. Furthermore, an additional Outside Director was installed in June 2008 and the Company currently has three Outside Directors out of ten Directors.
- 3) The company has a Group Advisory Committee as an advisory body to the Board of Directors, enabling the receipt of various advice and recommendations of knowledgeable persons from outside the Company for the benefit of the overall management of the Asahi Kasei Group.
- 4) Internal Auditing serves as the corporate organ for internal audits of the execution of duties in the Asahi Kasei Group in accordance with basic corporate regulations for internal audits. Results of the internal audits conducted by each group staff function are also reported to Internal Auditing, so that all information regarding results of internal audits in the Asahi Kasei Group are centralized at Internal Auditing.
- 5) In accordance with the audit policy adopted by the Board of Corporate Auditors, each Corporate Auditor audits Directors in the discharge of their duties by attending Board of Directors' meetings and examining business performance. Corporate Auditors of the Company and Corporate Auditors of the core operating companies exchange information on a regular basis. Our Corporate Auditors Office has multiple dedicated personnel who, independently from Directors, support the Corporate Auditors in their duties.
- 6) PricewaterhouseCoopers Aarata performs financial audits of the Company and the core operating companies in accordance with the Corporation Law and the Financial Instruments and Exchange Act.
- 7) Company standards stipulate that as a general rule a Director is not to concurrently serve as Director at four or more other companies whose shares are stock-market listed.
- 8) The Company has a performance-linked remuneration system as stated above, and remuneration of Directors is determined by the Board of Directors within the range stipulated therein.

Given the above, the current corporate governance system of the Asahi Kasei Group is considered to be optimum within the formulation of a holding company/core operating company configuration and a company with a Board of Corporate Auditors.

Audits

Internal Auditing is a corporate organ under the direct authority of the President of the holding company. Each year, Internal Auditing prepares plans for an internal audit in accordance with basic corporate regulations for internal audits, obtains the President's approval for these plans, and then performs the internal audit.

In accordance with the audit policy adopted by the Board of Corporate Auditors, each Corporate Auditor attends meetings of the Board of Directors and audits Directors in the discharge of their duties through examination of business performance. The Corporate Auditors Office provides staff to support Corporate Auditors in their duties.

PricewaterhouseCoopers Aarata is contracted as the Independent Auditors to perform financial audits in accordance with the Companies Act and Financial Instruments and Exchange Act. Partners of the

Independent Auditors designated to perform the audit for fiscal 2010 were Mr. Katsunori Sasayama and Mr. Keiichi Otsuka. The Independent Auditors form a team of assistants for performance of the audit in accordance with its audit plan. The team mainly comprises certified public accountants and junior accountants, and also includes certified information systems accountants and other specialist accountants.

Internal Auditing, the Board of Corporate Auditors, and the Corporate Auditors of core operating companies and other subsidiaries regularly meet to confirm the effectiveness of internal governance systems for legal compliance and risk management. The Board of Corporate Auditors provides counsel to the Independent Auditors with respect to its audit plan, and receives the results of the consolidated financial audit of Asahi Kasei each quarter and each fiscal year.

Adoption of Shareholder Rights Plan

The Asahi Kasei Group has established a basic corporate policy concerning the nature of parties who would control the company's financial and operational decisions. The adoption of a Shareholder Rights Plan, comprising measures in response to large acquisition of shares to prevent control of the company's financial and operational decisions by inappropriate parties in light of this basic corporate policy, was approved at the Ordinary General Meeting of Shareholders held in June 2008. Furthermore, renewal of the Shareholder Rights Plan was approved at the Ordinary General Meeting of Shareholders held in

June 2011.

The purpose of the Shareholder Rights Plan is to secure and heighten the company's corporate value and the common interest of shareholders in the event of a purchase of 20% or more of the company's shares, by ensuring necessary and sufficient information and time for shareholders to make proper judgment, by obtaining an opportunity to negotiate with the purchasing party, and otherwise. Please refer to the relevant news release at <http://www.asahi-kasei.co.jp/asahi/en/news/2011/e110511.html> for more details.

Compliance

Corporate Ethics

Our *Corporate Ethics – Basic Policy and Code of Conduct* is the standard and guide for ethical conduct throughout the day-to-day work of each and every member of the Asahi Kasei Group. It has been translated into English and Chinese, and it or an equivalent standard applies to all majority-held subsidiaries the world over.

Protection of Personal Information

Asahi Kasei is committed to the proper handling and use of personal information, in accordance with our basic policy. Education and training for all employees, including the distribution of an information security handbook which covers issues related to personal information protection, is monitored by the Corporate Ethics Committee.

Information Disclosure Policy

The Asahi Kasei Group has established an Information Disclosure Policy, enhancing the management and disclosure of corporate information to obtain greater corporate value. Corporate regulations for information disclosure based on this policy were adopted on July 1, 2008. The basic principles of the Information Disclosure Policy are shown below.

- With our Group Mission of “contributing to life and living for people around the world,” we hold “progressing in concert with society, and honoring the laws and standards of society as a good corporate citizen” as a Guiding Precept. “Ensuring transparency” is a
- fundamental element of our *Corporate Ethics – Basic Policy*. We proactively engage in information disclosure and communication based on these basic concepts.
- Corporate information is disclosed fairly, impartially, accurately, and as swiftly as possible to stakeholders such as customers, suppliers, shareholders, investors, employees, and local communities, and to the general public.
- In our communication with stakeholders and with the general public, we strive for dialog which fosters a relationship of trust, promoting greater understanding of the Asahi Kasei Group and its operations, to increase brand strength and heighten corporate value.

Compliance Monitoring by the Corporate Ethics Committee

Monitoring of compliance and oversight of education and training for compliance throughout the Asahi Kasei Group are performed by the Corporate Ethics Committee, which was formed in July 1998. Where shortcomings are discovered, the committee formulates and implements measures for improvement.

The committee discusses the training programs implemented at each group company, measures for prevention of sexual harassment, environmental countermeasures, the state of compliance with laws and regulations including personal information protection law, and operation of the Compliance Hotline.

Risk Management

The Asahi Kasei Group has a Risk Management Committee under its CSR Council to enhance the risk management system for prevention of operational crises and minimization of the effects should a crisis occur. Our Basic Risk Management Regulations, which were established by the Board of Directors in March 2007 (effective April 1, 2007), provide clear guidelines to heighten the capability and effectiveness for risk management and emergency response throughout the Asahi Kasei Group.

In June 2010, the Risk Management Committee introduced a Safety Confirmation System throughout the Asahi Kasei Group. Using this system, the safety of over 90% of our personnel was confirmed within two days after

the Great East Japan Earthquake of March 2011. In addition, the Asahi Kasei Group established an Emergency Disaster Response Headquarters to coordinate additional efforts to confirm the safety of personnel and collect information regarding the state of damage to our facilities. It also distributed emergency provisions to personnel who were unable to return home, and delivered relief supplies to the affected operating bases. In support of the people in the areas damaged by the earthquake and tsunami, the Asahi Kasei Group made a donation of ¥100 million and 500,000 rolls of Saran Wrap™ cling film, and delivered 60,000 boxes of Ziploc™ storage bags and 60,000 Ziploc™ freezer bags.

CSR at the Asahi Kasei Group


CSR in Action

We believe that CSR is achieved by raising corporate value for our various stakeholders through our business operations in accordance with our Group Mission of contributing to life and living for people around the world.

CSR Fundamentals

Based on a clear understanding of the effects of our operations on the global environment and the global community, our efforts and actions related to CSR are focused on four CSR Fundamentals: Compliance, Respect for Employee Individuality, Responsible Care*, and Corporate Citizenship.

Asahi Kasei Group CSR




* Responsible Care represents the commitment and initiative to secure and improve safety and environmental protection at every step of the product life-cycle through the individual determination and responsibility of each firm producing and handling chemical products. As of October 2010, fifty-four countries throughout the world have a Responsible Care program.

Framework for Advancement

The CSR Council, formed in April 2005 with the holding company President serving as chair, formulates CSR policy and guides the CSR effort throughout the Asahi Kasei Group. At the same time, it monitors specific CSR

initiatives implemented by its seven committees, including the Corporate Ethics Committee to ensure regulatory compliance and the Responsible Care Committee to guide efforts for environment, health, and safety.



Highlight

The Asahi Kasei Group is proactively involved in activities to preserve biodiversity as a founding member of the International Partnership for the *Satoyama* Initiative (IPSI), which was established at COP10 held in October 2010.

As part of this initiative, the Nobeoka Power Supply Dept. of Asahi Kasei Chemicals is advancing a project for

the sustainable utilization of the forest resources of the Gokase River watershed area as biomass fuel for power generation at a new power plant currently under construction. The sustainable utilization of forest resources in this way is expected to make a significant contribution to the preservation of biodiversity in the area.



Directors, Corporate Auditors, Executive Officers

(As of June 29, 2011)



Ichiro Itoh

Chairman &
Representative Director



Taketsugu Fujiwara

President & Representative Director
Presidential Executive Officer



Koji Fujiwara

Director
Primary Executive Officer



Yasuyuki Yoshida

Director
Primary Executive Officer



Tsutomu Inada

Director
Senior Executive Officer



Yuji Mizuno

Director
Senior Executive Officer



Masanori Mizunaga

Director
Senior Executive Officer



Yukiharu Kodama

Outside Director



Morio Ikeda

Outside Director



Norio Ichino

Outside Director

Kenji Nakamae

Corporate Auditor

Katsuhiko Yamazoe

Senior Executive Officer

Makoto Konosu

Executive Officer

Shoichiro Tonomura

Executive Officer

Toshiyuki Kawasaki

Corporate Auditor

Ryo Matsui

Lead Executive Officer

Masaki Sakamoto

Executive Officer

Yoshihiro Wada

Executive Officer

Kazuo Tezuka

Outside Corporate Auditor

Toshikatsu Sunami

Lead Executive Officer

Masahito Hirai

Executive Officer

Yuji Aoki

Outside Corporate Auditor

Shinichiro Nei

Lead Executive Officer

Toshio Asano

Executive Officer

Financial Section

Contents

- 40 Consolidated Eleven-Year Summary
- 42 Management's Discussion and Analysis
- 48 Risk Analysis
- 50 Consolidated Balance Sheets
- 52 Consolidated Statements of Income
- 53 Consolidated Statements of Comprehensive Income
- 54 Consolidated Statements of Changes in Net Assets
- 55 Consolidated Statements of Cash Flows
- 56 Notes to Consolidated Financial Statements
- 77 Report of Independent Auditors

Consolidated Eleven-Year Summary

Asahi Kasei Corporation and Consolidated Subsidiaries

For the years ended March 31

	2011	2010	2009 ^d	2008
Net sales	¥1,598,387	¥1,433,595	¥1,553,108	¥1,696,789
Chemicals	742,243	622,093	689,323	879,235
Life & Living ^a	—	—	—	—
Chemical and Chemical-related	—	—	—	—
Chemicals and Plastics	—	—	—	—
Homes	409,224	389,728	409,882	386,227
Housing and Construction Materials	—	—	—	—
Health Care^b	116,387	113,207	119,619	111,232
Fibers^b	108,761	101,201	116,405	114,072
Electronics^b	158,337	142,700	129,655	113,267
Construction Materials	47,418	47,024	60,927	55,732
Special Products and Services	—	—	—	—
Electronics	—	—	—	—
Membranes and Systems	—	—	—	—
Biotechnology and Medical Products	—	—	—	—
Engineering and Others	—	—	—	—
Others^b	16,017	17,642	27,297	37,024
Domestic sales	1,149,098	1,063,186	1,159,143	1,209,452
Overseas sales	449,289	370,409	393,965	487,337
Operating income	122,927	57,622	34,959	127,656
Ordinary income	118,219	56,367	32,500	120,456
Income (loss) before income taxes	98,342	46,056	19,031	105,599
Net income (loss)	60,288	25,286	4,745	69,945
Comprehensive income	45,088	—	—	—
Net income (loss) per share, yen	43.11	18.08	3.39	50.01
Capital expenditure	66,014	83,990	126,725	82,911
Depreciation and amortization	84,092	86,166	79,436	73,983
R&D expenditures	62,320	62,924	60,849	56,170
Cash dividends per share, yen	11.00	10.00	10.00	13.00

As of March 31

	2011	2010	2009	2008
Total assets	¥1,425,879	¥1,368,892	¥1,379,337	¥1,425,367
Inventories	256,248	251,084	273,539	272,372
Property, plant and equipment	418,354	447,497	441,271	424,193
Investments and other assets	220,773	226,331	218,477	234,873
Net worth^c	663,566	633,343	603,846	666,244
Net worth per share, yen	474.59	452.91	431.77	476.39
Net worth/total assets, %	46.5	46.3	43.8	46.7
Number of employees	25,016	25,085	24,244	23,854

a. The Life & Living segment was combined with the Chemicals segment in the year ended March 31, 2008.

b. For continuity, figures for business categories which were renamed are shown on the same line.

• From the year ended March 31, 2004, through the year ended March 31, 2009: Figures shown as Health Care are for the previous Pharma segment, and figures shown as Electronics are for the previous Electronics Materials & Devices segment.

• From the year ended March 31, 2001, through the year ended March 31, 2003: Figures shown as Fibers are those for the previous Fibers and Textiles sector, and figures shown as Others are those for the former Liquors, Services and Others sector.

• From the year ended March 31, 2004, through the year ended March 31, 2010: Figures shown as Others are those for the previous Services, Engineering and Others segment.

c. Net assets less minority interest. Though the year ended March 31, 2006, figures for shareholders' equity shown.

d. For comparison purposes, results for the year ended March 31, 2009, are recalculated to reflect the April 2010 transfer of electronic materials operations from the Chemicals segment and from Corporate Expenses to the Electronics segment, and the April 2010 transfer of Leona™ nylon 66 filament operations from the Chemicals segment to the Fibers segment.

Millions of yen, except where noted

2007	2006	2005 ^e	2004	2003 ^f	2003	2002	2001 ^g	2001
¥1,623,791	¥1,498,620	¥1,377,697	¥1,253,534	¥1,193,614	¥1,193,614	¥1,195,393	¥1,269,415	¥1,269,415
752,632	660,402	570,182	453,707	424,673	—	—	—	—
52,558	51,942	59,149	59,813	52,908	—	—	—	—
—	—	—	—	—	477,581	440,698	449,470	—
—	—	—	—	—	—	—	—	430,934
405,695	404,539	375,755	361,273	320,553	—	—	—	—
—	—	—	—	—	383,654	408,474	433,440	433,440
104,474	105,842	103,933	105,965	105,463	105,463	98,686	95,481	—
106,639	89,704	91,518	101,514	110,551	110,551	125,908	134,791	134,791
112,094	102,859	93,024	82,484	71,579	71,579	64,062	95,999	—
60,818	56,512	59,908	60,622	63,101	—	—	—	—
—	—	—	—	—	—	—	—	270,250
—	—	—	—	—	—	—	—	96,228
—	—	—	—	—	—	—	—	18,307
—	—	—	—	—	—	—	—	95,481
—	—	—	—	—	—	—	—	60,234
28,881	26,821	24,228	28,156	44,786	44,786	57,565	60,234	—
1,195,751	1,125,454	1,067,893	1,011,366	981,064	981,064	1,006,810	1,086,219	1,086,219
428,040	373,166	309,804	242,168	212,550	212,550	188,583	183,196	183,196
127,801	108,726	115,809	60,932	61,555	61,555	45,664	96,024	96,024
126,507	104,166	112,876	53,643	50,389	50,389	39,849	86,747	86,747
114,883	94,481	91,141	54,820	(100,869)	(100,869)	10,679	50,318	50,318
68,575	59,668	56,454	27,672	(66,791)	(66,791)	5,180	25,177	25,177
—	—	—	—	—	—	—	—	—
49.00	42.46	40.16	19.62	(47.63)	(47.63)	3.61	17.45	17.45
84,413	66,310	68,479	86,387	93,985	93,985	74,826	69,188	69,188
71,646	69,399	71,531	64,408	60,808	60,808	60,676	62,222	62,222
52,426	51,467	50,715	48,420	49,311	49,311	49,574	49,768	49,768
12.00	10.00	8.00	6.00	6.00	6.00	6.00	6.00	6.00

2007	2006	2005	2004	2003	2003	2002	2001	2001
¥1,459,922	¥1,376,044	¥1,270,057	¥1,249,206	¥1,212,374	¥1,212,374	¥1,193,011	¥1,240,008	¥1,240,008
240,006	214,062	202,521	181,609	176,788	176,788	180,826	196,510	196,510
426,959	414,368	419,969	428,302	427,188	427,188	415,193	419,168	419,168
281,502	284,390	223,958	226,825	198,697	198,697	181,618	176,177	176,177
645,655	594,211	511,726	450,451	407,639	407,639	496,826	516,013	516,013
461.50	424.34	365.43	321.41	290.92	290.92	353.16	357.70	357.70
44.2	43.2	40.3	36.1	33.6	33.6	41.6	41.6	41.6
23,715	23,030	23,820	25,011	25,730	25,730	26,227	26,695	26,695

e. For comparison purposes, results for the year ended March 31, 2005, are recalculated to reflect the April 2005 transfer of Leona™ nylon 66 filament operations from the Fibers segment to the Chemicals segment.

f. For comparison purposes, results by business category for the year ended March 31, 2003, are recalculated in accordance with the revised categories for the year ended March 31, 2004, which are aligned with the core operating companies in the holding company configuration adopted on October 1, 2003.

- The "fabricated home products" segment of the Chemical and Chemical-related sector is separated to an independent Life & Living segment. The remainder of the Chemical and Chemical-related sector is reclassified as the Chemicals segment.
- The Housing and Construction Materials sector is separated into the Homes segment and the Construction Materials segment.
- The Fibers and Textiles sector is renamed the Fibers segment.
- With the divestment of liquors operations, the Liquors, Services and Others sector is renamed the Services, Engineering and Others segment.

g. For comparison purposes, results by business category for the year ended March 31, 2001, are recalculated in accordance with the revised categories for the year ended March 31, 2002.

- Operations of the "membranes and systems" segment combine with the Chemicals and Plastics sector to form the Chemical and Chemical-related sector.
- The "electronics" segment is reclassified as the Electronics sector.
- Operations of the "biotechnology and medical products" segment are reclassified as the Health Care sector.
- The remaining operations comprise the Liquors, Services and Others sector, in place of the "engineering and others" segment.

Management's Discussion and Analysis

Fiscal year 2010 (April 1, 2010 – March 31, 2011)

Overview of Fiscal 2010 Consolidated Results

Operating environment

The Japanese economy was recovering in the first half as corporate performance improved with the effect of government stimulus measures and thanks to economic recovery in emerging markets. In the second half, however, the economy was severely affected by the rapid rise of the yen, a decline in automotive sales due to the expiration of government subsidies for fuel-efficient vehicles, high feedstock prices driven by political unrest in North Africa and the Middle East, and the impact of the Great East Japan Earthquake, resulting in uncertainty regarding the economic outlook.

Net sales, operating income

Consolidated net sales for the fiscal year increased by ¥164.8 billion (11.5%) from a year ago to ¥1,598.4 billion. Overseas sales increased, largely in Chemicals, by ¥78.9 billion (21.3%) to ¥449.3 billion, and increased by 2.3 percentage points as a portion of consolidated net sales from 25.8% to 28.1%. Domestic sales increased by ¥85.9 billion (8.1%) to ¥1,149.1 billion with high feedstock prices as well as high market prices buoyed by robust demand in the Chemicals segment.

Operating income increased by ¥65.3 billion (113.3%) to ¥122.9 billion. As a percentage of net sales, cost of sales increased by 2.1 percentage points to 74.7%, largely due to improved operating rates driven by demand recovery. SG&A increased by ¥6.5 billion, but decreased as a percentage of net sales by 1.6 percentage points to 17.6% due to the large increase in sales. Operating margin increased by 3.7 percentage points to 7.7%.

Non-operating income and expenses, ordinary income

Net non-operating expenses were ¥4.7 billion, ¥3.5 billion higher than the ¥1.3 billion of a year earlier, largely due to an increase in foreign exchange loss and the occurrence of litigation related expenses, although equity in earnings of affiliates increased. As a result, ordinary income increased by ¥61.9 billion (109.7%) to ¥118.2 billion.

Extraordinary income and loss


Extraordinary losses of ¥21.6 billion included ¥10.0 billion in business structure improvement expenses and a ¥4.9 billion loss on disposal of noncurrent assets. Combined with extraordinary income, the net extraordinary loss was ¥19.9 billion, ¥9.6 billion higher than a year earlier.

Net income

With ordinary income of ¥118.2 billion and the net extraordinary loss of ¥19.9 billion, income before income taxes was ¥98.3 billion. Income tax expense was ¥36.7 billion (current income taxes of ¥39.6 billion less deferred income taxes of ¥3.0 billion). Minority interests in income of consolidated subsidiaries was ¥1.4 billion. As a result, net income increased by ¥35.0 billion (138.4%) to ¥60.3 billion, and net income per share increased by ¥25.03 to ¥43.11 from the ¥18.08 of a year earlier.


Net Sales, Overseas Sales Ratio

(¥ billion) (%)




Operating Income, Operating Margin

(¥ billion) (%)




SG&A, SG&A Ratio

(¥ billion) (%)



Net Income, Net Income per Share

(¥ billion) (¥)



Results by Operating Segment

Beginning in fiscal 2010, Accounting Standard for Disclosures about Segments of an Enterprise and Related Information issued by the Accounting Standards Board of Japan (ASBJ Statement No. 17) and Guidance on Accounting Standard for Disclosures about Segments of an Enterprise and Related Information (ASBJ Guidance No. 20) have been applied, resulting in six reporting segments: Chemicals, Homes, Health Care, Fibers, Electronics, and Construction Materials.

In describing the state of the Asahi Kasei Group's businesses by major business classification, businesses not included in the above six reporting segments are categorized as "Others." The "Others" category is equivalent to the previous Services, Engineering and Others segment, including plant engineering and environmental engineering, research and analysis, and employment agency/staffing operations.

The operating expenses of one consolidated subsidiary previously included in Services, Engineering and Others have been included in "corporate expenses" beginning in fiscal 2010. The impact of this is immaterial.

Chemicals

Sales increased by ¥120.1 billion (19.3%) from a year ago to ¥742.2 billion and operating income increased by ¥38.3 billion (147.0%) to ¥64.4 billion.

Operating income in chemicals and derivative products operations increased as market prices for acrylonitrile and adipic acid remained high, buoyed by favorable demand in Asia. Operating income in polymer products operations


increased as demand recovery in automotive and electronics applications led to greater shipments. Operating income in specialty products operations increased as home-use products such as Saran Wrap™ as well as functional additives and coating materials performed well.

Homes


Sales increased by ¥19.5 billion (5.0%) from a year ago to ¥409.2 billion and operating income increased by ¥11.1 billion (43.9%) to ¥36.5 billion. Orders for order-built homes increased by ¥47.7 billion to ¥354.5 billion.

Operating income in order-built and pre-built homes operations increased with a rise in orders resulting in greater deliveries of both Hebel Haus™ unit homes and Hebel Maison™ apartment buildings, and with continuous cost reductions. Although our in-house mortgage securitization business was impacted by an increase in the proportion of customers utilizing the "Flat 35" fixed-rate mortgage, remodeling and real estate businesses performed well and operating income in housing-related operations was level with a year ago.


ROE



Chemicals



Homes



Health Care

Sales increased by ¥3.2 billion (2.8%) from a year ago to ¥116.4 billion and operating income increased by ¥3.0 billion (76.1%) to ¥7.0 billion.

Operating income in pharmaceuticals operations increased as Recomodulin™ recombinant thrombomodulin made a substantial contribution to results, and as shipments of the Flivas™ therapy for benign prostatic hyperplasia increased although NHI price revisions had a negative impact on product prices. Operating income in devices-related operations increased with greater shipments of APS™ polysulfone-membrane artificial kidneys and of therapeutic apheresis devices, although the strong yen had an impact on performance in each product category.

Fibers

Sales increased by ¥7.6 billion (7.5%) from a year ago to ¥108.8 billion and operating income increased by ¥7.0 billion to ¥4.2 billion.

Operations throughout the segment were impacted by the strong yen and high feedstock costs. Operating income from Bemberg™ regenerated cellulose increased with substantially greater shipments in non-lining applications such as innerwear and outerwear. Operating income from Roica™ elastic polyurethane filament increased with growing sales of functional yarns, from nonwovens with growing shipments in disposable diaper applications, and from Leona™ nylon 66 filament with growing shipments in automotive applications.

Electronics

Sales increased by ¥15.6 billion (11.0%) from a year ago to ¥158.3 billion and operating income increased by ¥7.0 billion (96.9%) to ¥14.3 billion.

Operating income in electronic devices operations increased as growth in shipments of LSIs for smartphones and other portable devices, particularly overseas, outweighed a sharp impact from the strong yen. In electronic materials operations, although shipments grew, most notably in Hipore™ Li-ion battery separator, operating income decreased slightly with the impact of declining product prices and high feedstock costs.

Construction Materials


Sales increased by ¥0.4 billion (0.8%) from a year ago to ¥47.4 billion and operating income increased by ¥0.9 (74.0%) billion to ¥2.1 billion.

Although operating costs in housing and building materials operations were reduced, operating income decreased with fewer shipments of Hebel™ autoclaved aerated concrete panels. Operating income in foundation system operations increased with growing shipments of Eazet™ and ATT Column™ small-scale piles in new applications. Operating income in insulation materials operations increased as shipments of Neoma™ phenolic foam insulation panels grew substantially, supported by government policy such as the eco-point program for energy conservation. Operating income in structural materials operations increased with growing shipments of the BasePack™ earthquake-resistant column base attachment system.

Health Care

(¥ billion) (¥ billion)

150 20




■ Net sales, left scale
■ Operating income, right scale
— Operating margin (%)

Fibers

(¥ billion) (¥ billion)

150 7.5




■ Net sales, left scale
■ Operating income (loss), right scale
— Operating margin (%)

Electronics

(¥ billion) (¥ billion)

200 30



■ Net sales, left scale
■ Operating income, right scale
— Operating margin (%)

Others

Sales decreased by ¥1.6 billion (9.2%) from a year ago to ¥16.0 billion and operating income decreased by ¥0.1 billion (6.4%) to ¥1.7 billion.

Liquidity and Capital Resources

Financial position

Total assets at fiscal year end were ¥1,425.9 billion, ¥57.0 billion (4.2%) higher than a year earlier.

Current assets increased by ¥95.2 billion (14.4%) to ¥755.7 billion, mainly because cash and deposits increased by ¥46.4 billion and notes and accounts receivable, trade, increased by ¥34.5 billion primarily due to a year-on-year increase in fourth quarter net sales.

Noncurrent assets decreased by ¥38.3 billion (5.4%) to ¥670.2 billion, with property, plant and equipment decreasing by ¥29.1 billion largely because capital expenditure was lower than depreciation and amortization, and with investment securities decreasing by ¥8.7 billion mainly due to decreased fair value.

Current liabilities increased by ¥55.1 billion (12.7%) to ¥489.9 billion, with a ¥15.0 billion increase in notes and accounts payable, trade, a ¥14.9 billion increase in short-term loans payable, and a ¥14.5 billion increase in advances received.

Noncurrent liabilities decreased by ¥29.0 billion (10.0%) to ¥260.4 billion, largely due to a ¥30.2 billion decrease in long-term loans payable.


Interest-bearing debt decreased by ¥10.7 billion to ¥253.9 billion.

Net assets increased by ¥30.9 billion (4.8%) from ¥644.7 billion to ¥675.6 billion. Net income was ¥60.3 billion, and dividend payments were ¥14.0 billion. Foreign currency translation adjustments decreased by ¥9.2 billion, and valuation difference on other securities decreased by ¥7.0 billion. As a result, net worth per share increased by ¥21.68 to ¥474.59, net worth/total assets increased from 46.3% to 46.5%, and debt-to-equity ratio decreased by 0.04 to 0.38.

Construction Materials

(¥ billion) (¥ billion)

90 6




■ Net sales, left scale
■ Operating income, right scale
— Operating margin (%)

Others

(¥ billion) (¥ billion)

40 12




■ Net sales, left scale
■ Operating income, right scale
— Operating margin (%)

Total Assets, Net Worth

(¥ billion)

1,500




■ Total assets
■ Net worth

Net Worth to Total Assets

(%)

50



Capital expenditure

Capital expenditure (capex) was primarily for new and expanded production plant and equipment in long-term growth fields. Investments were also made for rationalization, modification, maintenance, and IT systems to bring greater product reliability and cost reductions.

Capex by operating segment shown below is for property, plant and equipment and intangible assets, combined, before consumption tax.

A total of ¥66.0 billion was invested during the fiscal year for the expansion of businesses with competitive superiority, particularly in the Chemicals and Electronics segments, as well as for modification and rationalization.

	Totals for the year (¥ million)	Compared to previous year (%)
Chemicals	23,174	83.8
Homes	6,304	104.9
Health Care	7,427	81.0
Fibers	3,668	80.5
Electronics	20,267	89.0
Construction Materials	1,684	141.4
Others	981	105.8
Combined	63,505	87.9
Corporate assets and eliminations	2,509	21.4
Consolidated	66,014	78.6

Notable capex by operating segment was as follows.

Chemicals

Rationalization of equipment in Mizushima, other rationalization, labor-saving, and maintenance.

Homes

Leases, rationalization, labor-saving, and maintenance.

Health Care

New molding plant for Planova™ virus removal filters, new plant for therapeutic apheresis devices, rationalization, labor-saving, and maintenance.

Fibers

Rationalization, labor-saving, and maintenance.

Electronics

Capacity expansion for Hipore™ Li-ion battery separator, capacity expansion for LSIs, IT systems, rationalization, labor-saving, and maintenance.

Construction Materials

Rationalization, labor-saving, and maintenance.

Others


Rationalization, labor-saving, and maintenance.

Corporate assets

R&D equipment, IT systems, maintenance.


Interest-Bearing Debt, D/E Ratio

(¥ billion)



Capex, Depreciation and Amortization

(¥ billion)



Cash flows

Free cash flows* were a positive ¥69.3 billion, as cash generated, principally from operating income and depreciation and amortization, exceeded cash used, principally for acquisition of noncurrent assets and acquisition of investment securities. Cash flows from financing activities were a net ¥26.1 billion cash used, principally due to repayment of long-term loans payable. As a result, cash and cash equivalents at fiscal year end were ¥134.4 billion, ¥41.3 billion more than a year earlier.

Cash flows from operating activities

Cash used included a ¥36.5 billion increase in notes and accounts receivable, trade, largely in Chemicals, and ¥25.3 billion in income taxes paid. Income before income taxes generated ¥98.3 billion, and depreciation and amortization generated ¥84.1 billion. Net cash provided by operating activities was ¥148.1 billion, ¥21.2 billion less than a year earlier.

Cash flows from investing activities

Cash used included ¥63.7 billion for purchase of property, plant and equipment for continuing expansion of competitively superior operations and enhancement of overall competitiveness, ¥5.3 billion for purchase of intangible assets, and ¥7.6 billion for purchase of investment securities. Net cash used in investing activities was ¥78.8 billion, ¥21.3 billion less than a year earlier.


Cash flows from financing activities

In addition to ¥11.7 billion of net cash used to reduce interest-


bearing debt, including loans, ¥14.0 billion was used for dividend payments. Net cash used in financing activities was ¥26.1 billion, ¥48.9 less than a year earlier.

* Total of net cash provided by (used in) operating activities and net cash provided by (used in) investment activities.

Free Cash Flows



Cash Flows



Risk Analysis

Operating risks and non-operating risks which may materially influence investor decisions are described below. The management maintains awareness of the possibility that these scenarios may emerge and, to the fullest possible extent, implements measures to avoid their emergence and to minimize their impact on corporate performance in the event that they do emerge.

The description of risks given here includes elements which may emerge in the future, but as it is based on current evaluations at the time of preparation of this report, it does not include risks which could not be foreseen.

Crude oil and naphtha prices

Operating costs in operations based on petrochemicals are affected by prices for crude oil and naphtha. If crude oil and naphtha prices rise, selling prices for products derived from these feedstocks must be increased in a timely manner to maintain sufficient price spreads. Price spreads may diminish, thereby affecting our consolidated performance and financial condition.

Exchange rate fluctuation

Operations based overseas maintain accounts in the local currency where they operate. The yen value of items carried in these accounts is affected by the rate of exchange at the time of conversion to yen. Although measures such as currency exchange hedges are utilized to minimize the short-term effects of exchange rate fluctuations, such fluctuations may exceed the foreseeable range over the short to long term, thereby affecting our consolidated performance and financial condition.

Overseas operations

Overseas operations may face a variety of risks which cannot be foreseen, including the existence or emergence of economically unfavorable circumstances due to legal and regulatory changes, vulnerability of infrastructure, difficulty in hiring/retaining qualified employees, or other factors, and social or political instability due to terrorism, war, or other factors. Overseas operations may be impaired by such scenarios, thereby affecting our consolidated performance and business plans.

Housing-related tax policy, interest rate fluctuation

Operations in the Homes segment are affected by Japanese tax policies as they relate to home acquisition and by fluctuations in Japanese interest rates. Changes in Japanese tax policy, including consumption taxes, or fluctuations in Japanese interest rates may result in diminished housing demand, thereby affecting our consolidated performance and financial condition.

Profitability of electronics-related businesses

The electronics industry is characterized by sharp market cycles. The profitability of electronics-related businesses may decline significantly in a relatively short time, thereby affecting our consolidated performance and financial condition. Because products in this field rapidly become obsolete, the timely development and commercialization of leading-edge devices and materials is required. New product development may be delayed, or demand fluctuations may exceed expectations, thereby affecting our consolidated performance and financial condition.

Pharmaceuticals and medical devices

Pharmaceutical and medical device businesses may be significantly affected by government measures to curtail health care expenditure or other changes in government policy. Unforeseeable side effects or complications may emerge, significantly affecting these businesses. The pharmaceutical business additionally faces the possibility that product approval may be withdrawn as a result of Japan's reexamination system, and that competition may

intensify as a result of the market entry of generics. For pharmaceuticals and medical devices under development, regulatory approval may fail to be obtained, market demand may be lower than expected, and the national reimbursement prices may be lower than expected. Such scenarios may affect our consolidated performance and financial condition.

Industrial accidents and natural disasters

The occurrence of a significant industrial accident or natural disaster at a plant or elsewhere may result in a loss of public trust, the emergence of costs associated with accident response, including compensation, and opportunity loss due to plant shutdown caused by damage to plant facilities, supply chain disruptions which impede raw materials procurement, etc., thereby affecting our consolidated performance and financial condition.

Intellectual property, product liability, and legal regulation

An unfavorable ruling may emerge in a dispute relating to intellectual property, a product defect resulting in a large-scale recall and compensation whose costs exceed insurance coverage may emerge, and detrimental legal and regulatory changes may emerge in any country where we operate. Such scenarios may affect our consolidated performance and financial condition.

Irrecoverable credits

Credits extended to customers may become irrecoverable to an unforeseeable extent, necessitating additional losses or allowances to be recorded in financial accounts, and thereby affecting our consolidated performance and financial condition.

Consolidated Balance Sheets

Asahi Kasei Corporation and Consolidated Subsidiaries
March 31, 2011 and 2010

ASSETS	Millions of yen		Thousands of U.S. dollars (Note 1)
	2011	2010	2011
Current assets:			
Cash and deposits (Notes 9 and 11)	¥ 140,319	¥ 93,928	\$ 1,690,589
Notes and accounts receivable, trade	273,414	238,931	3,294,144
Short-term investment securities (Notes 9, 11 and 12)	371	985	4,472
Merchandise and finished goods	129,898	124,557	1,565,031
Work in progress	76,551	75,044	922,300
Raw materials and supplies	49,799	51,484	599,990
Deferred tax assets—current (Note 15)	23,131	23,106	278,689
Other	63,240	54,027	761,930
Allowance for doubtful accounts	(1,072)	(1,654)	(12,921)
Total current assets	755,651	660,408	9,104,224
Noncurrent assets:			
Property, plant and equipment			
Buildings and structures (Note 5(b), (d))	409,263	404,974	4,930,883
Accumulated depreciation	(231,474)	(224,608)	(2,788,847)
Buildings and structures, net	177,789	180,366	2,142,036
Machinery, equipment and vehicles (Note 5(b), (d))	1,192,132	1,169,979	14,363,040
Accumulated depreciation	(1,047,912)	(1,005,094)	(12,625,447)
Machinery, equipment and vehicles, net	144,220	164,885	1,737,593
Land (Note 5(d))	55,243	55,031	665,580
Lease assets (Note 10)	8,581	5,808	103,383
Accumulated depreciation	(3,118)	(1,132)	(37,561)
Lease assets, net	5,463	4,676	65,822
Construction in progress	22,173	27,380	267,140
Other (Note 5(b), (d))	118,718	115,024	1,430,339
Accumulated depreciation	(105,252)	(99,867)	(1,268,097)
Other, net	13,466	15,158	162,242
Subtotal	418,354	447,497	5,040,413
Intangible assets			
Goodwill	5,087	5,927	61,287
Other	26,015	28,729	313,429
Subtotal	31,101	34,656	374,715
Investments and other assets			
Investment securities (Notes 5(a), 11 and 12)	166,317	175,059	2,003,822
Long-term receivable (Note 11)	5,181	6,074	62,416
Deferred tax assets—noncurrent (Note 15)	22,005	15,383	265,122
Other	27,507	29,962	331,404
Allowance for doubtful accounts	(237)	(147)	(2,851)
Subtotal	220,773	226,331	2,659,913
Total noncurrent assets	670,228	708,485	8,075,042
Total assets	¥ 1,425,879	¥ 1,368,892	\$ 17,179,265

The accompanying notes are an integral part of these statements.

LIABILITIES AND NET ASSETS	Millions of yen		Thousands of U.S. dollars (Note 1)
	2011	2010	2011
Liabilities:			
Current liabilities:			
Notes and accounts payable, trade (Note 11)	¥ 136,407	¥ 121,409	\$ 1,643,461
Short-term loans payable (Notes 5(b), 11 and 21)	108,889	93,962	1,311,915
Commercial paper (Notes 11 and 21)	23,000	19,000	277,108
Lease obligations (Notes 10, 11 and 21)	1,522	1,123	18,333
Income taxes payable (Note 11)	24,085	12,160	290,183
Accrued expenses	97,745	91,371	1,177,649
Advances received	52,346	37,815	630,680
Provision for periodic repairs	3,239	8,191	39,021
Provision for product warranties	2,465	3,607	29,701
Asset retirement obligations (Notes 3(b) and 17)	512	—	6,164
Other	39,668	46,189	477,928
Total current liabilities	489,878	434,827	5,902,143
Noncurrent liabilities:			
Bonds payable (Notes 11 and 21)	25,000	25,000	301,205
Long-term loans payable (Notes 5(b), 11 and 21)	91,722	121,921	1,105,090
Lease obligations (Notes 10 and 11)	3,802	3,593	45,812
Deferred tax liabilities (Note 15)	6,374	7,597	76,794
Provision for retirement benefits (Note 14)	107,309	109,450	1,292,878
Provision for directors' retirement benefits	1,119	1,225	13,486
Provision for periodic repairs	2,131	169	25,679
Asset retirement obligations (Notes 3(b) and 17)	3,316	—	39,957
Long-term guarantee deposited (Note 11)	18,340	18,321	220,966
Other	1,284	2,101	15,468
Total noncurrent liabilities	260,399	289,378	3,137,336
Total liabilities	750,277	724,204	9,039,479
Net assets:			
Shareholders' equity			
Capital stock			
Authorized—4,000,000,000 shares			
Issued and outstanding—1,402,616,332 shares	103,389	103,389	1,245,645
Capital surplus	79,402	79,403	956,656
Retained earnings (Note 8(b)(ii))	478,681	432,114	5,767,244
Treasury stock (2011—4,420,688 shares, 2010—4,228,468 shares)	(2,115)	(2,017)	(25,481)
Total shareholders' equity	659,357	612,888	7,944,064
Accumulated other comprehensive income			
Valuation difference on other securities	29,647	36,692	357,196
Deferred gains (losses) on hedges	(140)	(109)	(1,686)
Foreign currency translation adjustments	(25,299)	(16,128)	(304,802)
Total accumulated other comprehensive income	4,209	20,455	50,708
Minority interests	12,036	11,346	145,014
Total net assets	675,602	644,688	8,139,787
Commitments and contingent liabilities (Notes 5(c) and 10)			
Total liabilities and net assets	¥1,425,879	¥1,368,892	\$17,179,265

The accompanying notes are an integral part of these statements.

Consolidated Statements of Income

Asahi Kasei Corporation and Consolidated Subsidiaries
Years Ended March 31, 2011 and 2010

	Millions of yen		Thousands of U.S. dollars (Note 1)
	2011	2010	2011
Net sales (Note 18)	¥1,598,387	¥1,433,595	\$19,257,678
Cost of sales (Note 6(a), (b))	1,193,646	1,100,688	14,381,278
Gross profit	404,741	332,907	4,876,400
Selling, general and administrative expenses (Note 6(a))	281,814	275,285	3,395,350
Operating income (Note 18)	122,927	57,622	1,481,051
Non-operating income:			
Interest income	1,118	1,071	13,471
Dividends income	2,273	2,276	27,380
Equity in earnings of affiliates	2,212	1,151	26,649
Other	4,248	3,394	51,187
Total non-operating income	9,851	7,891	118,686
Non-operating expenses:			
Interest expense	3,313	3,714	39,921
Foreign exchange loss	3,880	702	46,745
Litigation related expenses	1,908	—	22,992
Other	5,458	4,730	65,758
Total non-operating expenses	14,560	9,146	175,416
Ordinary income	118,219	56,367	1,424,321
Extraordinary income:			
Gain on sales of investment securities	416	112	5,014
Gain on sales of noncurrent assets (Note 6(c))	463	152	5,574
Reversal of allowance for doubtful accounts	84	—	1,017
Gain on change in equity	—	153	—
Gain on business transfer (Note 16)	736	—	8,869
Gain as a result of arbitration award	—	6,502	—
Total extraordinary income	1,699	6,919	20,474
Extraordinary loss:			
Loss on sales of investment securities	380	—	4,578
Loss on valuation of investment securities	651	1,918	7,845
Loss on disposal of noncurrent assets (Note 6(d))	4,879	2,944	58,779
Impairment loss (Notes 6(e) and 18)	2,404	836	28,959
Environmental expenses (Note 6(f))	1,185	1,482	14,277
Cumulative adjustment for adoption of accounting standard for asset retirement obligations (Note 17)	1,240	—	14,944
Loss on disaster (Note 6(g))	821	—	9,890
Business structure improvement expenses (Notes 6(h) and 18)	10,016	10,050	120,674
Total extraordinary loss	21,576	17,230	259,946
Income before income taxes and minority interests	98,342	46,056	1,184,848
Income taxes (Note 15) — current	39,628	17,107	477,440
— deferred	(2,952)	3,377	(35,568)
Total income taxes	36,675	20,483	441,873
Income before minority interests	61,667	25,573	742,976
Minority interests in income	1,379	286	16,620
Net income	¥ 60,288	¥ 25,286	\$ 726,356

The accompanying notes are an integral part of these statements.

Consolidated Statements of Comprehensive Income

Asahi Kasei Corporation and Consolidated Subsidiaries
Years Ended March 31, 2011 and 2010

	Millions of yen		Thousands of U.S. dollars (Note 1)
	2011	2010	2011
Income before minority interests	¥ 61,667	¥ —	\$ 742,976
Other comprehensive income			
Valuation difference on other securities	(7,059)	—	(85,052)
Deferred gains (losses) on hedges	(31)	—	(368)
Foreign currency translation adjustment	(7,114)	—	(85,711)
Share of other comprehensive income of affiliates accounted for using equity method	(2,375)	—	(28,612)
Total other comprehensive income (Note 7(b))	(16,579)	—	(199,743)
Comprehensive income (Note 7(a))	45,088	—	543,233
Comprehensive income attributable to:			
Owners of the parent	44,042	—	530,624
Minority interests	¥ 1,047	¥ —	\$ 12,609

The accompanying notes are an integral part of these statements.

Consolidated Statements of Changes in Net Assets

Asahi Kasei Corporation and Consolidated Subsidiaries
Years Ended March 31, 2011 and 2010

	Millions of yen										
	Shareholders' equity					Accumulated other comprehensive income					
	Capital stock	Capital surplus	Retained earnings (Note 8(b))	Treasury stock	Total shareholders' equity	Valuation difference on other securities	Deferred gains (losses) on hedges	Foreign currency translation adjustment	Total accumulated other comprehensive income	Minority interests	Total net assets
Balance at March 31, 2010	¥103,389	¥79,403	¥432,114	¥(2,017)	¥612,888	¥36,692	¥(109)	¥(16,128)	¥20,455	¥11,346	¥644,688
Changes during the fiscal year											
Dividends from surplus			(13,984)		(13,984)						(13,984)
Net income			60,288		60,288						60,288
Purchase of treasury stock				(116)	(116)						(116)
Disposal of treasury stock		(0)		18	18						18
Change of scope of consolidation			307		307						307
Change of scope of equity method			(43)		(43)						(43)
Net changes of items other than shareholders' equity						(7,045)	(31)	(9,170)	(16,246)	691	(15,555)
Total changes of items during the period	—	(0)	46,568	(98)	46,469	(7,045)	(31)	(9,170)	(16,246)	691	30,914
Balance at March 31, 2011	¥103,389	¥79,402	¥478,681	¥(2,115)	¥659,357	¥29,647	¥(140)	¥(25,299)	¥ 4,209	¥12,036	¥675,602

	Millions of yen										
	Shareholders' equity					Valuation, translation adjustments					
	Capital stock	Capital surplus	Retained earnings (Note 8(b))	Treasury stock	Total shareholders' equity	Valuation difference on other securities	Deferred gains (losses) on hedges	Foreign currency translation adjustment	Total valuation, translation adjustments	Minority interests	Total net assets
Balance at March 31, 2009	¥103,389	¥79,404	¥418,292	¥(1,946)	¥599,139	¥23,301	¥(178)	¥(18,416)	¥ 4,708	¥ 7,504	¥611,351
Changes during the fiscal year											
Dividends from surplus			(11,188)		(11,188)						(11,188)
Net income			25,286		25,286						25,286
Purchase of treasury stock				(96)	(96)						(96)
Disposal of treasury stock		(1)		25	24						24
Change of scope of consolidation			(10)		(10)						(10)
Change of scope of equity method			(267)		(267)						(267)
Net changes of items other than shareholders' equity						13,391	68	2,287	15,747	3,841	19,588
Total changes of items during the period	—	(1)	13,821	(71)	13,749	13,391	68	2,287	15,747	3,841	33,338
Balance at March 31, 2010	¥103,389	¥79,403	¥432,114	¥(2,017)	¥612,888	¥36,692	¥(109)	¥(16,128)	¥20,455	¥11,346	¥644,688

	Thousands of U.S. dollars (Note 1)										
	Shareholders' equity					Accumulated other comprehensive income					
	Capital stock	Capital surplus	Retained earnings (Note 8(b))	Treasury stock	Total shareholders' equity	Valuation difference on other securities	Deferred gains (losses) on hedges	Foreign currency translation adjustment	Total accumulated other comprehensive income	Minority interests	Total net assets
Balance at March 31, 2010	\$1,245,645	\$956,657	\$5,206,187	\$(24,297)	\$7,384,192	\$442,075	\$(1,317)	\$(194,318)	\$246,440	\$136,695	\$7,767,328
Changes during the fiscal year											
Dividends from surplus			(168,478)		(168,478)						(168,478)
Net income			726,356		726,356						726,356
Purchase of treasury stock				(1,399)	(1,399)						(1,399)
Disposal of treasury stock		(1)		215	214						214
Change of scope of consolidation			3,700		3,700						3,700
Change of scope of equity method			(521)		(521)						(521)
Net changes of items other than shareholders' equity						(84,878)	(369)	(110,485)	(195,732)	8,319	(187,413)
Total changes of items during the period	—	(1)	561,057	(1,185)	559,872	(84,878)	(369)	(110,485)	(195,732)	8,319	372,459
Balance at March 31, 2011	\$1,245,645	\$956,656	\$5,767,244	\$(25,481)	\$7,944,064	\$357,196	\$(1,686)	\$(304,802)	\$ 50,708	\$145,014	\$8,139,787

The accompanying notes are an integral part of these statements.

Consolidated Statements of Cash Flows

Asahi Kasei Corporation and Consolidated Subsidiaries
Years ended March 31, 2011 and 2010

	Millions of yen		Thousands of U.S. dollars (Note 1)
	2011	2010	2011
Cash flows from operating activities:			
Income before income taxes	¥ 98,342	¥ 46,056	\$ 1,184,848
Depreciation and amortization	84,092	86,166	1,013,162
Impairment loss	2,404	836	28,959
Amortization of goodwill	1,073	1,089	12,923
Amortization of negative goodwill	(266)	(190)	(3,199)
(Decrease) increase in provision for periodic repairs	(2,990)	2,187	(36,020)
Decrease in provision for product warranties	(1,139)	(5,790)	(13,726)
Decrease in provision for retirement benefits	(2,050)	(1,284)	(24,703)
Interest and dividend income	(3,391)	(3,347)	(40,850)
Interest expense	3,313	3,714	39,921
Equity in earnings of affiliates	(2,212)	(1,151)	(26,649)
Gain on sales of investment securities	(36)	(112)	(436)
Loss on valuation of investment securities	651	1,918	7,845
Gain on sale of property, plant and equipment	(463)	(152)	(5,574)
Loss on disposal of noncurrent assets	4,879	2,944	58,779
Gain on business transfer	(736)	—	(8,869)
Gain as a result of arbitration award	—	(6,502)	—
Increase in notes and accounts receivable, trade	(36,454)	(25,106)	(439,207)
(Increase) decrease in inventories	(4,841)	33,994	(58,320)
Increase in notes and accounts payable, trade	13,618	1,603	164,069
Increase in accrued expenses	6,676	2,555	80,437
Increase (decrease) in advances received	15,309	(2,476)	184,446
Other, net	(3,405)	20,048	(41,018)
Subtotal	172,376	157,003	2,076,817
Interest and dividend income, received	4,458	4,418	53,715
Interest expense, paid	(3,424)	(3,758)	(41,256)
Proceeds from arbitration award	—	6,502	—
Income taxes (paid) refund	(25,282)	5,143	(304,599)
Net cash provided by operating activities	148,128	169,308	1,784,676
Cash flows from investing activities:			
Payments into time deposits	(11,720)	—	(141,204)
Proceeds from withdrawal of time deposits	6,773	—	81,601
Purchase of property, plant and equipment	(63,651)	(84,482)	(766,875)
Proceeds from sales of property, plant and equipment	1,092	675	13,156
Purchase of intangible assets	(5,333)	(6,876)	(64,254)
Purchase of investment securities	(7,619)	(11,291)	(91,792)
Proceeds from sales of investment securities	1,303	5,272	15,702
Proceeds from purchase of investments in subsidiaries resulting in change in scope of consolidation	—	914	—
Additional purchase of investments in consolidated subsidiaries	(408)	—	(4,918)
Proceeds from business transfer	2,538	—	30,574
Payments of loans receivable	(5,840)	(12,623)	(70,363)
Collection of loans receivable	6,513	11,665	78,473
Other, net	(2,486)	(3,438)	(29,956)
Net cash used in investing activities	(78,838)	(100,185)	(949,855)
Cash flows from financing activities:			
Increase in short-term loans payable	71,335	7,744	859,459
Decrease in short-term loans payable	(72,682)	(9,956)	(875,685)
Proceeds from issuance of commercial paper	46,000	59,000	554,217
Redemption of commercial paper	(42,000)	(95,000)	(506,024)
Proceeds from long-term loans payable	6,910	5,633	83,258
Decrease in long-term loans payable	(19,878)	(29,863)	(239,491)
Proceeds from issuance of bonds	—	20,000	—
Redemption of bonds	—	(20,000)	—
Repayment of lease obligations	(1,345)	(908)	(16,208)
Purchase of treasury stock	(119)	(99)	(1,432)
Proceeds from disposal of treasury stock	18	24	212
Cash dividends paid	(13,984)	(11,188)	(168,478)
Cash dividends paid to minority shareholders	(547)	(342)	(6,586)
Other, net	147	(115)	1,772
Net cash provided by (used in) financing activities	(26,144)	(75,071)	(314,986)
Effect of exchange rate change on cash and cash equivalents	(2,698)	620	(32,501)
Net increase (decrease) in cash and cash equivalents	40,449	(5,327)	487,333
Cash and cash equivalents at beginning of year	93,125	98,092	1,121,989
Increase in cash and cash equivalents resulting from changes in scope of consolidation	876	360	10,557
Cash and cash equivalents at end of year (Note 9)	¥ 134,450	¥ 93,125	\$ 1,619,879

The accompanying notes are an integral part of these statements.

Notes to Consolidated Financial Statements

Asahi Kasei Corporation and Consolidated Subsidiaries

1. Major policies for preparing the consolidated financial statements

The consolidated financial statements, which are filed with the prime minister of Japan as required by the Financial Instruments and Exchange Act in Japan, are prepared in accordance with accounting principles generally accepted in Japan, which are different in certain respects from the application and disclosure requirements of International Financial Reporting Standards. The accompanying consolidated financial statements are a translation of those filed with the prime minister of Japan and incorporate certain modifications to enhance foreign readers' understanding of the financial statements. In addition, the notes to the consolidated financial statements include certain financial information which is not required under the disclosure regulations in Japan, but is presented herein as additional information. In addition, certain reclassifications of previously reported amounts have been made to conform to current year's presentation. Such modifications or reclassifications have no effect on net income or retained earnings.

The U.S. dollar amounts presented in the financial statements are included solely for the convenience of readers. These translations should not be construed as representations that the Japanese yen amounts actually represent, or have been or could be converted into U.S. dollars. As the amounts shown in U.S. dollars are for convenience only, and are not intended to be computed in accordance with generally accepted translation procedures, the approximate current exchange rate of ¥83=US\$1 prevailing on March 31, 2011, has been used.

Consolidation and investments in affiliated companies

The consolidated financial statements consist of the accounts of the parent company and 101 subsidiaries (98 subsidiaries at March 31, 2010, hereinafter collectively referred to as the "Company") which, with minor exceptions due to materiality, are all majority and wholly owned companies, including 9 core operating companies (Asahi Kasei Chemicals Corp., Asahi Kasei Homes Corp., Asahi Kasei Pharma Corp., Asahi Kasei Kuraray Medical Co., Ltd., Asahi Kasei

Medical Co., Ltd., Asahi Kasei Fibers Corp., Asahi Kasei Microdevices Corp., Asahi Kasei E-materials Corp. and Asahi Kasei Construction Materials Corp.), Tong Suh Petrochemical Corp. Ltd. (Korea), and Sanyo Petrochemical Co., Ltd. Material inter-company transactions and accounts have been eliminated.

Investments in unconsolidated subsidiaries and 20% to 50% owned companies in which the Company exercises significant influence are accounted for, with minor exceptions due to materiality, using the equity method of accounting. There were 49 such unconsolidated subsidiaries and 20% to 50% owned companies to which the equity method is applied at March 31, 2011 (49 at March 31, 2010), including Asahi Kasei Metals Ltd., Asahi Kasei Geotechnologies Co., Ltd. and Asahi Organic Chemicals Industry Co., Ltd.

Certain subsidiaries results are reported in the consolidated financial statements using a December 31 year-end. Material differences in inter-company transactions and accounts arising from the use of different fiscal year-ends are appropriately adjusted for through consolidation procedures.

All assets and liabilities of consolidated subsidiaries are valued using the fair value method. The excess of the cost over the underlying net equity of investments in subsidiaries and affiliated companies accounted for using the equity method of accounting is allocated to identifiable assets and liabilities based on fair values at the date of acquisition. The unassigned residual value in excess of the cost over the underlying net equity (the cost below the underlying net equity) is recognized as goodwill or negative goodwill. Amortization of goodwill and negative goodwill incurred through business combinations which took place before April 1, 2010, are performed by straight-line amortization over a reasonable period during which their effects would last, with the exception of minor amounts which are charged or credited to income in the year of acquisition.

2. Significant accounting policies

(a) Cash and cash equivalents

For cash flow statement purposes, cash and cash equivalents include all highly liquid investments, generally with original maturities of three months or less, which are readily convertible to known amounts of cash and are so near maturity that they present an insignificant risk of changes in value due to changes in interest rates.

(b) Inventories

Inventories held for sale in the ordinary course of business are stated at the lower of cost or net sales value. Residential lots and dwellings for sale are stated at specifically identified costs.

(c) Noncurrent assets and depreciation/amortization

Property, plant and equipment (except for lease assets) are stated at cost. Significant renewals and improvements are capitalized at cost, while maintenance and repairs are charged to income as incurred. Depreciation is provided for under the declining-balance method for property, plant and equipment, except for buildings which are depreciated using the straight-line method, at rates based on estimated useful lives of the assets, principally ranging from 5 to 60 years for buildings and from 4 to 22 years for machinery and equipment and vehicles.

Intangible fixed assets (except for lease assets), including software for internal use, are amortized using the straight-line method over the estimated useful lives of the assets. The estimated useful life of software for internal use is mainly 5 years.

Lease assets (financing lease transactions without title transfer) are depreciated/amortized on a straight-line basis over the period of the lease with no residual value. For financing lease transactions without title transfer whose transaction date is before March 31, 2008, the previous method of accounting for lease transactions continues to be applied, with periodic lease charges for financing leases charged to income as incurred.

(d) Significant allowances

i) Allowance for doubtful accounts

Estimates of the unrecoverable portion of receivables, generally

based on historical rates and for specific receivables of particular concern based on individual estimates of recoverability, are recognized as allowance for doubtful accounts.

ii) Provision for periodic repairs

The portion of foreseeable periodic repair expenses deemed to correspond to normal wear and tear of plant and equipment as of the closing date of the consolidated fiscal period is recognized as provision for periodic repairs.

iii) Provision for product warranties

Estimates of product warranty expenses based on historical rates and the amount required for remediation of deficient eave assembly specification are recognized as provision for product warranties.

iv) Provision for retirement benefits

Provision for retirement benefits represent the estimated present value of projected benefit obligations in excess of the fair value of the plan assets. Unrecognized actuarial gains/losses, resulting from variances between actual results and economic estimates or actuarial assumptions, are amortized on a straight-line basis primarily over the following 10 years. Unrecognized prior service costs are amortized on a straight-line basis primarily over the following 10 years.

v) Provision for directors' retirement benefits

Provision is made for lump-sum indemnities to directors and corporate auditors equal to the estimated liability calculated under the internal rules of the Company.

(e) Significant revenue and expense recognition

i) Construction activities that are realizable as of current fiscal year end.

The percentage-of-completion method (progress of work is estimated using the percentage of costs incurred to the total projected costs).

ii) Other construction activities

The completed-contract method.

(f) Financial instruments

i) Securities

Securities are classified into four categories: trading securities, held-to-maturity debt securities, equity securities of unconsolidated subsidiaries and affiliates, and other securities. At March 31, 2011 and 2010, the Company did not have trading securities or held-to-maturity debt securities.

Equity securities of unconsolidated subsidiaries and affiliates are accounted for, with minor exceptions due to materiality, using the equity method of accounting.

Other securities whose fair values are readily determinable are carried at fair value with net unrealized gains or losses included as a component of net assets, net of related taxes. Other securities whose fair values are not readily determinable are stated at cost. In cases where any significant decline in the realizable value is assessed to be other than temporary, the cost of other securities is devalued by the impaired amount and is charged to income.

Realized gains and losses are determined using the average cost method and are reflected in the income statements.

ii) Derivative financial instruments

All derivatives are stated at fair value. Gains or losses arising from changes in fair value are charged or credited to income for the period in which they arise, except for derivatives that are designated as hedging instruments. Gains or losses arising from changes in fair value of these qualifying hedges are deferred as "Deferred gains or losses on hedges" to be offset against gains or losses of the underlying hedged assets and liabilities.

(g) Taxes

Accrued income taxes are stated at the estimated amount payable

for corporation, enterprise, and inhabitant taxes. The asset and liability approach is used to recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities.

In Japan, the consumption tax system is designed so that all goods and services are taxed at a flat rate of 5% unless specified otherwise. Assets, liabilities, and profit and loss accounts are stated net of consumption tax.

The Company has elected to file its return under the consolidated tax filing system.

(h) Translation of foreign currencies

Foreign currency receivables and payables are translated into Japanese yen at the exchange rates prevailing at the balance sheet date. Resulting gains and losses are charged or credited to income for the period.

Assets and liabilities of foreign subsidiaries and 20% to 50% owned companies accounted for using the equity method of accounting are translated into Japanese yen at year-end exchange rates, and income and expenses of same are translated into Japanese yen at the average exchange rate for the fiscal year. Shareholders' equity of foreign subsidiaries and 20% to 50% owned companies is translated into Japanese yen at the historical exchange rates. The translation differences in Japanese yen amounts arising from the use of different rates are recognized as foreign currency translation adjustments in the balance sheets.

A portion of the foreign currency translation adjustment is allocated to minority interest and the Company's portion is presented as a separate component of net assets in the balance sheets.

3. Changes in significant accounting policies

(a) Application of Accounting Standard for Equity Method of Accounting for Investments and Practical Solution on Unification of Accounting Policies Applied to Affiliates Accounted for Using the Equity Method

Accounting Standard for Equity Method of Accounting for Investments (Accounting Standards Board of Japan (ASBJ) Statement No. 16) and Practical Solution on Unification of Accounting Policies Applied to Affiliates Accounted for Using the Equity Method (PITF No. 24) have been applied beginning from the fiscal year ended March 31, 2011. This change has no impact on the consolidated financial statements.

(b) Application of Accounting Standard for Asset Retirement Obligations

Accounting Standard for Asset Retirement Obligations (ASBJ Statement No. 18) and Guidance on Accounting Standard for Asset Retirement Obligations (ASBJ Guidance No. 21) have been applied beginning from the fiscal year ended March 31, 2011. As a result, income before income taxes and minority interests was ¥1,738 million (US\$20,936 thousand) lower than it would have been if the previous method had been used. The impact on operating income and ordinary income was immaterial.

(c) Application of Accounting Standard for Business Combinations and related matters

Accounting Standard for Business Combinations (ASBJ Statement No. 21), Accounting Standard for Consolidated Financial Statements (ASBJ Statement No. 22), Partial Amendments to Accounting Standard for Research and Development Costs (ASBJ Statement No. 23), Revised Accounting Standard for Business Divestitures (ASBJ Statement No. 7), Revised Accounting Standard for Equity Method of Accounting for Investments (ASBJ Statement No. 16), and Revised Guidance on Accounting Standard for Business Combinations and Accounting Standard for Business Divestitures (ASBJ Guidance No. 10) have been applied beginning from the fiscal year ended March 31, 2011. With the application of Accounting Standard for Consolidated Financial Statements (ASBJ Statement No. 22), the evaluation method for assets and liabilities of consolidated subsidiaries changed from the partial fair value evaluation method to the full fair value evaluation method. The impact of this change on the consolidated financial statements was immaterial.

4. Additional information

A consolidated subsidiary, Asahi Kasei Pharma Corp. has an ongoing legal action against Actelion Ltd. of Switzerland which acquired CoTherix, Inc. of the US, claiming compensation for damages incurred due to unlawful acts in relation to performance of

a license agreement to develop Fasudil Rho-kinase inhibitor. For this, a total of ¥1,908 million (US\$22,993 thousand) was recorded as litigation related expenses under non-operating expenses in the consolidated statements of income for the year ended March 31, 2011.

5. Notes to Consolidated Balance Sheets

(a) Investment securities

Among investment securities, shares of unconsolidated subsidiaries and affiliates as of March 31, 2011 and 2010, amounted to ¥63,690 million (US\$767,346 thousand) and ¥61,501 million, respectively.

Included in those amounts are investments in joint ventures of

¥34,266 million (US\$412,839 thousand) and ¥33,654 million, respectively.

(b) Hypothecated assets and secured debt

A summary of assets pledged as collateral and secured debt as of March 31, 2011 and 2010, is shown below:

	Millions of yen		Thousands of U.S. dollars
	2011	2010	2011
Hypothecated assets			
Buildings and structures	¥341	¥433	\$4,114
Machinery, equipment and vehicles	12	16	139
Other	0	0	2
	¥353	¥449	\$4,255
Secured debt			
Short-term loans payable	¥109	¥24	\$1,308
Long-term loans payable	423	620	5,092
	¥531	¥644	\$6,400

Besides the above, investment securities pledged to suppliers as transaction guarantee at March 31, 2011 and 2010, were ¥87 million (US\$1,047 thousand) and ¥98 million, respectively.

(c) Contingent liabilities

Contingent liabilities at March 31, 2011 and 2010, arising in the ordinary course of business are as follows:

	Millions of yen		Thousands of U.S. dollars
	2011	2010	2011
Loans guaranteed	¥31,592	¥8,920	\$380,630
Commitment for guarantees	760	1,144	9,151
Letters of awareness	309	797	3,725
Completion guarantees	15,002	10,605	180,746
Notes discounted	37	13	452
	¥47,700	¥21,479	\$574,703

The parent company and certain of its subsidiaries and affiliates are defendants in several pending lawsuits. However, based upon the information currently available to both the Company and its legal counsel, management of the Company believes that any damages from such lawsuits will not have a material effect on the Company's consolidated financial statements.

(d) Reduction entries due to state subsidies, etc.

Cumulative reduction entries due to state subsidies, etc. for the acquisition of property, plant and equipment as of March 31, 2011 and 2010, were ¥7,268 million (US\$87,570 thousand) and ¥5,936 million, respectively. The breakdown of reduction entries as of March 31, 2011, is as follows:

	Millions of yen		Thousands of U.S. dollars
	2011	2010	2011
Buildings and structures	¥3,095	¥2,612	\$37,291
Machinery, equipment and vehicles	3,810	2,958	45,904
Land	226	252	2,728
Other	137	113	1,646
	¥7,268	¥5,936	\$87,570

6. Notes to Consolidated Statements of Income

(a) Selling, general and administrative expenses

Major components of selling, general and administrative expenses are as follows:

	Millions of yen		Thousands of U.S. dollars
	2011	2010	2011
Freight and storage	¥33,946	¥32,102	\$408,985
Salaries and benefits	94,383	90,623	1,137,148
Research and development*	44,745	44,846	539,094

* The aggregate amounts of research and development expenses included in manufacturing costs and selling, general and administrative expenses for the years ended March 31, 2011 and 2010, were ¥62,320 million (US\$750,846 thousand) and ¥62,924 million, respectively.

(b) Loss on devaluation of inventories

Inventories held for sale in the ordinary course of business are stated at the lower of cost or net sales value. Loss on devaluation of inventories for the years ended March 31, 2011 and 2010, was as follows:

	Millions of yen		Thousands of U.S. dollars
	2011	2010	2011
	¥(429)	¥(5,241)	\$(5,172)

(c) Gain on sales of noncurrent assets

Gain on sales of noncurrent assets for the year ended March 31, 2011, was primarily gain on the sale of land, etc. amounting to ¥423 million (US\$5,097 thousand). Gain on sales of noncurrent assets for the year ended March 31, 2010, was comprised of sales of machinery and equipment, etc. amounting to ¥152 million.

(d) Loss on disposal of noncurrent assets

Loss on disposal of noncurrent assets for the years ended March 31, 2011 and 2010, was primarily loss on abandonment and sale of buildings, machinery and equipment, etc. The abandonment and sale of buildings, machinery and equipment, etc. was performed under a single, all-inclusive contract for each facility.

(e) Impairment losses

Impairment losses for the years ended March 31, 2011 and 2010, were as follows:

Use	Asset class	Location	Millions of yen		Thousands of U.S. dollars
			2011	2010	2011
Production facility for ammonia	Machinery and equipment, etc.	Kurashiki, Okayama	¥3,154	¥ —	\$37,994
Production facility for synthetic fibers	Machinery and equipment, etc.	USA	1,977	—	23,821
Production facility for autoclaved aerated concrete (AAC) panels	Machinery and equipment, etc.	Mizuho, Gifu	—	1,365	—
Production facility for synthetic resin	Machinery and equipment, etc.	Sodegaura, Chiba	—	955	—
Production facility for resin molding	Machinery and equipment, etc.	Fuji, Shizuoka	708	—	8,525
Production facility for benzene	Machinery and equipment, etc.	Kurashiki, Okayama	651	—	7,841
Production facility for performance paper	Machinery and equipment, etc.	Gobo, Wakayama	—	531	—
Research facility for pharmaceuticals	Machinery and equipment, etc.	Fuji, Shizuoka	330	—	3,979
Rental facilities	Buildings, etc.	Nobeoka, Miyazaki	295	—	3,555
Idle assets	Land	Atsugi, Kanagawa, and elsewhere	—	198	—
Production facility for fine-pattern devices	Machinery and equipment, etc.	Hyuga, Miyazaki	79	108	956
Production facility for synthetic resin	Machinery and equipment, etc.	Kurashiki, Okayama	52	—	627

Grouping of operating assets is based on managerial accounting categories, with consideration given to production process, geographic location, and domain of authority for making investment decisions. Idle assets are recorded separately in each fixed assets class.

With respect to assets shown in the above table, the book value was reduced to the recoverable amount due to diminished profitability. The recoverable amount is stated as value for future usage, which is calculated as discounted future cash flow with applicable discount rate of 6% and 5%, as of March 31, 2011 and 2010, respectively. The resulting extraordinary losses for production facility for ammonia, production facility for resin molding, production facility for benzene and research facility for pharmaceuticals were recorded under business structure improvement expenses for the year ended March 31, 2011. The resulting extraordinary losses for production facility for autoclaved aerated concrete (AAC) panels and production facility for synthetic resin was recorded under business structure improvement expenses for the year ended March 31, 2010. For idle land of which the market value has significantly decreased, the book value is reduced to the recoverable amount. The recoverable amount is measured at the net selling price primarily based on the value appraised by real estate appraisers.

(f) Environmental expenses

Environmental expenses for the year ended March 31, 2011, were mainly for decontamination of idle land, etc. and those for the year ended March 31, 2010, were mainly for the treatment of polychlorinated biphenyl (PCB) wastes, etc.

(g) Loss on disaster

Loss on disaster for the year ended March 31, 2011, was primarily fixed costs incurred during suspension of operations amounting to ¥410 million (US\$4,940 thousand), loss on disposal of inventories amounting to ¥332 million (US\$4,002 thousand) and loss on disposal of facilities, etc. amounting to ¥79 million (US\$948 thousand).

(h) Business structure improvement expenses

Major components of business structure improvement expenses were as follows:

	Millions of yen		Thousands of U.S. dollars
	2011	2010	2011
Loss on disposal and devaluation of assets and others	¥ 5,174	¥ 7,730	\$ 62,335
Impairment of fixed assets	4,842	2,320	58,339
	¥10,016	¥10,050	\$120,674

7. Notes to Consolidated Statements of Comprehensive Income

For the year ended March 31, 2011

(a) Comprehensive income for the previous fiscal year

	Millions of yen	Thousands of U.S. dollars
	2010	2010
Comprehensive income attributable to owners of the parent company	¥41,033	\$494,377
Comprehensive income attributable to minority interests	458	5,523
	¥41,492	\$499,900

(b) Other comprehensive income for the previous fiscal year

	Millions of yen	Thousands of U.S. dollars
	2010	2010
Valuation difference on other securities	¥13,332	\$160,625
Deferred gains on hedges	69	827
Foreign currency translation adjustment	2,045	24,643
Share of other comprehensive income of affiliates accounted for using equity method	473	5,700
	¥15,919	\$191,796

(Additional information)

Accounting Standard for Presentation of Comprehensive Income (ASBJ Statement No. 25) has been applied beginning from the fiscal year ended March 31, 2011. The items "accumulated other comprehensive income" and "total accumulated other comprehensive income" are exactly the same as "valuation and translation adjustments" and "total valuation and translation adjustments" of the previous fiscal year, respectively.

8. Notes to Consolidated Statements of Changes in Net Assets

For the year ended March 31, 2011

(a) Class and total number of issued and outstanding shares and treasury stock

	Thousands of shares			Number of shares as of March 31, 2011
	Number of shares as of March 31, 2010	Increase in number of shares during the fiscal year	Decrease in number of shares during the fiscal year	
Issued and outstanding shares				
Common stock	1,402,616	—	—	1,402,616
Total	1,402,616	—	—	1,402,616
Treasury stock				
Common stock (Notes 1 & 2)	4,228	230	37	4,421
Total	4,228	230	37	4,421

Notes: 1. The increase of 230 thousand shares in common stock of treasury stock was due to purchase of shares in quantities of less than one share unit.

2. The decrease of 37 thousand shares in common stock of treasury stock was due to sale of shares in quantities of less than one share unit.

(b) Dividends

i) Cash dividends paid

1) The following was resolved by the Board of Directors on May 10, 2010.

Dividends for common stock

Total dividends	¥6,992 million (US\$84,240 thousand)
Dividend per share	¥5.00 (US\$0.06)
Date of record	March 31, 2010
Payment date	June 7, 2010

2) The following was resolved by the Board of Directors on November 2, 2010.

Dividends for common stock

Total dividends	¥6,992 million (US\$84,245 thousand)
Dividend per share	¥5.00 (US\$0.06)
Date of record	September 30, 2010
Payment date	December 1, 2010

ii) Dividends for which the date of record falls within the fiscal year under review but the payment date occurs in the following fiscal year

1) The following was resolved by the Board of Directors on May 11, 2011.

Dividends for common stock

Total dividends	¥8,389 million (US\$101,074 thousand)
Source of dividends	Retained earnings
Dividend per share	¥6.00 (US\$0.07)
Date of record	March 31, 2011
Payment date	June 7, 2011

For the year ended March 31, 2010

(a) Class and total number of issued and outstanding shares and treasury stock

	Thousands of shares			
	Number of shares as of March 31, 2009	Increase in number of shares during the fiscal year	Decrease in number of shares during the fiscal year	Number of shares as of March 31, 2010
Issued and outstanding shares				
Common stock	1,402,616	—	—	1,402,616
Total	1,402,616	—	—	1,402,616
Treasury stock				
Common stock (Notes 1 & 2)	4,071	211	53	4,228
Total	4,071	211	53	4,228

Notes: 1. The increase of 211 thousand shares in common stock of treasury stock was due to purchase of shares in quantities of less than one share unit.
2. The decrease of 53 thousand shares in common stock of treasury stock was due to sale of shares in quantities of less than one share unit.

(b) Dividends

i) Cash dividends paid

1) The following was resolved by the Board of Directors on May 12, 2009.

Dividends for common stock

Total dividends	¥4,196 million
Dividend per share	¥3.00
Date of record	March 31, 2009
Payment date	June 3, 2009

2) The following was resolved by the Board of Directors on November 2, 2009.

Dividends for common stock

Total dividends	¥6,992 million
Dividend per share	¥5.00
Date of record	September 30, 2009
Payment date	December 1, 2009

ii) Dividends for which the date of record falls within the fiscal year under review but the payment date occurs in the following fiscal year

1) The following was resolved by the Board of Directors on May 10, 2010.

Dividends for common stock

Total dividends	¥6,992 million
Source of dividends	Retained earnings
Dividend per share	¥5.00
Date of record	March 31, 2010
Payment date	June 7, 2010

9. Note to Consolidated Statements of Cash Flows

Cash and cash equivalents

Reconciliation of cash and cash equivalents on the consolidated statements of cash flows to the amounts disclosed on the consolidated balance sheets at March 31, 2011 and 2010, is as follows:

	Millions of yen		Thousands of U.S. dollars
	2011	2010	2011
Cash and deposits	¥ 140,319	¥93,928	\$1,690,589
Time deposits with deposit term of over 3 months	(6,240)	(1,788)	(75,182)
Money market funds and others included in short-term investment securities	371	985	4,472
Cash and cash equivalents	¥ 134,450	¥93,125	\$1,619,879

10. Leases

(a) Financing lease transactions

Financing lease transactions without title transfer

i) Components of lease assets are as follows:

- Property, plant and equipment: Mainly model homes (buildings and structures) for housing operations
- Intangible fixed assets: Software

ii) Depreciation of lease assets:

As stated in 2. Significant accounting policies (c) Noncurrent assets and depreciation/amortization. The financing lease transactions without title transfer which occurred prior to March 31, 2008, are accounted for on a basis similar to operating lease.

Such lease transactions accounted for as operating lease be accounted for as financing lease, cost and related accumulated amortization, computed using the straight-line method over the term of the lease, at March 31, 2011 and 2010, would have been as follows:

	Millions of yen		
	2011		
	Cost	Accumulated amortization	Net amount
Buildings and structures	¥2,118	¥1,868	¥250
Machinery, equipment and vehicles	212	134	78
Property, plant and equipment, other	639	497	142
Intangible fixed assets, other	241	179	62
	¥3,210	¥2,678	¥532

	Millions of yen		
	2010		
	Cost	Accumulated amortization	Net amount
Buildings and structures	¥5,863	¥4,503	¥1,360
Machinery, equipment and vehicles	269	156	113
Property, plant and equipment, other	981	678	303
Intangible fixed assets, other	259	149	110
	¥7,372	¥5,486	¥1,886

	Thousands of U.S. dollars		
	2011		
	Cost	Accumulated amortization	Net amount
Buildings and structures	\$25,524	\$22,512	\$3,012
Machinery, equipment and vehicles	2,549	1,609	940
Property, plant and equipment, other	7,698	5,991	1,707
Intangible fixed assets, other	2,898	2,152	746
	\$38,669	\$32,264	\$6,405

The future lease payments under the Company's financing leases at March 31, 2011 and 2010, including amounts representing interest, were as follows:

	Millions of yen		Thousands of U.S. dollars
	2011	2010	2011
Due within one year	¥412	¥1,333	\$4,968
Due after one year	119	552	1,437
	¥532	¥1,886	\$6,405

Lease charges were ¥1,213 million (US\$14,610 thousand) and ¥2,229 million for the years ended March 31, 2011 and 2010, respectively. The amortization amounts of the leased assets, computed using the straight-line method over the term of the leases and no residual value, were ¥1,213 million (US\$14,610 thousand) and ¥2,229 million for the years ended March 31, 2011 and 2010, respectively. No impairment loss is allocated to the leased assets.

(b) Operating lease transactions

Future lease payments for the non-cancelable portion of the Company's operating leases at March 31, 2011 and 2010, were as follows:

	Millions of yen		Thousands of U.S. dollars
	2011	2010	2011
Due within one year	¥4,456	¥4,651	\$53,688
Due after one year	7,856	11,697	94,655
	¥12,312	¥16,349	\$148,342

11. Financial instruments

(a) State of financial instruments

i) Policy related to financial instruments

The Company raises long-term funds as required mainly for its planned capital expenditures by borrowing from banks, borrowing from life insurance companies, issuing bonds, etc. A portion of the surplus funds is invested only in highly stable financial assets. Short-term working funds are raised

by bank borrowings, issuance of commercial paper, etc. Derivative transactions are mainly entered into for the purpose of reducing risks related to assets and liabilities which are exposed to risks of fluctuations of exchange rate and interest rate. Derivatives are not traded for speculative purposes.

ii) Components of financial instruments, their risks, and management of risks

As operating receivables, notes and accounts receivable, trade, are exposed to credit risk of customers. As the business of the Company spans a wide range of fields, operating receivables are not excessively concentrated on specific customers, but each group company monitors and manages the state of credit for each customer.

Investment securities are exposed to the risk of fluctuations in market price, but they are mainly shares in supplier companies, etc., held for policy purposes. Fair value is periodically evaluated, and the financial condition of the issuing company is monitored.

As operating liabilities, notes and accounts payable, trade, generally have a payment term of 1 year or less.

Variable interest-rate borrowings are exposed to the risk of interest rate fluctuations, but derivatives (interest currency swaps, interest-rate swaps) are used as hedges to fix interest expenses for a portion of long-term variable interest-rate borrowings.

Operating receivables and operating liabilities include those denominated in currencies other than Japanese yen, and are thus exposed to the risk of exchange rate fluctuations. In order to minimize the effects of short-term exchange-rate fluctuations, the Company hedges with derivative transactions (forward exchange contracts) in principle within the range of the underlying receivables and liabilities.

Derivative transactions are exposed to the credit risk of transacting financial institutions, but the state of credit is verified through periodical monitoring. Such transactions are performed and managed in accordance with each company's internal regulations which stipulate the related authority, procedures, limits, etc.

Borrowings are exposed to liquidity risk, but the parent company specifies standards for required on-hand funds based on the Company's funding plans, prepares and revises plans for cash receipts and disbursements as appropriate, and enters into commitment-line agreements with transacting financial institutions to manage such risk.

Loan securitization in housing operations is exposed to the risk of interest rate fluctuations between the time of execution of housing loans and the time of execution of their securitization, but derivative transactions (interest rate swaps) are entered into to reduce such risk.

iii) Supplementary explanation of fair value of financial instruments

Fair value of financial instruments includes value based on market price, and, in the case where no market price exists, a reasonably calculated value. As variable factors are incorporated in its calculation, fair value may change due to the adoption of different assumptions, conditions, etc. Amount of contract regarding derivative transactions in the note 13 "Derivative financial instruments" is not itself an indication of the market risk of the derivative transactions.

(b) Fair value of financial instruments

Amounts carried on the consolidated balance sheets, their fair values, and the differences between them as of March 31, 2011 and 2010, are as shown below.

Financial instruments whose fair values are deemed extremely difficult to determine are not included in this table (See Notes 2), 3) and 4) below).

	Millions of yen		
	2011		
	Carrying amount	Fair value	Difference
Cash and deposits	¥140,319	¥140,319	¥ —
Notes and accounts receivable, trade	273,414		
Allowance for doubtful accounts (*1)	(1,028)		
	272,386	272,386	—
Short-term investment securities			
Other securities	116	116	—
Investment securities			
Other securities	93,921	93,921	—
Long-term receivables	5,860		
Allowance for doubtful accounts (*1)	(11)		
	5,849	6,249	400
Total assets	512,590	512,991	400
Notes and accounts payable, trade	136,407	136,407	—
Short-term loans payable	76,611	76,611	—
Commercial paper	23,000	23,000	—
Income taxes payable	24,085	24,085	—
Bonds payable	25,000	25,311	(311)
Long-term loans payable	123,493	125,156	(1,663)
Lease obligations	5,324	5,343	(19)
Long-term guarantee deposited	5,845	5,731	114
Total liabilities	419,766	421,644	(1,879)
Derivative financial instruments (*2)	(419)	(419)	—

	Millions of yen		
	2010		
	Carrying amount	Fair value	Difference
Cash and deposits	¥ 93,928	¥ 93,928	¥ —
Notes and accounts receivable, trade	238,931		
Allowance for doubtful accounts (*1)	(1,543)		
	237,388	237,388	—
Short-term investment securities			
Other securities	112	112	—
Investment securities			
Other securities	105,303	105,303	—
Long-term receivables	6,844		
Allowance for doubtful accounts (*1)	(73)		
	6,770	7,125	355
Total assets	443,501	443,856	355
Notes and accounts payable, trade	121,409	121,409	—
Short-term loans payable	78,302	78,302	—
Commercial paper	19,000	19,000	—
Income taxes payable	12,160	12,160	—
Bonds payable	25,000	24,808	192
Long-term loans payable	137,406	138,385	(980)
Lease obligations	4,716	4,774	(58)
Long-term guarantee deposited	5,694	5,583	111
Total liabilities	403,686	404,421	(735)
Derivative financial instruments (*2)	(200)	(200)	—

	Thousands of U.S. dollars		
	2011		
	Carrying amount	Fair value	Difference
Cash and deposits	\$1,690,589	\$1,690,589	\$ —
Notes and accounts receivable, trade	3,294,144		
Allowance for doubtful accounts (*1)	(12,386)		
	3,281,758	3,281,758	—
Short-term investment securities			
Other securities	1,394	1,394	—
Investment securities			
Other securities	1,131,577	1,131,577	—
Long-term receivables	70,601		
Allowance for doubtful accounts (*1)	(130)		
	70,471	75,292	4,821
Total assets	6,175,788	6,180,610	4,821
Notes and accounts payable, trade	1,643,461	1,643,461	—
Short-term loans payable	923,023	923,023	—
Commercial paper	277,108	277,108	—
Income taxes payable	290,183	290,183	—
Bonds payable	301,205	304,949	(3,745)
Long-term loans payable	1,487,870	1,507,902	(20,032)
Lease obligations	64,146	64,376	(230)
Long-term guarantee deposited	70,424	69,052	1,372
Total liabilities	5,057,420	5,080,054	(22,634)
Derivative financial instruments (*2)	(5,051)	(5,051)	—

(*1) Specific allowance for doubtful accounts is deducted from notes and accounts receivable, trade, and long-term loans receivable.

(*2) Net amount of assets and liabilities resulted from derivative transactions is shown. In the case of a net liability, the amount is shown in parentheses.

Note 1) Method of calculating fair value of financial instruments; securities and derivative financial instruments

i) Assets

1) Cash and deposits; notes and accounts receivable, trade

As their fair value approximates book value due to their short maturity, the corresponding book value amount is used as fair value.

2) Short-term investment securities, investment securities

The stock exchange price is used to determine fair value of these traded stocks. Refer to the Note 12 "Marketable securities and investment securities" for information regarding securities based on each objective for which they are held.

3) Long-term receivables

The carrying amount shown includes long-term loans receivable scheduled for repayment within one year. Their fair value is determined by a method of calculation in which the total amount of principal and interest is discounted using the interest rate that would apply if equivalent long-term loans were newly issued. For long-term loans receivable that have a variable interest rate, as they are deemed to reflect market interest rates within a short term, book value is used as fair value.

ii) Liabilities

1) Notes and accounts payable, trade; short-term loans payable; commercial paper; income taxes payable

As their fair value approximates book value due to their short maturity, the corresponding book value amount is used as fair value.

2) Bonds payable

With regard to fair value of the bonds payable issued by the parent company, for those with market price, fair value is determined by the market price. For those without market price that are subject to exceptional treatment for interest rate swaps, fair value is determined by a method of calculation in which the total amount of principal and interest, treated as a unit with such interest rate swaps, is discounted using the interest rate that would apply if equivalent bonds were newly issued.

3) Long-term loans payable

The carrying amount shown includes long-term loans payable that are scheduled for repayment within one year of March 31, 2011 and 2010, amounting to ¥32,278 million (US\$388,892 thousand) and ¥15,660 million, respectively. Their fair value is determined by a method of calculation in which the total amount of principal and interest is discounted using the interest rate that would apply if equivalent long-term loans were newly entered. Of long-

term loans payable that have a variable interest rate, fair value of those subject to exceptional treatment of interest rate swaps is determined by a method of calculation in which the total amount of principal and interest, treated as a unit with such interest rate swaps, is discounted using the interest rate that would apply if equivalent long-term loans were newly entered, and book value is used as fair value of others, as they are deemed to reflect market interest rates within a short term.

4) Lease obligations

The carrying amount shown is the total amount of lease obligations under current liabilities and lease obligations under noncurrent liabilities. Present value, calculated by discounting the total amount of principal and interest using the presumed interest rate that would apply if lease transactions were newly made, is used as the fair value.

5) Long-term guarantee deposited

In case where the deposit period can be estimated, the fair value of long-term guarantee deposited is determined through calculation of the discount over that period.

iii) Derivative transactions

Refer to the Note 13 "Derivative financial instruments."

Note 2) For equity investments in nonpublic companies, with a carrying amount as of March 31, 2011 and 2010, amounting to ¥72,652 million (US\$875,323 thousand) and ¥70,630 million, respectively, fair value is not included in short-term investment securities or in investment securities, as no market price exists and it is deemed extremely difficult to determine fair value due to the impossibility of estimating future cash flows.

Note 3) A portion of the carrying amount of long-term loans payable, as of March 31, 2011 and 2010, amounting to ¥507 million (US\$6,112 thousand) and ¥176 million, respectively, is for loans from the Japan Science and Technology Agency, and the timing of repayment is yet to be determined as it begins after development success is certified. Fair value is not included as it is deemed extremely difficult to determine due to the impossibility of estimating future cash flows.

Note 4) Within long-term guarantee deposited, the fair value of a portion having a carrying amount as of March 31, 2011 and 2010, amounting to ¥12,495 million (US\$150,542 thousand) and ¥12,628 million, respectively, is not included as no market price exists and it is deemed extremely difficult to determine fair value due to the impossibility of estimating future cash flows.

Note 5) For monetary credits and securities with maturity, amount scheduled for redemption subsequent to the closing date.

	Millions of yen			
	2011			
	Due within one year	Due after one year, within five years	Due after five years, within ten years	Due after more than ten years
Cash and deposits	¥140,319	¥ —	¥ —	¥ —
Notes and accounts receivable, trade	273,414	—	—	—
Short-term investment securities, investment securities				
Government and municipal bonds	2	2	—	—
Long-term receivables	679	5,166	15	—
	¥414,414	¥5,168	¥15	¥ —

	Millions of yen			
	2010			
	Due within one year	Due after one year, within five years	Due after five years, within ten years	Due after more than ten years
Cash and deposits	¥ 93,928	¥ —	¥ —	¥ —
Notes and accounts receivable, trade	238,931	—	—	—
Short-term investment securities, investment securities				
Government and municipal bonds	2	5	—	—
Long-term receivables	769	6,059	15	—
	¥333,631	¥6,064	¥15	¥ —

	Thousands of U.S. dollars			
	2011			
	Due within one year	Due after one year, within five years	Due after five years, within ten years	Due after more than ten years
Cash and deposits	\$1,690,589	\$ —	\$ —	\$ —
Notes and accounts receivable, trade	3,294,144	—	—	—
Short-term investment securities, investment securities				
Government and municipal bonds	27	27	—	—
Long-term receivables	8,184	62,236	181	—
	\$4,992,944	\$62,263	\$181	\$ —

Note 6) For bonds payable, long-term loans payable, lease obligations, and other interest-bearing debt, amount scheduled for repayment subsequent to the closing date. Refer to Note 21 "Borrowings"

12. Marketable securities and investment securities

(a) Other securities with available fair value

The aggregate cost, carrying amount which was identical to fair value, and gross unrealized gains and losses of debt and equity securities classified as other securities for which fair values were available at March 31, 2011 and 2010, were as follows:

	Millions of yen		
	2011		
	Carrying amount	Cost	Unrealized gains (losses)
Securities with unrealized gains:			
Equity securities	¥ 85,780	¥ 32,629	¥ 53,151
Securities with unrealized losses:			
Equity securities	8,141	11,440	(3,299)
Debt securities	116	116	—
	8,256	11,555	(3,299)
	¥ 94,037	¥ 44,185	¥ 49,852

Note) For equity investment in nonpublic companies, with a carrying amount of ¥72,652 million, fair value is not included in short-term investment securities or in investment securities, as no market price exists and it is deemed extremely difficult to determine fair value.

	Millions of yen		
	2010		
	Carrying amount	Cost	Unrealized gains (losses)
Securities with unrealized gains:			
Equity securities	¥ 96,284	¥ 33,280	¥ 63,004
Securities with unrealized losses:			
Equity securities	9,019	10,415	(1,396)
Debt securities	0	0	—
	9,019	10,415	(1,396)
	¥ 105,303	¥ 43,695	¥ 61,608

Note) For equity investment in nonpublic companies, with a carrying amount of ¥70,630 million, fair value is not included in short-term investment securities or in investment securities, as no market price exists and it is deemed extremely difficult to determine fair value.

	Thousands of U.S. dollars		
	2011		
	Carrying amount	Cost	Unrealized gains (losses)
Securities with unrealized gains:			
Equity securities	\$1,033,499	\$393,126	\$640,372
Securities with unrealized losses:			
Equity securities	98,078	137,829	(39,750)
Debt securities	1,394	1,394	—
	99,472	139,222	(39,750)
	\$1,132,970	\$532,348	\$600,622

Note) For equity investment in nonpublic companies, with a carrying amount of US\$875,323 thousand, fair value is not included in short-term investment securities or in investment securities, as no market price exists and it is deemed extremely difficult to determine fair value.

(b) The realized gains and losses on the sale of other securities during the year ended March 31 2011 and 2010, were as follows:

	Millions of yen		Thousands of U.S. dollars
	2011	2010	2011
	Selling amount	¥1,292	¥275
Gain on sales of securities	416	112	5,014
Loss on sales of securities	380	—	4,578

(c) Loss on other devaluation of investment securities whose fair values are readily determinable for the years ended March 31, 2011 and 2010, was ¥651 million (US\$7,845 thousand) and ¥1,918 million, respectively.

13. Derivative financial instruments

(a) Derivative financial instruments for which hedge accounting is not applied

i) Foreign exchange forward contracts

		Millions of yen			
		2011			
Classification	Items	Amount of contract	Amount of contract over 1 year	Fair value	Profit (loss) from valuation
	Foreign exchange forward contracts				
	Selling				
Off-market transactions	U.S. dollar	¥13,234	¥ —	¥ (159)	¥ (159)
	Euro	2,359	—	(104)	(104)
	Thai baht	469	—	(15)	(15)
	Buying				
	U.S. dollar	1,505	—	12	12
		¥17,567	¥ —	¥ (268)	¥ (268)

		Millions of yen			
		2010			
Classification	Items	Amount of contract	Amount of contract over 1 year	Fair value	Profit (loss) from valuation
	Foreign exchange forward contracts				
	Selling				
Off-market transactions	U.S. dollar	¥11,406	¥ —	¥ (105)	¥ (105)
	Euro	3,518	—	(8)	(8)
	Thai baht	479	—	(27)	(27)
	Buying				
	U.S. dollar	1,311	—	16	16
		¥16,714	¥ —	¥ (124)	¥ (124)

		Thousands of U.S. dollars			
		2011			
Classification	Items	Amount of contract	Amount of contract over 1 year	Fair value	Profit (loss) from valuation
	Foreign exchange forward contracts				
	Selling				
Off-market transactions	U.S. dollar	\$159,445	\$ —	\$(1,922)	\$(1,922)
	Euro	28,425	—	(1,259)	(1,259)
	Thai baht	5,648	—	(184)	(184)
	Buying				
	U.S. dollar	18,130	—	139	139
		\$211,648	\$ —	\$(3,225)	\$(3,225)

(b) Derivative financial instruments for which hedge accounting is applied

i) Foreign exchange forward contracts

		Millions of yen			
		2011			
Classification	Items	Hedged assets / liabilities	Amount of contract	Amount of contract over 1 year	Fair value
	Foreign exchange forward contracts				
	Selling				
Principled treatment	U.S. dollar	Accounts receivable, trade	¥ 9,467	¥ —	¥(121)
	Euro	Accounts receivable, trade	936	—	(40)
	Buying				
	U.S. dollar	Accounts payable, trade	370	—	9
	Euro	Accounts payable, trade	4	—	(0)
	Singapore dollar	Accounts payable, trade	13	—	0
			¥10,790	¥ —	¥(152)

			Millions of yen		
			2010		
Classification	Items	Hedged assets / liabilities	Amount of contract	Amount of contract over 1 year	Fair value
	Foreign exchange forward contracts				
	Selling				
Principled treatment	U.S. dollar	Accounts receivable, trade	¥3,263	¥ —	¥(79)
	Euro	Accounts receivable, trade	698	—	5
	Buying				
	U.S. dollar	Accounts payable, trade	53	—	(1)
	Euro	Accounts payable, trade	60	—	(1)
			¥4,075	¥ —	¥(77)

			Thousands of U.S. dollars		
			2011		
Classification	Items	Hedged assets / liabilities	Amount of contract	Amount of contract over 1 year	Fair value
	Foreign exchange forward contracts				
	Selling				
Principled treatment	U.S. dollar	Accounts receivable, trade	\$114,059	\$ —	\$(1,453)
	Euro	Accounts receivable, trade	11,278	—	(480)
	Buying				
	U.S. dollar	Accounts payable, trade	4,460	—	106
	Euro	Accounts payable, trade	45	—	(3)
	Singapore dollar	Accounts payable, trade	159	—	4
			\$130,002	\$ —	\$(1,826)

ii) Interest rate swaps, and interest rate and currency swaps

			Millions of yen		
			2011		
Classification	Items	Hedged assets / liabilities	Amount of contract	Amount of contract over 1 year	Fair value
Exceptional treatment for an interest rate swaps	Interest rate swaps				
	Receive fixed/pay floating	Long-term loans payable	¥ 5,000	¥ —	(*)
	Pay fixed/receive floating	Long-term loans payable	43,884	25,915	(*)
Exceptional treatment for an interest rate swap and currency swaps	Interest rate and currency swaps				
	U.S. dollar receive fixed/ Japanese yen pay floating	Bonds payable	5,000	5,000	(*)
	U.S. dollar receive floating/ Thai baht pay fixed	Long-term loans payable	1,093	820	(*)
			¥54,978	¥31,735	—

			Millions of yen		
			2010		
Classification	Items	Hedged assets / liabilities	Amount of contract	Amount of contract over 1 year	Fair value
Exceptional treatment for an interest rate swaps	Interest rate swaps				
	Receive fixed/pay floating	Long-term loans payable	¥ 5,000	¥ 5,000	(*)
	Pay fixed/receive floating	Long-term loans payable	45,178	44,054	(*)
Exceptional treatment for an interest rate swap and currency swaps	Interest rate and currency swaps				
	U.S. dollar receive fixed/ Japanese yen pay floating	Bonds payable	5,000	5,000	(*)
	U.S. dollar receive floating/ Thai baht pay fixed	Long-term loans payable	731	585	(*)
			¥55,909	¥54,638	—

			Thousands of U.S. dollars		
			2011		
Classification	Items	Hedged assets / liabilities	Amount of contract	Amount of contract over one year	Fair value
Exceptional treatment for an interest rate swaps	Interest rate swaps				
	Receive fixed/pay floating	Long-term loans payable	\$ 60,241	\$ —	(*)
	Pay fixed/receive floating	Long-term loans payable	528,727	312,231	(*)
Exceptional treatment for an interest rate swap and currency swaps	Interest rate and currency swaps				
	U.S. dollar receive fixed/ Japanese yen pay floating	Bonds payable	60,241	60,241	(*)
	U.S. dollar receive floating/ Thai baht pay fixed	Long-term loans payable	13,174	9,881	(*)
			\$662,383	\$382,353	—

(*) Fair value of interest rate swaps and interest currency swaps for which exceptional treatment is applied, is included in fair value of the corresponding long-term loans payable and bonds payable for which hedge accounting is applied.

14. Provision for retirement benefits

Upon terminating employment, employees of the parent company and its major subsidiaries in Japan are entitled, under most circumstances, to lump-sum severance indemnities and/or pension payments determined by reference mainly to their current basic rate of pay and length of service. Additional benefits may be granted to employees depending on the conditions under which termination of employment occurs. Certain foreign subsidiaries have defined benefit pension plans or defined contribution plans.

The obligation for these severance indemnity benefits is provided for through accruals, contributory funded defined benefit pension plans, contributory funded defined benefit enterprise pension plans and non-contributory funded tax-qualified pension plans.

Information on provision for retirement benefits at March 31, 2011 and 2010, was as follows:

	Millions of yen		Thousands of U.S. dollars
	2011	2010	2011
(a) Projected benefit obligations	¥(310,990)	¥(295,842)	\$(3,746,865)
(b) Fair value of plan assets	164,396	170,895	1,980,680
(c) Unfunded benefit obligations [(a)+(b)]	(146,593)	(124,947)	(1,766,185)
(d) Unrecognized actuarial gains/losses	46,746	24,478	563,210
(e) Unrecognized prior service costs	(2,692)	(4,019)	(32,440)
(f) Amount shown on balance sheet [(c)+(d)+(e)]	(102,539)	(104,488)	(1,235,415)
(g) Prepaid pension cost	4,769	4,961	57,463
(h) Provision for retirement benefits [(f)-(g)]	¥(107,309)	¥(109,450)	\$(1,292,878)

Note: The figures in the above table do not include additional benefit payables amounting to ¥111 million (US\$1,341 thousand) and ¥45 million at March 31, 2011 and 2010, respectively. The amounts were recorded as part of current liabilities on the consolidated balance sheets at March 31, 2011 and 2010.

Periodic retirement benefit expenses for employees for the years ended March 31, 2011 and 2010, include the following components:

	Millions of yen		Thousands of U.S. dollars
	2011	2010	2011
Service cost*	¥ 9,031	¥ 9,235	\$108,804
Interest cost	7,237	7,313	87,193
Expected return on plan assets	(4,219)	(3,797)	(50,831)
Amortization of unrecognized actuarial gains/losses	2,317	3,969	27,910
Amortization of unrecognized prior service costs	(1,378)	(1,375)	(16,602)
Retirement benefit expenses	¥12,987	¥15,346	\$156,474

Note: In addition to the above costs, additional benefits amounting to ¥878 million (US\$10,584 thousand) and ¥717 million were charged to income for the years ended March 31, 2011 and 2010, respectively.

* Not including contributions made by employees.

The assumptions used in calculation of the above information are as follows:

	2011	2010
Discount rate	Mainly 2.0%	Mainly 2.5%
Expected rate of return on plan assets	Mainly 2.5%	Mainly 2.5%
Method of attributing the projected benefits to periods of employee service	Straight-line basis	Straight-line basis
Amortization of unrecognized prior service costs	Mainly 10 years	Mainly 10 years
Amortization of unrecognized actuarial gains/losses	Mainly 10 years	Mainly 10 years

15. Taxes

Income taxes applicable to the parent company and subsidiaries in Japan include (1) corporation tax, (2) enterprise tax, and (3) inhabitants tax.

Significant components of the deferred tax assets and liabilities at March 31, 2011 and 2010, were as follows:

	Millions of yen		Thousands of U.S. dollars
	2011	2010	2011
Deferred tax assets:			
Provision for retirement benefits	¥ 43,436	¥ 44,158	\$ 523,329
Tax loss carryforwards	12,741	11,377	153,501
Accrued bonuses	8,904	6,994	107,274
Loss on disposal of noncurrent assets	5,533	4,061	66,660
Impairment loss	4,605	2,684	55,485
Unrealized gain on noncurrent assets and others	4,302	4,053	51,834
Devaluation of investment securities	3,287	2,853	39,604
Accrued enterprise tax	2,322	1,330	27,976
Provision for repairs	2,316	3,346	27,901
Depreciation	2,146	649	25,856
Devaluation of inventories	1,459	1,296	17,576
Asset retirement obligations	1,456	—	17,542
Provision for product warranties	1,171	1,636	14,106
Environmental expenses	953	1,146	11,484
Allowance for doubtful accounts	412	823	4,967
Other	7,445	9,267	89,703
Subtotal deferred tax assets	102,488	95,673	1,234,799
Less: Valuation allowance	(21,904)	(18,336)	(263,900)
Total deferred tax assets	80,585	77,336	970,899
Deferred tax liabilities:			
Valuation difference on other securities	(22,454)	(27,166)	(270,534)
Reserve for noncurrent assets reduction	(13,402)	(13,316)	(161,466)
Reserve for special depreciation	(247)	(149)	(2,971)
Other	(5,720)	(5,814)	(68,912)
Total deferred tax liabilities	(41,822)	(46,445)	(503,882)
Net deferred tax assets	¥ 38,762	¥ 30,891	\$ 467,017

Net deferred tax assets (liabilities) at March 31, 2011 and 2010, were included in the following line items on the consolidated balance sheets.

	Millions of yen		Thousands of U.S. dollars
	2011	2010	2011
Current assets—deferred tax assets	¥23,131	¥23,106	\$278,689
Non-current assets—deferred tax assets	22,005	15,383	265,122
Current liabilities—deferred tax liabilities	—	—	—
Non-current liabilities—deferred tax liabilities	(6,374)	(7,597)	(76,794)

Reconciliation of the differences between the statutory tax rate and the effective income tax rate for the years ended March 31, 2011 and 2010, was as follows:

	2011		2010
Statutory tax rate	40.7%	Statutory tax rate	40.7%
Increase (reduction) in taxes resulting from:		Increase (reduction) in taxes resulting from:	
Non-deductible expenses and non-taxable income	1.4	Non-deductible expenses and non-taxable income	4.0
Equalization of inhabitants taxes	0.4	Equalization of inhabitants taxes	1.0
Equity in earnings of unconsolidated subsidiaries and affiliates	(0.8)	Amortization of goodwill	0.4
Undistributed earnings of foreign subsidiaries	0.7	Equity in earnings of unconsolidated subsidiaries and affiliates	(0.8)
Difference of tax rates for foreign subsidiaries	(4.4)	Undistributed earnings of foreign subsidiaries	1.5
Valuation allowance	4.0	Valuation allowance	7.2
R&D expenses deductible from income taxes	(5.1)	Unrealized profit	(2.2)
Other	0.4	R&D expenses deductible from income taxes	(8.1)
Effective income tax rate	37.3%	Other	0.8
		Effective income tax rate	44.5%

16. Business combinations, etc.

For the year ended March 31, 2011

Business divestiture

Business divestiture in the fiscal year ended March 31, 2011, was as follows:

(a) Outline of the business divestiture

i) Name of the transferee

Aime Corp.

ii) Nature of the divested businesses

Contact lens and lens-care product businesses of Asahi Kasei Aime Co., Ltd, a consolidated subsidiary of the parent company

iii) Main reasons for the divestiture

Asahi Kasei Aime Co., Ltd. had developed its businesses with conventional (long-term use) hard and soft contact lenses as the main products. During the past 10 years in the contact lens market, demand for disposable lenses increased rapidly, while demand for conventional lenses decreased dramatically. As disposable lenses became dominant in the soft contact lens market where Asahi Kasei Aime had enjoyed strength, the expansion of this business was significantly impacted. Under these circumstances, US-based CooperVision, Inc., with which Asahi Kasei Aime had a business alliance in the development of contact lens materials, etc., suggested a transfer of Asahi Kasei Aime's business to them. After extensive negotiations, on December 1, 2010, Asahi Kasei Aime's contact lens and lens-care product businesses (excluding manufacturing functions), were transferred to Aime Corp., which was newly established in Japan by CooperVision. This was based on a judgment that joint development with CooperVision's product lineup, rather than Asahi Kasei Aime on its own, would enhance business efficiency and competitiveness, and thus be optimal for the development of businesses focused on contact lenses.

iv) Date of divestiture

December 1, 2010

v) Overview of transactions including statutory form

Business transfer for which consideration received is limited to assets including cash.

(b) Overview of accounting treatment implemented

i) Amount of gain on business transfer

¥736 million (US\$8,869 thousand)

ii) Appropriate book value of assets and liabilities pertaining to the transferred businesses

	Millions of yen	Thousands of U.S. dollars
	2011	2011
Current assets	¥1,677	\$20,204
Noncurrent assets	133	1,598
Total assets	1,810	21,802
Current liabilities	4	52
Total liabilities	4	52

iii) Accounting treatment

Considering that investments related to the transferred contact lens and lens-care businesses were liquidated, the differences between the fair value of assets received in consideration of such transfer and the amount corresponding to shareholders' equity pertaining to the transferred businesses was recognized as gain on transfer.

(c) Name of reporting segment in which the divested businesses were included

Health Care

(d) Approximate amount of income (loss) pertaining to the divested businesses recorded in the consolidated statements of income during the fiscal year ended March 31, 2011.

	Millions of yen	Thousands of U.S. dollars
	2011	2011
Net sales	¥2,077	\$25,026
Operating loss	(302)	(3,639)

For the year ended March 31, 2010

Transactions under common control, etc.

Transactions under common control, etc. in the fiscal year ended March 31, 2010, were as follows:

(a) Establishment of Asahi Kasei E-materials Corp. through a business split of the electrochemicals-related operations of Asahi Kasei Chemicals Corp. and Asahi Kasei Microdevices Corp.

i) Name and nature of business subject to transaction, statutory form of business combination, name of company after transaction, and outline and purpose of transaction

1) Name and nature of business subject to transaction

Name of business:

Electronics-related operations of the parent company and of consolidated subsidiaries Asahi Kasei Chemicals Corp. and Asahi Kasei Microdevices Corp.

Nature of business:

Production and sales of Hipore™ Li-ion rechargeable battery separators, light diffusion plates, APR™ photopolymer and printing plate making systems, Pimel™ photosensitive polyimide precursor, Sunfort™ dry film photoresist, glass fabric for printed wiring boards, photomask pellicles, etc.

2) Statutory form of business combination

Establishment of Asahi Kasei E-materials Corp. by business split of electrochemicals-related operations of the parent company, Asahi Kasei Chemicals Corp., and Asahi Kasei Microdevices Corp.

3) Name of company after transaction

Asahi Kasei E-materials Corp.

4) Outline and purpose of transaction

Asahi Kasei E-materials Corp. was established through a business split of the electrochemicals-related operations of the parent company, Asahi Kasei Chemicals Corp., and Asahi Kasei Microdevices Corp. in order to clarify those operations as a field of focus for growth for the Asahi Kasei Group and to facilitate greater management efficiency in a structure for swift execution of strategic decisions and resource investment.

ii) Outline of the accounting treatment implemented

This transaction was accounted for as a transaction under common control based on the Accounting Standard for Business Combinations issued by the Business Accounting Council in Japan and the Accounting Standard for Business Divestitures (Accounting Standard No. 7) and Guidance on Accounting Standard for Business Combinations and Accounting Standard for Business Divestitures (Accounting

Standard Guidance No. 10) issued by the Accounting Standards Board of Japan.

(b) Business split of Leona™ filament business from Asahi Kasei Chemicals Corp. to Asahi Kasei Fibers Corp.

i) Name and nature of business subject to transaction, statutory form of business combination, name of company after transaction, and outline and purpose of transaction

- 1) Name and nature of business subject to transaction
Name of business:
Leona™ filament business of consolidated subsidiary Asahi Kasei Chemicals Corp.
Nature of business:
Production and sale of Leona™ nylon 66 filament
- 2) Statutory form of business combination
Business split from Asahi Kasei Chemicals Corp. to Asahi Kasei Fibers Corp.
- 3) Name of company after transaction
Asahi Kasei Fibers Corp.
- 4) Outline and purpose of transaction
For the further expansion and development of the Leona™ filament business, it is essential to reinforce and accelerate applications development based on advanced

technical know-how in the field of fibers. Asahi Kasei Fibers Corp. holds the realignment of its business portfolio from apparel to industrial-use materials as a pillar of mid-term management strategy, and it can be expected that by transferring the Leona™ filament business, which is focused on industrial applications such as tire cord and air bags, this portfolio realignment can be accelerated through the pursuit of synergies with existing fiber business, in both technology and marketing. The Leona™ filament business of Asahi Kasei Chemicals Corp. was therefore split off to be absorbed by Asahi Kasei Fibers Corp.

ii) Outline of the accounting treatment implemented

This transaction was accounted for as a transaction under common control based on the Accounting Standard for Business Combinations issued by the Business Accounting Council in Japan and the Accounting Standard for Business Divestitures (Accounting Standard No. 7) and Guidance on Accounting Standard for Business Combinations and Accounting Standard for Business Divestitures (Accounting Standard Guidance No. 10) issued by the Accounting Standards Board of Japan.

17. Asset retirement obligation

As of March 31, 2011

Asset retirement obligations recorded on the consolidated balance sheet

(a) Outline of relevant asset retirement obligations

Due to commitments pertaining to restoration to original state before vacating in accordance with land lease agreements such as for offices, and due to commitments to dismantle leased buildings upon termination of lease period, etc., in accordance with lease agreements for model home parks, relevant asset retirement obligations are recorded in the consolidated balance sheet.

In accordance with building lease agreements such as for the head offices, commitments pertaining to restoration to original state

before vacating are recognized as asset retirement obligations. However, instead of recording the relevant asset retirement obligations as liabilities, the amount of deposit that can not ultimately be expected to be collected was calculated in a reasonable manner, and of that, the amount corresponding to the fiscal year ended March 31, 2011, was recorded under operating expenses.

(b) Method of calculating the amount of relevant asset retirement obligations

The calculation of asset retirement obligations is based on the following: expected term of use of 4 to 55 years, inflation rate of 0.0% to 3.3%, and discount rate of 0.3% to 6.0%.

(c) Increase (decrease) in the total amount of asset retirement obligations in the fiscal year ended March 31, 2011.

	Millions of yen	Thousands of U.S. dollars
	2011	2011
Balance at beginning of year*	¥ 4,038	\$ 48,648
Increase due to asset retirement obligations accrued	346	4,168
Adjustment due to passage of time	173	2,090
Decrease due to fulfillment of asset retirement obligations	(420)	(5,056)
Decrease due to foreign exchange fluctuation	(310)	(3,729)
Balance at end of year	¥ 3,828	\$ 46,121

* Balance at beginning of year after application of Accounting Standard for Asset Retirement Obligations (ASBJ Statement No. 18) and Guidance on Accounting Standard for Asset Retirement Obligations (ASBJ Guidance No. 21).

With regard to asset retirement obligations for which the method of calculating the amount of deposit that can not ultimately be expected to be collected and then recording the amount corresponding to the fiscal year ended March 31, 2011, under operating expenses rather than recording the asset retirement obligations as liabilities, the amount of such deposit calculated at the beginning of the fiscal year was ¥1,553 million. With adjustment to include ¥66 million accrued due to lease agreements newly entered into, the total amount recorded in the fiscal year was ¥1,619 million.

18. Business segment information

(a) Overview of reportable segments

The Company is organized under a holding company configuration with core operating companies performing operations in eight business fields.

Separate financial information is available in these eight units, and the Board of Directors carries out periodic review to allocate management resources and evaluate business performance.

The eight units are combined into six reportable segments of Chemicals, Homes, Health Care, Fibers, Electronics, and Construction Materials through application of Paragraph 13 of "Accounting Standard for Disclosures about Segments of an Enterprise and Related Information."

Main products of the six reportable segments are as follows:

Chemicals

The Company produces, processes and sells chemicals and derivative products (such as ammonia, nitric acid, caustic soda, acrylonitrile, styrene, adipic acid, methyl methacrylate (MMA) and acrylic resin), polymer products (such as Stylac™-AS styrene-acrylonitrile, Stylac™-ABS acrylonitrile-butadiene-styrene, Tenac™ polyacetal, Xyron™ modified polyphenylene ether (mPPE), Leona™ polyamide 66, Suntec™ polyethylene, synthetic rubber, and polystyrene), specialty products (such as coating materials, latex, Ceolus™ microcrystalline cellulose, explosives, explosion-bonded metal clad, Microza™ UF and MF membranes and systems, ion-exchange membranes and electrolysis systems, Saran Wrap™ cling film, Ziploc™ storage bags, and plastic films, sheets, and foams).

Homes

The Company constructs Hebel Haus™ order-built unit homes and Hebel Maison™ apartments, and operates related businesses such as condominiums, residential land development, remodeling, real estate, and home financing.

Health Care

The Company manufactures and sells pharmaceuticals (such as Recomodulin™, Elcitonin™, Flivas™, Toledomin™, and Bredinin™), Lucica™GA-L assay kits, L series enriched liquid diets, APS™ polysulfone-membrane artificial kidneys, therapeutic apheresis devices, Planova™ virus removal filters, and Sepacell™ leukocyte reduction filters.

Fibers

The Company produces, processes, and sells Roica™ elastic polyurethane filament, Bemberg™ cupro fiber, nonwoven fabrics (such as Eltas™ spunbond and Lamous™ artificial suede), Leona™ nylon 66 filament, and polyester filament.

Electronics

The Company manufactures and sells Hipore™ Li-ion battery separators, photomask pellicles, APR™ photosensitive resin and printing plate making systems, Pimel™ photosensitive polyimide precursor, Sunfort™ dry film photoresist, mixed-signal LSIs, Hall elements, and glass fabric for printed wiring boards.

Construction Materials

The Company produces and sells Hebel™ autoclaved aerated concrete (AAC) panels, Neoma™ phenolic foam insulation panels, foundation piles, and steel-frame structural components.

(b) Methods to determine net sales, income or loss, assets, and other items by reportable business segment

Profit by reportable business segment is stated on an operating income basis. Intersegment net sales and transfers are based on the values of transactions undertaken between third parties.

(c) Information concerning net sales, income or loss, assets, and other items for each reportable segment

Millions of yen									
2011									
	Chemicals	Homes	Health Care	Fibers	Electronics	Construction Materials	Sub total	Others (Note 1)	Total
Sales:									
External customers	¥742,243	¥409,224	¥116,387	¥108,761	¥158,337	¥47,418	¥1,582,370	¥16,017	¥1,598,387
Intersegment	18,657	160	81	1,732	729	14,152	35,510	23,950	59,461
Total	760,899	409,384	116,468	110,493	159,066	61,570	1,617,880	39,968	1,657,848
Operating income	64,379	36,476	7,045	4,197	14,258	2,091	128,444	1,706	130,151
Assets	563,034	265,342	165,277	102,163	178,739	39,570	1,314,126	49,268	1,363,394
Other items									
Depreciation (Note 2)	31,460	4,266	10,833	6,945	23,882	2,795	80,181	862	81,043
Amortization of goodwill	443	—	610	5	14	—	1,073	—	1,073
Investments in affiliates accounted for using equity method	36,295	—	272	4,124	2,759	—	43,450	15,975	59,425
Increase in property, plant and equipment, and intangible assets	23,174	6,304	7,427	3,668	20,267	1,684	62,524	981	63,505
Millions of yen									
2010									
	Chemicals	Homes	Health Care	Fibers	Electronics	Construction Materials	Sub total	Others (Note 1)	Total
Sales:									
External customers	¥622,093	¥389,728	¥113,207	¥101,201	¥142,700	¥47,024	¥1,415,953	¥17,642	¥1,433,595
Intersegment	16,495	24	96	1,772	1,159	13,048	32,593	23,541	56,134
Total	638,588	389,752	113,303	102,973	143,859	60,072	1,448,547	41,182	1,489,729
Operating income (loss)	26,068	25,340	3,999	(2,764)	7,243	1,202	61,087	1,822	62,909
Assets	533,296	232,031	164,161	110,426	174,131	39,981	1,254,027	46,506	1,300,533
Other items									
Depreciation (Note 2)	31,968	4,309	11,556	7,719	23,587	3,263	82,403	799	83,201
Amortization of goodwill	447	—	635	—	6	—	1,089	—	1,089
Investments in affiliates accounted for using equity method	17,302	—	356	4,228	2,315	—	24,202	16,489	40,691
Increase in property, plant and equipment, and intangible assets	27,649	6,009	9,173	4,556	22,761	1,191	71,339	927	72,266

Thousands of U.S. dollars

	2011								
	Chemicals	Homes	Health Care	Fibers	Electronics	Construction Materials	Sub total	Others (Note 1)	Total
Sales:									
External customers	\$8,942,683	\$4,930,410	\$1,402,253	\$1,310,373	\$1,907,673	\$571,307	\$19,064,699	\$ 192,980	\$19,257,678
Intersegment	224,778	1,930	976	20,863	8,786	170,503	427,837	288,558	716,395
Total	9,167,461	4,932,341	1,403,229	1,331,236	1,916,459	741,810	19,492,535	481,538	19,974,073
Operating income	775,646	439,466	84,876	50,565	171,779	25,190	1,547,521	20,559	1,568,080
Assets	6,783,545	3,196,891	1,991,295	1,230,880	2,153,485	476,747	15,832,843	593,585	16,426,428
Other items									
Depreciation (Note 2)	379,036	51,402	130,514	83,676	287,734	33,674	966,036	10,383	976,419
Amortization of goodwill	5,339	—	7,355	60	168	—	12,923	—	12,923
Investments in affiliates accounted for using equity method	437,283	—	3,277	49,687	33,247	—	523,495	192,465	715,960
Increase in property, plant and equipment, and intangible assets	279,203	75,955	89,482	44,194	244,180	20,287	753,301	11,818	765,119

Notes: 1. The "Others" category is equivalent to the previous Services, Engineering and Others segment, including plant engineering and environmental engineering, research and analysis, and employment agency/staffing operations.
2. Amortization of goodwill is not included.

(d) Reconciliation of differences between total amounts of reportable segments and amounts appearing in the consolidated financial statements (adjustment of difference)

Sales	Millions of yen		Thousands of U.S. dollars
	2011	2010	2011
Total of reporting segments	¥1,617,880	¥1,448,547	\$19,492,535
Net sales in "Others" category	39,968	41,182	481,538
Elimination of intersegment transactions	(59,461)	(56,134)	(716,395)
Net sales on consolidated statements of income	¥1,598,387	¥1,433,595	\$19,257,678

Operating income	Millions of yen		Thousands of U.S. dollars
	2011	2010	2011
Total of reporting segments	¥128,444	¥ 61,087	\$1,547,521
Operating income in "Others" category	1,706	1,822	20,559
Elimination of intersegment transactions	708	1,438	8,532
Corporate expenses, etc.*	(7,932)	(6,726)	(95,561)
Operating income on consolidated statements of income	¥122,927	¥ 57,622	\$1,481,051

*Corporate expenses, etc. include corporate revenue, basic research expense, and group management expense, etc. which are not allocated to reporting segments.

Assets	Millions of yen		Thousands of U.S. dollars
	2011	2010	2011
Total of reporting segments	¥1,314,126	¥1,254,027	\$15,832,843
Assets in "Others" category	49,268	46,506	593,585
Elimination of intersegment transactions	(167,618)	(164,202)	(2,019,494)
Corporate assets*	230,103	232,562	2,772,331
Total net assets on consolidated balance sheets	¥1,425,879	¥1,368,892	\$17,179,265

*Corporate assets include assets of the parent company and those of a financial subsidiary—surplus operating funds (cash and deposits), long-term investment capital (investment securities, etc.), and land, etc.

Other items	Total of reportable segments		Others		Adjustments (Note 1)		Amounts from consolidated financial statements					
	Millions of yen		Millions of yen		Millions of yen		Thousands of U.S. dollars		Thousands of U.S. dollars			
	2011	2010	2011	2010	2011	2010	2011	2010	2011	2010		
Depreciation (Note 2)	¥80,181	¥82,403	¥966,036	¥ 862	¥ 799	¥ 10,383	¥3,049	¥ 2,965	¥36,738	¥84,092	¥86,166	¥1,013,158
Amortization of goodwill	¥ 1,073	¥ 1,089	¥ 12,923	¥ —	¥ —	¥ —	¥ —	¥ —	¥ —	¥ 1,073	¥ 1,089	¥ 12,923
Investments in associates accounted for using equity method	¥43,450	¥24,202	¥523,495	¥15,975	¥16,489	¥192,465	¥ —	¥ —	¥ —	¥59,425	¥40,691	¥ 715,960
Increase in property, plant and equipment, and intangible assets	¥62,524	¥71,339	¥753,301	¥ 981	¥ 927	¥ 11,818	¥2,509	¥11,724	¥30,224	¥66,014	¥83,990	¥ 795,344

Notes: 1. Adjustments include elimination of intersegment transactions and Corporate expenses, etc.
2. Amortization of goodwill is not included.

(Additional information)

Accounting Standard for Disclosures about Segments of an Enterprise and Related Information (ASBJ Statement No. 17) and the Guidance on Accounting Standard for Disclosures about Segments of an Enterprise and Related Information (ASBJ Guidance No. 20) have been applied beginning from the fiscal year ended March 31, 2011.

(e) Related Information

i) Information on products and services

Please refer to (c) Information concerning net sales, income or loss, assets, and other items for each reportable segment.

ii) Geographic information

1) Net sales

Millions of yen								Thousands of U.S. dollars			
2011				2010				2011			
Japan	China	Other regions	Total	Japan	China	Other regions	Total	Japan	China	Other regions	Total
¥1,149,098	¥169,637	¥279,652	¥1,598,387	¥1,063,186	¥134,271	¥236,138	¥1,433,595	\$13,844,558	\$2,043,814	\$3,369,307	\$19,257,678

2) Property, plant and equipment

Geographic information is not shown because over 90% of the amount of property, plant and equipment on the consolidated balance sheets is located in Japan.

3) Information by major customer

Information by major customer is not shown because no customer accounts for 10% or more of net sales on the statements of income.

19. Information about related parties

For the year ended March 31, 2011

Related party transactions

Transactions between consolidated subsidiaries of the company submitting the consolidated financial statements and related parties

Subsidiaries, affiliates, etc. of the company submitting the consolidated financial statements

Type of related party	An affiliated company
Name of company	PTT Asahi Chemical Co., Ltd.
Location	Rayong, Thailand
Paid-in capital	14,246 million Thai baht
Business line	Chemicals
Holding ratio of voting rights (of which, indirect holding ratio)	48.5% (48.5%)
Relationship with the related party	Debt guarantee
Nature of transaction	Completion guarantee
Transaction amount	¥15,002 million
Item	—
Balance at end of year	—

20. Per share information

Reconciliation of the differences between basic and diluted net assets per share and net income per share for the years ended March 31, 2011 and 2010, was as follows:

	Yen		U.S. dollars
	2011	2010	2011
Basic net assets per share	¥474.59	¥452.91	\$5.72
Basic net income per share	¥ 43.11	¥ 18.08	\$0.52

(a) Net assets per share

	Millions of yen		Thousands of U.S. dollars
	2011	2010	2011
Total net assets	¥ 675,602	¥ 644,688	\$8,139,787
Amount deducted from total net assets	12,036	11,346	145,014
<i>of which, minority interest</i>	12,036	11,346	145,014
Net assets allocated to capital stock	¥ 663,566	¥ 633,343	\$7,994,772
Number of shares of capital stock outstanding at fiscal year end used in calculation of net assets per share (thousand)	1,398,196	1,398,388	1,398,196

(b) Net income per share

	Millions of yen		Thousands of U.S. dollars
	2011	2010	2011
Net income	¥ 60,288	¥ 25,286	\$ 726,356
Amount not allocated to capital stock	—	—	—
Net income allocated to capital stock	¥ 60,288	¥ 25,286	\$ 726,356
Weighted-average number of shares of capital stock (thousand)	1,398,311	1,398,463	1,398,311

As the Company had no dilutive securities at March 31, 2011 and 2010, the Company does not disclose diluted net income per share for the years ended March 31, 2011 and 2010.

21. Borrowings

(a) Bonds payable at March 31, 2011 and 2010, comprised the following:

	Millions of yen		Thousands of U.S. dollars
	2011	2010	2011
Unsecured 1.90% Euro yen bonds due in 2013	¥ 5,000	¥ 5,000	\$ 60,241
Unsecured 1.46% yen bonds due in 2019	20,000	20,000	240,964
	¥25,000	¥25,000	\$301,205

Notes 1) The current portion of bonds payable is recorded under current liabilities on the consolidated balance sheets.

2) In the case of floating interest rates, the rate at the end of March is shown.

3) The aggregate annual maturities of long-term debt after March 31, 2011, are as follows:

Year ending March 31	Millions of yen	Thousands of U.S. dollars
2012	¥ —	\$ —
2013	—	—
2014	5,000	60,241
2015	—	—
2016 and thereafter	20,000	240,964
	¥25,000	\$301,205

(b) Loans payable at March 31, 2011 and 2010, are comprised of the following:

	Millions of yen		Thousands of U.S. dollars
	2011	2010	2011
Short-term loans payable with interest rate 0.88%	¥ 76,611	¥ 77,763	\$ 923,023
Current portion of long-term loans payable with interest rate 1.10%	32,278	16,199	388,892
Current portion of lease obligations with interest rate 2.36%	1,522	1,123	18,333
Long-term loans payable (except portion due within one year) with interest rate 1.07%	91,722	121,921	1,105,090
Lease obligations (except portion due within one year) with interest rate 2.28%	3,802	3,593	45,812
Commercial paper with interest rate 0.20% (due within one year)	23,000	19,000	277,108
	¥228,935	¥239,600	\$2,758,259

Notes 1) Interest rates shown are weighted average interest rates for the balance outstanding at the end of March.

2) The aggregate annual maturities of long-term loans payable and lease obligations (except portion due within one year) after March 31, 2012, are as follows:

Year ending March 31	Long-term loans payable		Lease obligations	
	Millions of yen	Thousands of U.S. dollars	Millions of yen	Thousands of U.S. dollars
2013	¥ 29,805	\$ 359,092	¥ 1,556	\$ 18,747
2014	23,404	281,980	1,363	16,423
2015	7,444	89,686	658	7,924
2016	1,891	22,788	206	2,483
2017 and thereafter	28,671	345,432	20	236

3) The timing of repayments for the loan payables from Japan Science and Technology Agency have yet to be determined as they begin after the development success is certified. Thus, the related aggregate annual maturities for these long-term loans payable after March 31, 2011 are not included in the above.



Report of Independent Auditors

To the Board of Directors of Asahi Kasei Corporation

We have audited the accompanying consolidated balance sheet of Asahi Kasei Corporation (“the Company”) and its subsidiaries as of March 31, 2011, and the related consolidated statements of income, comprehensive income, changes in net assets and cash flows for the year then ended, all expressed in Japanese yen. These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit.

We conducted our audit in accordance with auditing standards generally accepted in Japan. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company and its subsidiaries as of March 31, 2011, and the results of their operations and their cash flows for the year then ended in conformity with accounting principles generally accepted in Japan.

The U.S. dollar amounts in the accompanying consolidated financial statements with respect to the year ended March 31, 2011 are presented solely for convenience. Our audit also included the translation of Japanese yen amounts into U.S. dollar amounts and, in our opinion, such translation has been made on the basis described in Note 1 to the consolidated financial statements.

PricewaterhouseCoopers Arata

July 26, 2011

PricewaterhouseCoopers Arata
Sumitomo Fudosan Shiodome Hamarikyu Bldg., 8-21-1 Ginza, Chuo-ku, Tokyo 104-0061, Japan
T: +81 (3) 3546 8450, F: +81 (3) 3546 8451, www.pwc.com/jp/assurance

Major Subsidiaries and Affiliates

As of April 1, 2011

Company	Main products/business line		Paid-in capital (million)	Equity interest (%)
Chemicals Segment				
Asahi Kasei Chemicals Corp.*	Chemicals	¥	3,000	100.0
Asahi Kasei Pax Corp.*	Packaging products and solutions	¥	490	100.0
Asahi Kasei Home Products Corp.*	Cling film, other household products	¥	250	100.0
Asahi Kasei Metals Ltd.	Aluminum paste	¥	250	100.0
Asahi Kasei Finechem Co., Ltd.*	Specialty chemicals	¥	325	100.0
Asahi Kasei Geotechnologies Co., Ltd.	Sale of civil engineering materials	¥	132	100.0
Asahi SKB Co., Ltd.	Shotgun cartridges	¥	100	100.0
Asahi Kasei Clean Chemical Co., Ltd.	Water treatment equipment, environmental chemicals	¥	100	100.0
Asahi Kasei Technoplus Co., Ltd.*	Processing of plastic and fiber	¥	160	99.4
Japan Elastomer Co., Ltd.*	Synthetic rubber	¥	1,000	75.0
Sundic Inc.	Biaxially oriented polystyrene sheet	¥	1,500	50.0
Wacker Asahikasei Silicone Co., Ltd.	Silicone	¥	1,050	50.0
Okayama Chemical Co., Ltd.	Caustic soda, chlorine	¥	1,000	50.0
Kayaku Japan Co., Ltd.	Industrial explosives	¥	60	50.0
PS Japan Corp.*	Polystyrene	¥	5,000	62.1
Asahikasei Plastics (America) Inc.*	Compounded performance resin operations	US\$	17.8**	100.0
Asahi Kasei Plastics North America, Inc.*	Coloring and compounding of performance resin	US\$	21.7**	100.0
Sun Plastech Inc.*	Sale of purging compound	US\$	1.0	100.0
Tong Suh Petrochemical Corp., Ltd.*	Acrylonitrile, sodium cyanide	W	50,642	100.0
Asahi Kasei Chemicals Korea Co., Ltd.	Sale of adipic acid	W	1,500	100.0
Asahikasei Plastics (Shanghai) Co., Ltd.	Sale of performance resin	CNY	18	100.0
Asahikasei (Suzhou) Plastics Compound Co., Ltd.	Coloring and compounding of performance resin	CNY	50	51.0
Asahi-DuPont POM (Zhangjiagang) Co., Ltd.	Polyacetal	US\$	32.0	50.0
Asahi Kasei Performance Chemicals Corp.*	High-performance HDI-based polyisocyanate	CNY	149	100.0
Asahi Kasei Microza (Hangzhou) Co., Ltd.*	Industrial filtration membranes and systems	CNY	49	100.0
Asahi Kasei Plastics (Hong Kong) Co., Ltd.	Sale of performance resin	US\$	2.6	100.0
Asahi Kasei Plastics Singapore Pte. Ltd.*	Performance resin	US\$	46.0	100.0
Polyxylenol Singapore Pte. Ltd.*	PPE powder	US\$	35.0	70.0
Asahi Kasei Synthetic Rubber Singapore Pte. Ltd.	Synthetic rubber	US\$	15.0	100.0
PTT Asahi Chemical Co., Ltd.	Acrylonitrile, methyl methacrylate	B	12,400	48.5
Asahikasei Plastics (Thailand) Co., Ltd.	Coloring and compounding of performance resin	B	140	100.0
PT Nippisun Indonesia	Coloring and compounding of styrenic resin	US\$	6.3	25.7
Asahi Kasei Plastics Europe SA/NV*	Sale of compounded performance resin	€	5.0	100.0
Homes Segment				
Asahi Kasei Homes Corp.*	Housing	¥	3,250	100.0
Asahi Kasei Jyuko Co., Ltd.*	Steel frames	¥	2,820	100.0
Asahi Kasei Mortgage Corp.*	Financial services	¥	1,000	100.0
Asahi Kasei Reform Co., Ltd.*	Home maintenance and remodeling	¥	250	100.0
Asahi Kasei Real Estate, Ltd.*	Home leasing, real estate brokerage	¥	200	100.0
Asahi Kasei Home Construction Corp.*	Construction of homes	¥	100	100.0
Health Care Segment				
Asahi Kasei Pharma Corp.*	Pharmaceuticals	¥	3,000	100.0
Asahi Kasei Kuraray Medical Co., Ltd.*	Hemodialyzers, therapeutic apheresis devices	¥	800	93.0
Asahi Kasei Medical Co., Ltd.*	Medical devices, medical systems	¥	200	100.0
Med-Tech Inc.*	Medical devices	¥	140	68.3
Asahi Kasei Bioprocess, Inc.*	Bioprocess equipment and systems	US\$	30.0	100.0
Asahi Kasei Medical America Inc.*	Sale of medical devices, medical systems	US\$	0.5	93.0
Asahi Kasei Medical Trading (Korea) Co., Ltd.*	Sale of medical devices, medical systems	W	1,000	100.0
Asahi Kasei Medical (Hangzhou) Co., Ltd.*	Hemodialyzers; sale of medical devices	CNY	163	93.0
Asahi Kasei Medical Trading (Taiwan) Co. Ltd.*	Sale of medical devices, medical systems	NT\$	5	100.0
Asahi Kasei Medical Europe GmbH*	Sale of medical devices, medical systems	€	0.2	93.0

* Consolidated subsidiary

** Including capital reserve

Company	Main products/business line	Paid-in capital (million)	Equity interest (%)
Asahi Kasei Medical Trading Ltd. Sti.	Sale of medical devices, medical systems	YTL 5,000	100.0
Asahi Kasei Bioprocess Europe SA/NV*	Sale of virus removal filters	€ 0.5	100.0
Asahi Pharma Spain, SL	Pharmaceuticals	€ 0.1	100.0
Fibers Segment			
Asahi Kasei Fibers Corp.*	Fibers, textiles	¥ 3,000	100.0
Kyokuyo Sangyo Co., Ltd.*	Processing of fibers and textiles	¥ 80	100.0
DuPont-Asahi Flash Spun Products Co., Ltd.	Flash spun products	¥ 450	50.0
Asahi Kasei Spandex America, Inc.*	Spandex	US\$ 32.3**	100.0
Hangzhou Asahikasei Spandex Co., Ltd.*	Spandex	CNY 132	100.0
Hangzhou Asahikasei Textiles Co., Ltd.*	Warp-knit spandex textiles	CNY 78	82.5
Formosa Asahi Spandex Co., Ltd.	Spandex	NT\$ 802	50.0
Asahi Chemical (HK) Ltd.*	Promotion and marketing of fibers and textiles	HK\$ 65	100.0
Thai Asahi Kasei Spandex Co., Ltd.*	Spandex	B 1,350	60.0
Asahi Kasei Spunbond (Thailand) Co., Ltd.	Spunbond nonwovens	B 225	100.0
Asahi Kasei Spandex Europe GmbH*	Spandex	€ 19.6**	100.0
Asahi Kasei Fibers Italy SRL*	Sale of cupro cellulosic fiber	€ 3.0	100.0
Asahi Kasei Fibers Deutschland GmbH	Sale of artificial suede	€ 0.3	100.0
Electronics Segment			
Asahi Kasei Microdevices Corp.*	Electronic devices	¥ 3,000	100.0
Asahi Kasei E-materials Corp.*	Electronic materials	¥ 3,000	100.0
Asahi Kasei Epoxy Co., Ltd.*	Epoxy resin	¥ 300	100.0
Asahi Kasei Microsystems Co., Ltd.*	LSIs	¥ 50	100.0
Asahi-Schwebel Co., Ltd.*	Glass fabric	¥ 50	100.0
Asahi Kasei Electronics Co., Ltd.*	Hall elements	¥ 50	100.0
Asahi Kasei Power Devices Corp.*	Power management semiconductors	¥ 100	80.0
AKM Semiconductor, Inc.*	Sale of LSIs	US\$ 2.9	100.0
Asahi Kasei Microdevices Korea Corp.	Electronic devices marketing and technical support	W 820	100.0
Asahi Kasei E-materials Korea Inc.	Energy and electronic materials	W 5,500	100.0
Asahi Kasei Electronics Materials (Suzhou) Co., Ltd.*	Dry film photoresist	CNY 181	100.0
Asahi Kasei Microdevices (Shanghai) Co., Ltd.	Electronic devices marketing and technical support	CNY 14	100.0
Asahi Kasei Microdevices Taiwan Corp.	Electronic devices marketing and technical support	NT\$ 10	100.0
Asahi Kasei EMD Taiwan Corp.	Sale of pellicles	NT\$ 1.0	100.0
Asahi Kasei Wah Lee Hi-Tech Corp.*	Dry film photoresist	NT\$ 49	80.6
Asahi-Schwebel (Taiwan) Co., Ltd.*	Glass fabric	NT\$ 326	51.0
Asahi Kasei Microdevices Europe SAS	Electronic devices marketing and technical support	€ 0.4	100.0
Asahi Photoproducts (Europe) SA/NV*	Sale of photopolymer, printing-plate making systems	€ 3.4	100.0
Asahi Photoproducts (UK) Ltd.*	Sale of photopolymer, printing-plate making systems	£ 0.3	100.0
Construction Materials Segment			
Asahi Kasei Construction Materials Corp.*	Construction materials	¥ 3,000	100.0
Asahi Kasei Foundation Systems Corp.*	Installation of piles	¥ 200	100.0
Asahi Kasei Extech Corp.*	Exterior wall panel installation	¥ 50	100.0
Others (formerly Services, Engineering and Others segment)			
Asahi Research Center Co., Ltd.*	Information and analysis	¥ 1,000	100.0
Asahi Finance Co., Ltd.	Investment, finance	¥ 800	100.0
Asahi Kasei Engineering Corp.*	Plant, equipment, process engineering	¥ 400	100.0
Asahi Kasei Trading Co., Ltd.*	Sale of Asahi Kasei products	¥ 98	100.0
Sun Trading Co., Ltd.*	Sale of Asahi Kasei products	¥ 94	100.0
Asahi Kasei Amidas Co., Ltd.*	Employment agency, consulting	¥ 80	100.0
AJS Inc.	Computer software, IT systems	¥ 800	49.0
Asahi Organic Chemicals Industry Co., Ltd.	Synthetic resin, fabricated plastic products	¥ 5,000	30.1
Asahi Kasei America, Inc.*	Business support services	US\$ 0.1	100.0
Asahi Kasei Business Management (Shanghai) Co., Ltd.	Business support services	US\$ 3.0	100.0

* Consolidated subsidiary

** Including capital reserve

Corporate Profile

As of March 31, 2011

Company Name	Asahi Kasei Corporation
Date of Establishment	May 21, 1931
Paid-in Capital	¥103,388,521,767
Employees	25,016 (consolidated) 810 (non-consolidated)

Asahi Kasei Group Offices

Asahi Kasei Corporation

Tokyo Head Office

1-105 Kanda Jinbocho, Chiyoda-ku
Tokyo 101-8101 Japan
Phone: +81-3-3296-3000
Fax: +81-3-3296-3161

Osaka Head Office

3-3-23 Nakanoshima, Kita-ku
Osaka 530-8205 Japan
Phone: +81-6-7636-3111
Fax: +81-6-7636-3077

Beijing Office

Room 1407
New China Insurance Tower
No.12 Jian Guo Men Wai Avenue
Chao Yang District
Beijing 100022 China
Phone: +86-10-6569-3939
Fax: +86-10-6569-3938

Asahi Kasei Business Management (Shanghai) Co., Ltd.

8/F, One ICC
Shanghai International Commerce Centre
No. 999 Huai Hai Zhong Road
Shanghai 200031 China
Phone: +86-21-6391-6111
Fax: +86-21-6391-6686

Asahi Kasei America, Inc.

535 Madison Avenue, 33rd Floor
New York, NY 10022 USA
Phone: +1-212-371-9900
Fax: +1-212-371-9050

Core Operating Companies

Asahi Kasei Chemicals

1-105 Kanda Jinbocho, Chiyoda-ku
Tokyo 101-8101 Japan
Phone: +81-3-3296-3200

Asahi Kasei Homes

1-24-1 Nishi-shinjuku, Shinjuku-ku
Tokyo 160-8345 Japan
Phone: +81-3-3344-7111

Asahi Kasei Pharma

1-105 Kanda Jinbocho, Chiyoda-ku
Tokyo 101-8101 Japan
Phone: +81-3-3296-3600

Asahi Kasei Kuraray Medical

1-105 Kanda Jinbocho, Chiyoda-ku
Tokyo 101-8101 Japan
Phone: +81-3-3296-3750

Asahi Kasei Medical

1-105 Kanda Jinbocho, Chiyoda-ku
Tokyo 101-8101 Japan
Phone: +81-3-3296-3750

Asahi Kasei Fibers

3-3-23 Nakanoshima, Kita-ku
Osaka 530-8205 Japan
Phone: +81-6-7636-3500

Asahi Kasei Microdevices

1-105 Kanda Jinbocho, Chiyoda-ku
Tokyo 101-8101 Japan
Phone: +81-3-3296-3911

Asahi Kasei E-materials

1-105 Kanda Jinbocho, Chiyoda-ku
Tokyo 101-8101 Japan
Phone: +81-3-3296-3939

Asahi Kasei Construction Materials

1-105 Kanda Jinbocho, Chiyoda-ku
Tokyo 101-8101 Japan
Phone: +81-3-3296-3500

Investors Information


As of March 31, 2011

Stock Listings	Tokyo, Osaka, Nagoya, Fukuoka, Sapporo
Stock Code	3407
Authorized Shares	4,000,000,000
Outstanding Shares	1,402,616,332
Transfer Agent	Sumitomo Trust & Banking Co., Ltd. 4-5-33 Kitahama, Chuo-ku Osaka 541-8639 Japan
Independent Auditors	PricewaterhouseCoopers Aarata
Number of Shareholders	116,237


Largest Shareholders	% of equity*
Master Trust Bank of Japan, Ltd. (trust account)	6.63
Japan Trustee Services Bank, Ltd. (trust account)	5.67
Nippon Life Insurance Co.	5.22
Asahi Kasei Group Employee Stockholding Assn.	3.25
Sumitomo Mitsui Banking Corp.	2.53
Tokio Marine & Nichido Fire Insurance Co., Ltd.	1.84
SSBT OD05 Omnibus Account Treaty Clients	1.77
Japan Trustee Services Bank, Ltd. (trust account 9)	1.56
Mizuho Corporate Bank, Ltd.	1.45
Sumitomo Life Insurance Co.	1.40

* Percentage of equity ownership after exclusion of treasury stock.


Distribution by Type of Shareholder



Distribution by Number of Shares Held



Stock Chart



In this annual report, the TM symbol indicates a trademark or registered trademark of Asahi Kasei Corporation, affiliated companies, or third parties granting rights to Asahi Kasei Corporation or affiliated companies.

ASAHI KASEI CORPORATION

1-105 Kanda Jinbocho, Chiyoda-ku, Tokyo 101-8101 Japan
www.asahi-kasei.co.jp

Corporate Communications
Tel: +81-3-3296-3008, Fax: +81-3-3296-3162



Printed in Japan
2011.11